result
total
isol
escherichia
coli
n
acinetobact
speci
n
klebsiella
pneumonia
n
pseudomona
aeruginosa
n
citrobact
freundii
n
alarmingli
n
bacteri
isol
recov
esblproduc
k
pneumonia
found
predomin
n
follow
e
coli
n
p
aeruginosa
n
acinetobact
speci
n
discuss
andor
conclus
found
high
preval
nosocomi
bacteria
produc
esbl
hospit
prompt
special
attent
manag
patient
well
urgent
need
implement
infect
control
strategi
prevent
dissemin
strain
esbl
detect
routin
perform
clinic
laboratori
fals
report
would
result
treatment
failur
despit
vitro
sensit
analysi
biofilm
format
abil
antibiot
resist
escherichia
coli
klebsiella
pneumonia
strain
sinan
baho
shivanthi
samarasingh
background
biofilm
format
repres
one
major
health
problem
due
difficulti
erad
studi
focu
seek
new
antibiot
treat
biofilm
littl
focu
bacteri
virul
factor
gene
relat
biofilm
format
aim
object
work
tri
find
relationship
biofilm
format
quorum
sens
qs
virul
factor
gene
might
give
new
insight
use
new
therapeut
altern
tradit
antibiot
method
work
amount
biofilm
format
antibiot
resist
strain
escherichia
coli
klebsiella
pneumonia
differ
time
point
growth
hour
determin
use
biofilm
format
assay
tissu
cultur
plate
assay
tcp
six
well
well
tissu
cultur
plate
use
studi
use
lb
broth
nutrient
broth
static
shake
incub
condit
result
result
show
amount
biofilm
produc
vari
accord
bacteri
growth
stage
hour
growth
cultur
condit
static
shake
addit
type
growth
media
discuss
andor
conclus
conclus
quantiti
biofilm
produc
affect
strain
type
growth
stage
cultur
condit
use
result
next
step
select
highest
biofilm
produc
strain
delet
one
qs
control
virul
gene
studi
effect
strain
biofilm
format
abil
result
aspir
cultur
posit
patient
mean
number
isol
per
sampl
fineneedl
aspir
compar
wound
swab
correl
isol
aspir
swab
two
aspir
yield
signific
growth
yield
heavi
moder
growth
wound
swab
one
wound
swab
addit
organ
pseudomona
sp
isol
wound
one
wound
swab
yield
scanti
coliform
growth
nil
growth
aspir
two
close
inflam
cellulit
area
nil
growth
aspir
wound
swab
taken
discuss
andor
conclus
fna
microbiopsi
techniqu
studi
use
small
amount
tissu
sampl
pain
patient
possibl
obtain
aspir
close
cellulit
tissu
simpl
swab
possibl
aspir
result
yield
less
pathogen
fewer
organ
compar
wound
swab
reflect
accur
state
wound
infect
respons
antimicrobi
treatment
trend
variat
antimicrobi
suscept
test
laboratori
north
west
england
implic
interpret
surveil
data
background
problem
antibiot
resist
well
understood
within
infect
prevent
commun
remain
confus
potenti
risk
resist
disinfect
antisept
biocid
substanc
aim
object
assess
avail
literatur
knowledg
applic
biocid
substanc
identifi
risk
relev
microbi
resist
substanc
potenti
risk
promot
antibiot
resist
method
review
evalu
avail
literatur
result
wherea
antibiot
resist
defin
increas
minimum
inhibitori
concentr
resist
biocid
substanc
must
defin
fail
defin
log
reduct
accord
accept
standard
outlin
en
concentr
contact
time
deliv
kill
standard
test
organ
also
genet
determin
resist
must
distinguish
phenotyp
adapt
found
eg
biofilm
use
definit
develop
relev
resist
biocid
substanc
observ
year
routin
use
notabl
antibiot
resist
found
even
broad
clinic
use
substanc
given
broad
unspecif
mode
action
biocid
unlik
happen
correct
use
biocid
substanc
like
avoid
subleth
exposur
microb
condit
support
microbi
growth
select
reduc
risk
also
demonstr
correct
use
biocid
substanc
promot
antibiot
resist
discuss
andor
conclus
conclud
correct
use
biocid
substanc
may
provid
opportun
reduc
risk
spread
antibiot
resist
hospit
includ
patient
mix
may
bia
result
prevent
effect
benchmark
antimicrobi
prescrib
qualiti
indic
aim
object
develop
implement
standardis
audit
methodolog
use
patient
mix
special
staff
examin
antimicrobi
stewardship
indic
across
region
achiev
agre
audit
standard
method
qualiti
indic
audit
standard
data
collect
criteria
patient
specialti
applic
hospit
region
agre
trust
antimicrobi
pharmacist
collect
analys
data
patient
case
agre
special
novemb
decemb
result
rang
mean
report
antimicrobi
choic
reason
rang
mean
standard
indic
document
rang
mean
standard
stopreview
date
document
rang
mean
standard
hour
prescrib
decis
rang
mean
standard
pharmacist
screen
rang
mean
standard
reason
screen
rang
mean
standard
consult
review
rang
mean
discuss
andor
conclus
audit
allow
consist
approach
data
collect
patient
mix
data
interpret
compar
indic
region
achiev
wide
variat
mani
indic
data
use
highlight
outli
achiev
trust
encourag
best
practic
share
across
region
audit
repeat
annual
allow
effect
comparison
drawn
method
blood
isol
lrcon
character
mechan
lr
speci
identif
done
sequenc
rrna
gene
demograph
data
clinic
antibiot
histori
comorbid
condit
record
chart
review
linezolid
glycopeptid
mic
determin
microbroth
dilut
etest
respect
pcr
perform
cfr
gene
domain
v
region
rrna
mutat
detect
sequenc
five
copi
rrna
gene
result
lr
observ
divers
speci
con
haemolyticu
cohnii
arletta
lrcon
noscomi
acquir
patient
comorbid
without
prior
exposur
linezolid
clindamycin
chloramphenicol
mean
age
year
month
year
isol
suscept
vancomycin
teicoplanin
resist
linezolid
mic
rang
cfr
gene
detect
isol
novel
mutat
detect
n
n
domain
v
region
rrna
one
isol
arletta
show
mutat
among
three
isol
mutat
identifi
correl
linezolid
mic
cfr
gene
type
mutat
detect
number
mutant
copi
discuss
andor
conclus
lr
emerg
divers
speci
con
without
prior
exposur
multipl
mechan
contribut
resist
novel
mutat
detect
resist
mediat
cfr
gene
great
concern
rapidli
dissemin
capabl
transmit
horizont
divers
speci
id
bacteriophag
prophylaxi
healthcareassoci
infect
hai
neurosurg
intens
care
unit
icu
background
phage
use
prevent
andor
treat
infecti
diseas
bacteri
etiolog
almost
centuri
aim
object
purpos
research
establish
effect
singl
administr
bacteriophag
patient
neurosurg
icu
circul
hospit
pathogen
method
patient
prolong
mechan
ventil
icu
administ
ml
dose
pfuml
bacteriophag
cocktail
per
os
patient
multipl
administr
phage
cocktail
combin
host
rang
antibioticresist
strain
abaumannii
kpneumonia
paeruginosa
isol
icu
antiphag
iggantibodi
test
enzymelink
immunosorb
assay
elisa
result
abaumannii
kpneumonia
paeruginosa
isol
sampl
patient
endotrach
aspir
eta
blood
urin
fece
content
first
episod
trial
one
day
therapi
effect
sanit
confirm
case
pharmacokinet
test
shown
per
os
administ
bacteriophag
penetr
gastrointestin
tract
blood
fece
urin
eta
repeat
therapi
result
signific
erad
pathogen
antiphag
immun
intak
prepar
test
elisa
presenc
signific
titer
specif
iggantibodi
discuss
andor
conclus
right
cours
action
use
bacteriophag
cocktail
icu
establish
fix
content
phage
speci
cocktail
subsequ
select
phage
strain
mandatori
alter
new
phage
strain
case
repeat
administr
patient
activ
current
pathogen
icu
exist
phage
bank
transit
ribotyp
clostridium
difficil
univers
hospit
norway
michaela
lelek
silj
bakken
andr
ingebretsen
akershu
univers
hospit
oslo
univers
hospit
background
clostridium
difficil
associ
diarrhoea
cdad
caus
consider
morbid
mortal
worldwid
emerg
virul
clone
increas
cdad
morbid
mani
countri
aim
object
assur
earli
outbreak
detect
hospit
establish
local
cdad
surveil
system
method
cdad
diagnos
hospit
microbiolog
laboratori
twostep
method
use
lamptechnolog
posit
sampl
subsequ
cultur
c
difficil
isol
ribotyp
nation
c
difficil
refer
laboratori
infect
control
staff
monitor
new
case
weekli
result
case
cdad
identifi
acquir
cdad
hour
admit
hospit
acquir
cdad
outsid
hospit
treat
primari
care
ribotyp
occur
sole
hospit
patient
found
patient
admit
other
origin
outsid
hospit
discuss
andor
conclus
depart
highest
occur
cdad
infecti
diseas
depart
haematolog
depart
signific
accumul
specif
ribotyp
ward
distribut
ribotyp
hospit
differ
previous
publish
distribut
countri
antimicrobi
suscept
pattern
staphylococcu
aureu
isol
clinic
specimen
convent
newer
antimicrobi
eastern
india
srujana
mohanti
bijayini
behera
subhrajyoti
sahu
ashok
k
praharaj
india
institut
medic
scienc
aiim
bhubaneswar
odisha
india
india
institut
medic
scienc
aiim
bhubaneswar
odisha
india
background
global
spread
methicillin
resist
staphylococcu
aureu
mrsa
constitut
one
seriou
contemporari
challeng
treatment
hospitalacquir
infect
aim
object
aim
assess
antibiot
suscept
pattern
aureu
clinic
specimen
tertiari
care
hospit
eastern
india
method
aureu
isol
identifi
use
standard
method
juli
april
antimicrobi
suscept
test
perform
per
clsi
use
standard
discdiffus
etest
result
total
aureu
obtain
pu
respiratori
tract
urin
blood
bodi
fluid
cathet
tip
overal
mrsa
multidrug
resist
mrsa
highest
respiratori
sampl
follow
urin
blood
high
resist
penicillin
erythromycin
ciprofloxacin
lowlevel
resist
linezolid
tigecyclin
rifampicin
doxycyclin
suscept
teicoplanin
isol
suscept
vancomcin
mic
demonstr
reduc
vancomycin
suscept
rv
mic
proport
isol
rv
similar
mrsa
methicillinsensit
aureu
mssa
discuss
andor
conclus
high
percentag
aureu
demonstr
rv
may
limit
use
mrsa
associ
increas
complic
mssa
infect
linezolid
tigecyclin
rifampicin
doxycyclin
may
consid
altern
glycopeptid
resist
increas
global
commensur
increas
use
rate
vancomycin
resist
along
antibiot
among
aureu
investig
period
manag
complic
urosepsi
patient
signific
comorbid
balanc
antimicrobi
therapi
surgic
intervent
keith
yuen
meli
altunel
adeel
anwar
sulman
hasni
philip
stanley
background
diabet
urosepsi
imag
confirm
emphysemat
pyelonephr
augmentin
resist
enterobact
cultur
admiss
urin
blood
clinic
condit
deterior
piperacillintazobactam
switch
meropenem
empir
repeat
imag
confirm
renal
abscess
format
radiologicallyguid
drainag
pu
yield
enterobact
drain
fluid
grew
vre
patient
discharg
recoveri
made
three
week
ertapenem
linezolid
readmiss
requir
due
persist
urosepsi
compound
multiorgan
failur
urin
cultur
enterobact
ampc
posit
remain
carbapenem
sensit
imag
third
seri
show
renal
abscess
recurr
amen
drainag
clinic
deterior
initi
recoveri
meropenem
attempt
continu
treatment
commun
urin
cultur
enterobact
resist
carbepenem
secondari
ampc
activ
porin
loss
readmiss
cultur
yield
two
differ
strain
e
coli
esbl
produc
ciprofloxacin
carbapenem
sensit
resist
strain
imag
show
repeat
recurr
renal
abscess
drain
radiolog
treatment
meropenem
linezolid
ciprofloxacin
caspofungin
saw
mark
clinic
improv
repeat
invas
cultur
yield
growth
discuss
andor
conclus
sourc
control
key
manag
urosepsi
empir
escal
antimicrobi
treatment
time
clinic
deterior
without
sourc
control
abscess
drainag
case
led
prolong
carbapenem
use
inevit
develop
carbapenem
resist
nephrectomi
indic
due
recur
sepsi
howev
one
consid
nephron
preserv
patient
signific
cardiovascular
comorbid
high
periop
morbid
mortal
associ
unstabl
patient
background
neutropen
sepsi
lead
caus
morbid
mortal
amongst
cancer
patient
receiv
treatment
manag
remain
challeng
nice
guidelin
discourag
routin
empir
use
aminoglycosid
broadspectrum
antibiot
toxic
concern
howev
emerg
resist
strain
microorgan
clinician
must
identifi
risk
adjust
antimicrobi
agent
base
local
antibiogram
aim
object
review
antibiot
usag
microbi
identif
antimicrobi
sensit
amongst
adult
neutropen
sepsi
method
data
collect
part
retrospect
audit
neutropen
sepsi
hillingdon
hospit
result
eightythre
case
neutropen
sepsi
sixtythre
patient
fortytwo
haematooncolog
patient
twentyon
oncolog
twentyseven
fiftyeight
posit
cultur
result
gramneg
organ
eight
isol
resist
strain
includ
six
case
enterobacteriacea
two
case
stenotrophomona
maltophilia
within
six
resist
strain
enterobacteriacea
three
isol
esbl
produc
two
ampc
beta
produc
one
tazocin
resist
anoth
mechan
five
six
resist
enterobacteriacea
strain
identifi
haematooncolog
patient
four
strain
resist
singl
agent
tazocin
sensit
gentamicin
meropenem
discuss
andor
conclus
small
studi
support
use
gentamicin
tazocin
firstlin
emper
antimicrobi
therapi
highrisk
haematooncolog
patient
close
collabor
microbiolog
frontlin
clinician
essenti
provid
optimum
antimicrobi
therapi
neutropen
sepsi
overview
bacteri
popul
aim
studi
determin
cadexom
iodin
monotherapi
could
reduc
biofilm
phenotyp
bacteria
colon
diabet
foot
ulcer
dfu
invivo
result
staphylococcu
aureu
staphylococcu
epidermidi
prevotella
melaninogenica
elizabethkingia
meningoseptica
propionibacterium
acn
pseudomona
stutzeri
abund
bacteri
speci
present
across
sampl
treatment
observ
signific
decreas
divers
chang
commun
composit
treatment
increas
bacteri
abund
presenc
biofilm
determin
via
scan
electron
microscop
found
iodosorb
reduc
remov
biofilm
sampl
wherea
reveal
chang
start
produc
biofilm
log
reduct
biofilm
cell
indic
patient
reduct
log
possibl
discuss
andor
conclus
given
inher
toler
biofilm
mani
form
antimicrobi
cadexom
iodosorb
demonstr
abil
decreas
bacteri
divers
load
biofilm
format
effect
topic
antimicrobi
mayb
increas
use
adjunct
therapi
biofilm
base
woundcar
model
addit
analysi
wound
characterist
shift
commun
divers
requir
clarifi
wound
bacteri
load
increas
appar
use
cadexom
iodin
routin
wash
patient
octenisani
way
forward
kati
hardi
gill
abbott
jane
codd
kati
sunnock
hannah
gil
sahida
shabir
carolyn
lewi
peter
hawkey
mark
webber
public
health
england
heart
england
nh
foundat
trust
background
antisept
bodi
wash
use
part
decolonis
treatment
patient
known
colonis
mrsa
also
move
use
antisept
bodi
wash
routin
wash
patient
durat
hospit
stay
aim
object
octenisan
introduc
trust
wide
routin
wash
patient
studi
aim
review
introduct
assess
use
accept
suscept
method
usag
data
form
number
bottl
octenisan
ascertain
march
april
two
questionnair
develop
determin
staff
patient
opinion
regard
inform
receiv
antisept
usag
accept
mic
mbc
octenisan
establish
panel
mrsa
isol
pre
post
octenisan
introduct
result
usag
octenisan
vari
clinic
area
total
staff
patient
questionnair
complet
demonstr
need
improv
commun
regard
avail
correct
durat
applic
know
correct
durat
patient
staff
state
would
happi
continu
use
octenisan
skin
irrit
report
eleven
isol
mbc
number
increas
post
introduct
versu
discuss
andor
conclus
octenisan
wide
accept
staff
patient
need
improv
commun
ensur
product
use
effect
especi
light
evid
increas
decreas
suscept
fq
resist
rate
scarc
resist
first
line
drug
trickl
singapor
four
rifampicin
resist
six
multi
drug
resist
case
annual
incid
tb
equival
tb
casesyear
concern
rais
widespread
use
fq
often
urinari
respiratori
tract
condit
may
select
fq
resist
mtb
nt
awar
nt
test
enough
isol
note
fq
resist
amongst
hospit
strain
enterobacteriacea
concern
rifampicin
resist
becom
common
may
unearth
hidden
problem
fq
resist
may
precipit
emerg
xdr
tb
aim
object
measur
preval
fluoroquinolon
resist
mtbc
method
clinic
sampl
patient
submit
smear
subsequ
tb
pcr
posit
test
quinolon
resist
amplif
sequenc
quinolon
resist
determin
region
result
singl
mutat
associ
quinolon
resist
either
found
three
sampl
discuss
andor
conclus
fq
resist
rate
lower
rate
report
studi
usa
lower
rate
seen
local
mtbc
resist
first
line
drug
result
observ
mgit
pzaresist
pnca
mutat
isol
pnca
mutat
detect
mgit
pzasuscept
isol
sensit
pnca
sequenc
detect
resist
confid
interv
ci
specif
ci
identifi
mutat
previous
report
literatur
discuss
andor
conclus
amongst
isol
pnca
sequenc
good
predictor
pzaresist
use
conjunct
mgit
three
new
mutat
identifi
futur
research
includ
evalu
pyrazinamidas
activ
rpsa
pand
gene
background
nonintrins
colistin
resist
gramneg
bacilli
crgnb
associ
poor
clinic
outcom
aim
object
describ
microbiolog
clinic
outcom
patien
colonis
infect
crgnb
method
retrospect
search
microbiolog
databas
crgnb
isol
result
crgnb
isol
identifi
k
pneumonia
p
aeruginosa
baumannii
individu
patient
colistin
mic
rang
mgl
median
age
year
rang
male
eight
patient
admit
icu
two
patient
receiv
kidney
transplant
abroad
within
preced
month
six
patient
requir
mechan
ventil
hospit
stay
patient
central
venou
access
patient
activ
crgnb
infect
caus
k
pneumonia
bacteraemia
urinari
tract
infect
secondari
bacteraemia
hospit
acquir
pneumonia
intraabdomin
infect
treatment
regimen
includ
tigecyclin
meropenem
cotrimoxazol
colistin
median
durat
day
rang
clinic
microbiolog
respons
achiev
patient
five
patient
colonis
crgnb
k
pneumonia
p
aeruginosa
baumannii
site
colonis
respiratori
tract
wound
urinari
tract
patient
spontan
microbiolog
clearanc
demonstr
patient
within
median
durat
day
overal
median
hospit
stay
day
median
icu
stay
day
allcaus
mortal
discuss
andor
conclus
crgnb
infect
rel
uncommon
associ
consider
morbid
mortal
manag
mdr
xdrtb
year
experi
tertiari
referr
centr
naeem
desai
farnaz
dave
emma
mceldowney
susan
humphrey
alec
bonington
pennin
acut
hospit
trust
background
multidrug
resist
tuberculosi
mdrtb
defin
infect
mycobacterium
tuberculosi
strain
resist
least
rifampicin
isoniazid
wherea
extens
drugresist
tuberculosi
xdrtb
addit
resist
fluoroquinolon
least
one
inject
second
line
drug
amikacin
kanamycin
capreomycin
case
mdrtb
two
case
xdrtb
report
uk
patient
requir
complex
costli
antibiot
regimen
signific
toxic
outcom
remain
poor
highlight
need
clinic
experi
newer
agent
bedaquilin
aim
object
aim
present
experi
manag
mdrxdrtb
well
present
find
three
patient
manag
use
bedaquilin
result
unit
manag
thirteen
patient
mdrtb
one
patient
xdrtb
present
three
patient
receiv
six
month
bedaquilin
compassion
use
programm
part
treatment
cours
explor
challeng
two
mdrtb
case
led
bedaquilin
use
second
phase
patient
treatment
sensit
led
use
bedaquilin
outset
case
xdrtb
furthermor
discuss
signific
risk
toxic
bedaquilin
includ
prolong
qtc
interv
suggest
monitor
schedul
three
patient
improv
follow
treatment
requir
tb
treatment
date
discuss
andor
conclus
case
seri
highlight
complex
manag
resist
tb
add
experienti
evid
use
bedaquilin
prospect
multicentr
observ
studi
mecillinam
suscept
pathogen
urinari
bacteria
healthcar
network
unit
kingdom
background
mani
patient
infect
requir
intraven
antimicrobi
treatment
suitabl
receiv
antibiot
commun
opat
outpati
parenter
antimicrobi
therapi
servic
servic
includ
administr
intraven
antimicrobi
treatment
hospit
outpati
clinic
home
gener
specialist
nurs
patient
selfadminist
follow
train
uk
uncertainti
regard
servic
repres
best
valu
money
aim
object
studi
aim
estim
costeffect
differ
opat
servic
method
cost
effect
decis
analyt
model
develop
use
discret
event
simul
techniqu
model
estim
cost
outcom
use
qualiti
adjust
life
year
qali
opat
servic
simul
includ
nurs
consult
room
capac
given
popul
risk
result
short
term
infect
hospit
outpati
administr
expens
servic
provid
neglig
qali
gain
compar
servic
provid
nurs
visit
home
administr
home
specialist
nurs
estim
costeffect
servic
long
term
infect
whilst
patient
selfadministr
cheapest
option
specialist
nurs
administr
offer
qali
gain
result
combin
two
servic
costeffect
configur
discuss
andor
conclus
nurs
administr
patient
selfadministr
intraven
antimicrobi
treatment
costeffect
strategi
howev
lack
servic
capac
result
treatment
delay
greater
health
risk
increas
cost
eventu
impact
servic
costeffect
caus
organ
antimicrobi
resist
seen
asymptomat
symtomat
renal
transplant
recipi
rebecca
bamber
harriet
hugh
shafi
malik
vinod
mathrani
microbiolog
dept
univers
hospit
wale
public
health
wale
background
littl
current
uk
data
type
resist
profil
infect
urinari
pathogen
standard
approach
investig
treatment
patient
data
publish
usa
extrapol
local
popul
aim
object
detail
cultur
result
renal
transplant
outpati
symptomat
nonsymptomat
aim
guid
futur
therapi
ensur
current
sop
follow
provid
use
inform
clinician
detail
resist
profil
organ
particular
refer
potenti
impact
routin
use
cotrimoxazol
prophylaxi
method
result
initi
pilot
studi
reveal
sampl
identifi
anywher
request
form
transplant
patient
therefor
process
use
correct
sop
patient
asymptomat
despit
signific
growth
urin
sampl
spectrum
organ
found
unusu
e
coli
exampl
multidrug
resist
common
routin
popul
introduc
transplant
barcod
sticker
made
possibl
collect
far
larger
data
set
next
month
result
urin
collect
month
period
follow
sticker
introduct
analysi
organ
grown
resist
pattern
efficaci
transplant
sop
discuss
andor
conclus
result
suggest
transplant
patient
benefit
specif
sop
handl
routin
urin
antibiot
guidelin
may
need
alter
reflect
pathogen
affect
group
clindamycin
resist
rate
group
b
strep
gb
perinat
matern
sampl
east
london
hospit
underrecognis
resist
problem
background
earli
onset
neonat
group
b
streptococcu
diseas
eogb
frequent
caus
sever
infect
new
born
infant
reduc
risk
nation
guidanc
state
women
gb
detect
vagin
swabsurin
sampl
current
pregnanc
offer
intrapartum
antibiot
prophylaxi
iap
labour
antibiot
penicillinallerg
women
problemat
due
gb
resist
clindamycin
current
guidanc
state
gb
clindamycin
resist
rate
england
wale
health
protect
agenc
data
aim
object
evalu
current
gb
clindamycin
resist
rate
perinat
women
east
london
hospit
method
winpath
search
antibiogram
gb
isol
vagin
swabsmidstream
urin
sampl
msu
women
attend
hospit
matern
servic
april
april
preval
gb
clindamycin
resist
calcul
use
data
result
gb
isol
vagin
swab
msu
gb
isol
clindamycin
resist
isolatesa
resist
rate
discuss
andor
conclus
hospit
gb
clindamycin
resist
rate
doubl
state
nation
guidanc
howev
awar
among
obstetrician
low
gb
antibiogram
check
prescrib
clindamycin
iap
penicillinallerg
women
glycopeptid
antibiot
use
altern
clindamycin
resist
detect
determin
despit
state
antibiot
polici
local
clindamycin
resist
rate
gb
matern
sampl
review
inform
gb
iap
antibiot
choic
penicillinallerg
women
obstetrician
made
awar
antibiot
resist
issu
id
antimicrobi
suscept
molecular
epidemiolog
extend
spectrum
betalactamas
produc
enterobacteriacea
hamad
medic
corpor
qatar
mazen
sid
ahm
anand
deshmukh
devendra
bansal
emad
ibrahim
ali
sultan
hamad
medic
corpor
weill
cornellmedicin
qatar
background
emerg
extend
spectrum
beta
lactamas
esbl
produc
isol
import
clinic
therapeut
implic
high
preval
esblproduc
enterobacteriacea
report
literatur
variou
clinic
sampl
aim
object
present
studi
undertaken
evalu
preval
esblproduc
enterobacteriacea
well
molecular
character
antimicrobi
suscept
patient
admit
intens
care
unit
icu
hamad
medic
corpor
hmc
doha
qatar
novemb
octob
method
total
enterobacteriacea
isol
includ
studi
identif
suscept
done
phoenix
becton
dickinson
esblproduc
confirm
doubl
disk
potenti
recommend
clsi
molecular
analysi
esblproduc
perform
use
polymeras
chain
reaction
pcr
result
isol
confirm
esblproduc
sensit
meropenem
routin
suscept
assay
esbl
produc
resist
amoxicillinclavulan
acid
ceftriaxon
cefepim
among
esbl
produc
gene
preval
bla
ctxm
highest
follow
bla
shv
bla
tem
discuss
andor
conclus
present
studi
show
high
preval
esblproduc
enterobacteriacea
within
icu
facil
hmc
qatar
emphas
need
judici
use
antibiot
implement
strict
infect
control
measur
background
nation
health
servic
england
commiss
qualiti
innov
antimicrobi
resist
aim
reduc
total
antibiot
consumpt
use
broadspectrum
antibiot
secondari
care
howev
robust
baselin
antibiot
use
data
lack
hospitalis
children
aim
object
describ
explain
prescript
pattern
antibiot
within
paediatr
unit
uk
provid
baselin
antibiot
prescrib
futur
improv
use
cquin
amr
guidanc
method
point
preval
survey
pp
paediatr
unit
across
uk
standardis
studi
protocol
antimicrobi
resist
prescrib
european
children
arpec
project
use
inpati
yearsold
includ
except
neonat
result
total
children
hospitalis
day
pp
antibiot
proport
children
receiv
antibiot
show
wide
variat
district
gener
tertiari
hospit
children
prescrib
antibiot
respect
quarter
children
antibiot
therapi
receiv
either
medic
surgic
prophylaxi
parenter
administr
main
prescrib
rout
antibiot
prescript
type
hospit
gener
paediatr
unit
high
prescrib
critic
broadspectrum
antibiot
ie
carbapenem
piperacillintazobactam
discuss
andor
conclus
provid
robust
baselin
antibiot
prescrib
hospitalis
children
relat
current
nation
stewardship
effort
uk
repeat
pp
linkag
resist
data
need
part
antibiot
stewardship
strategi
tackl
issu
suboptim
antibiot
use
hospitalis
children
gramneg
bacteraemiaa
retrospect
audit
arpit
vya
dina
elzima
essam
rizkalla
univers
hospit
leicest
ketter
gener
hospit
background
gramneg
bacteraemia
gnb
associ
high
mortal
rate
administ
appropri
antibiot
treatment
promptli
affect
overal
prognosi
outcom
aim
object
retrospect
audit
aim
review
isol
investig
manag
mortal
hospit
patient
gnb
ketter
gener
hospit
england
method
retrospect
audit
cover
two
month
period
patient
gnb
exist
databas
includ
n
defin
gnb
confirm
gramneg
organ
blood
cultur
defin
mortal
associ
gnb
patient
deceas
data
collect
use
hospit
tpath
softwar
discharg
letter
hospit
haematolog
biochem
databas
patient
note
possibl
data
analys
use
spreadsheet
microsoft
excel
result
result
show
case
gnb
associ
mortal
common
empir
antibiot
choic
tazocin
monotherapi
case
averag
microbiolog
call
within
day
id
organ
day
sensit
organ
lead
antibiot
chang
case
common
organ
e
coli
urinari
tract
infect
common
presum
sourc
infect
gnb
show
high
resist
rate
amoxicillin
coamoxiclav
trimethoprim
case
urin
sampl
sent
cultur
discuss
andor
conclus
gnb
associ
high
mortal
hospit
patient
urin
sampl
cultur
sensit
must
sent
case
especi
e
coli
common
caus
organ
reaudit
month
closedloop
control
system
precis
deliveri
vancomycin
silico
proofofconcept
akash
philip
timothi
rawson
luke
moor
alison
holm
pant
georgiou
pau
herrero
imperi
colleg
london
background
wide
interand
intraindividu
pharmacokinet
pk
variabl
observ
vancomycin
therapi
develop
investig
insilico
two
close
loopsystem
precis
antimicrobi
deliveri
vancomycin
defin
pkpd
target
method
proportionalintegralderiv
pid
control
iter
learn
control
ilc
design
control
continu
intermitt
vancomycin
infus
respect
use
therapeut
drug
monitor
level
oneand
twocompart
pk
model
obtain
patient
receiv
vancomycin
use
evalu
control
variabl
weight
clearanc
ethnic
gender
age
consid
intraday
variabl
clearanc
sensor
error
simul
produc
realist
insilico
condit
pid
control
continu
vancomycin
sensor
assum
areaunderthecurv
auc
minimuminhibitoryconcentr
mic
auc
mic
defin
success
target
control
pid
control
evalu
use
twocompart
model
setpoint
ie
plasma
concentr
period
adjust
eg
hourli
order
achiev
overal
target
ilc
control
test
use
onecompart
model
sampl
time
mg
initi
dose
trough
level
setpoint
mgl
result
pid
control
achiev
setpoint
auc
mic
individu
less
hour
icl
control
simul
individu
achiev
auc
mic
individu
auc
mic
may
associ
toxic
discuss
andor
conclus
pid
ilc
control
simul
attain
requir
pkpd
target
pk
profil
obtain
within
accept
rang
observ
clinic
practic
provid
evid
support
potenti
feasibl
use
closedloop
system
antimicrobi
deliveri
carbapenemaseproduc
organ
nh
lothian
rapid
reliabl
detect
confirm
geoff
toner
kate
templeton
fiona
hamilton
clark
russel
background
carbapenemaseproduc
organ
pose
increas
clinic
threat
global
increas
resist
carbapenem
often
consid
last
line
antibiot
treatment
gramneg
infect
led
requir
rapid
robust
method
analysi
carbapenemas
activ
organ
aim
object
septemb
nh
lothian
perform
inhous
multiplex
realtim
pcr
vim
ndm
kpc
imp
carbapenemaseproduc
organ
alongsid
rapidec
carba
np
test
detect
growth
chromid
carba
smart
media
sensit
specif
assay
assess
month
period
method
review
detail
investig
isol
period
septemb
aug
includ
carbapenamaseposit
isol
carbapenemaseneg
isol
result
sensit
specif
inhous
pcr
detect
vim
ndm
kpc
imp
big
target
assess
chromogen
screen
agar
chromid
carba
smart
sensit
specif
detect
carbapenemaseproduc
organ
rapidec
carba
np
sensit
specif
two
produc
isol
two
imiproduc
isol
posit
rapidec
carba
np
characteris
armrl
colindal
discuss
andor
conclus
overal
compil
carbapenemaseproduc
organ
month
period
nh
lothian
ndm
vim
imp
kpc
imi
robust
reliabl
rapid
workflow
laboratori
detect
carbapenemaseproduc
organ
valid
use
nh
lothian
surveil
antifung
resist
pattern
oral
candida
infect
noha
seoudi
wala
belhaj
qmul
background
oral
microbiolog
investig
form
import
role
manag
orofaci
infect
patient
care
recent
public
health
england
phe
updat
oral
mucos
standard
microbiolog
investig
smi
candida
infect
one
frequent
oral
infect
requir
proper
diagnosi
optimum
manag
especi
increas
immunocompromis
popul
report
emerg
antifung
resist
therefor
studi
analys
antifung
resist
oral
candida
infect
aim
object
analys
antifung
resist
pattern
oral
candida
infect
report
one
oral
microbiolog
laboratori
dental
hospit
uk
method
data
oral
microbiolog
laboratori
report
collect
electron
retrospect
twoyear
period
subsequ
oral
candida
report
studi
sensit
pattern
analys
result
period
januari
decemb
total
oral
mucos
swab
receiv
swab
grew
yeast
yeast
isol
identifi
speci
level
suscept
test
perform
report
candida
candida
report
sensit
ambizom
itraconazol
nystatin
caspofungin
voriconazol
fluconazol
echinocandin
resist
report
nonalbican
candida
candida
glabrata
candida
krusei
candida
guilliermondii
discuss
andor
conclus
studi
highlight
candida
isol
oral
infect
remain
sensit
commonli
use
antifung
agent
howev
sensit
test
still
justifi
case
failur
treatment
immunocompromis
patient
infect
nonalbican
candida
joanna
walker
ann
mari
karcher
michael
lockhart
ben
parcel
background
present
less
one
percent
gram
posit
organ
linezolid
resist
resist
result
mutat
chromosom
gene
sinc
scottish
nation
alert
flag
newli
identifi
plasmid
mediat
transfer
mechan
via
cfr
gene
recent
optra
gene
optra
gene
encod
abc
transport
confer
resist
oxazolidinon
phenicol
identifi
three
separ
optra
mediat
linezolid
resist
enterococcu
faecali
isol
urin
sampl
nh
grampian
extrem
rare
identifi
resist
mechan
aim
object
describ
three
case
investig
risk
factor
acquir
infect
identifi
potenti
link
patient
method
review
lab
system
record
vitek
sensit
type
comparison
collat
clinic
inform
establish
whether
patient
manag
acut
episod
urinari
infect
identifi
epidemiolog
risk
factor
acquir
isol
includ
past
medic
histori
hospit
admiss
link
farm
travel
histori
includ
ireland
result
result
lab
system
search
case
histori
gp
interview
describ
discuss
andor
conclus
plasmid
mediat
mechan
consider
public
health
import
due
potenti
transfer
confer
resist
strain
speci
background
publish
literatur
resourcelimit
set
infrequ
although
urinari
tract
infect
uti
common
caus
outpati
present
antibiot
use
pointofcar
test
poct
interpret
relat
antibiot
use
antibiot
resist
aim
object
aim
assess
diagnost
accuraci
poct
role
uti
antibiot
stewardship
oneyear
retrospect
analysi
three
clinic
thailandmyanmar
border
nonpregn
adult
present
urinari
symptom
poct
urin
dipstick
microscopi
compar
cultur
signific
growth
classifi
pure
growth
singl
organ
cfuml
result
patient
femal
common
symptom
dysuria
suprapub
pain
urinari
frequenc
exclud
contamin
sampl
uti
diagnos
signific
growth
cultur
escherichia
coli
produc
extendedspectrum
esbl
posit
urin
dipstick
leucocyt
esteras
andor
nitrat
posit
compar
posit
microscopi
white
blood
cell
bacteria
epitheli
cell
higher
sensit
vs
lower
specif
vs
respect
combin
poct
result
best
sensit
specif
nearli
one
ten
patient
receiv
antimicrobi
organ
fulli
sensit
discuss
andor
conclus
one
rapid
costeffect
poct
inaccur
use
alon
healthcar
worker
imped
antibiot
stewardship
high
esbl
set
appropri
prescrib
improv
concurr
use
concord
result
urin
dipstick
microscopi
develop
antimicrobi
stewardship
peer
review
system
east
england
pharmaci
infect
network
emma
cramp
hinchingbrook
nh
hospit
background
number
uk
nation
guidelin
support
antimicrobi
stewardship
pulish
recent
divers
resourc
given
produc
differ
expert
group
differ
time
point
make
challeng
team
establish
guidanc
follow
respons
recommend
nation
resourc
review
collat
one
complet
am
tool
provid
clariti
enabl
recommend
follow
intent
use
tool
enabl
peer
review
am
activ
acut
nh
trust
east
england
region
aim
object
develop
tool
facilit
peer
review
antimicrobi
stewardship
activ
acut
hospit
eoe
method
guidanc
nation
document
relat
antimicrobi
stewardship
review
use
formul
draft
tool
tool
circul
eoe
region
antimicrobi
pharmacist
network
comment
draft
tool
use
part
pilot
peer
review
visit
two
acut
hospit
result
feedback
receiv
particip
pilot
peer
review
inform
public
final
peer
review
tool
tool
abl
identifi
gap
antimicrobi
stewardship
practic
site
discuss
andor
conclus
next
stage
implement
adopt
peer
review
process
use
tool
across
east
england
region
hope
system
provid
uniqu
systemat
review
am
activ
lead
recommend
improv
share
best
practic
throughout
region
surgeon
come
manag
cutan
abscess
know
isa
incis
swab
antibiot
stewardship
richard
pilkington
jonathan
moor
luke
banburi
health
educ
north
east
dept
microbiolog
gateshead
nh
trust
background
cutan
abscess
commonli
encount
clinic
practic
convent
wisdom
dictat
incis
drainag
id
treatment
choic
role
antibiot
microbiolog
sampl
time
drainag
less
well
establish
hospit
success
pathway
identifi
manag
patient
requir
surgic
intervent
aim
object
evalu
microbiolog
sampl
sent
use
result
well
consid
therapi
patient
pathway
receiv
intent
improv
pathway
antibiot
stewardship
method
case
review
case
identifi
swab
taken
antibiot
prescrib
analys
cultur
result
result
carri
perian
abdomin
axillabreast
lower
limb
swab
taken
case
sampl
cultur
neg
expect
gram
neg
anaerob
flora
frequent
isol
form
perian
swab
gram
posit
flora
site
vari
antibiot
practic
note
discuss
andor
conclus
mainstay
treatment
cutan
abscess
surgic
hospit
pathway
work
well
identifi
patient
requir
conduct
surgeri
howev
present
sampl
sent
major
case
antibiot
practic
variabl
propos
pathway
develop
provid
select
framework
case
microbiolog
work
like
benefici
improv
antibiot
stewardship
make
best
use
preciou
resourc
id
implement
antimicrobi
stewardship
train
mentorship
programm
encourag
key
nurs
led
antibiot
convers
franc
kerr
paula
smith
david
watson
steve
mccormick
nh
lanarkshir
background
antimicrobi
resist
recognis
issu
nurs
patient
contact
health
profession
key
posit
influenc
safe
effect
prescrib
administr
antibiot
aim
object
implement
ward
base
antimicrobi
stewardship
programm
nurs
highlight
key
opportun
intervent
encourag
antibiot
convers
act
effect
safeti
net
method
ward
buzz
session
ran
week
may
june
materi
train
test
separ
train
focus
antibiot
polici
key
opportun
initi
antibiot
convers
prepost
train
questionnair
use
assess
impact
train
nurs
confid
level
pair
ttest
use
assess
impact
result
nurs
train
prepost
questionnair
return
n
nurs
said
chang
practis
would
recommend
train
colleagu
statist
signific
increas
confid
initi
convers
p
observ
pretrain
nurs
convers
per
week
posttrain
convers
statist
signific
increas
confid
assess
vancomycin
level
p
demonstr
signific
chang
confid
gentamicin
seen
p
overal
nurs
confid
queri
antibiot
prescrib
clear
safeti
benefit
patient
discuss
andor
conclus
although
sampl
size
small
nurs
show
increas
awar
antibiot
polici
increas
confid
use
result
increas
nurs
initi
antibiot
convers
nurs
feedback
posit
felt
strongli
train
would
benefit
colleagu
action
plan
formul
ensur
rollout
nurs
staff
european
antibiot
awar
day
eaad
activ
across
scotland
view
experi
commun
pharmaci
team
antonella
tonna
jacqui
sneddon
anita
weidmann
derek
stewart
robert
gordon
univers
school
pharmaci
life
scienc
scottish
medicin
consortium
background
eaad
european
wide
public
health
initi
encouarg
respons
use
antibiot
amongst
gener
public
commun
pharmaci
team
across
scotland
support
partak
eaad
activ
coordin
scottish
antimicrobi
prescrib
group
sapg
includ
use
commun
pharmaci
version
self
help
guid
publish
royal
colleg
gener
practition
distribut
commun
pharmaci
aim
object
explor
view
experi
commun
pharmaci
team
across
scotland
use
self
help
guid
method
qualit
semistructur
indepth
telephon
facetofac
interview
undertaken
purpos
sampl
commun
pharmaci
team
member
includ
pharmacist
dispens
interview
schedul
develop
valid
pilot
interview
audiorecord
transcrib
verbatim
data
analys
themat
use
framework
approach
result
twenti
seven
employe
consent
interview
twenti
particip
pharmacist
nineteen
employe
work
mainli
larg
chain
across
five
region
practis
five
year
interviewe
thought
pharmaci
ideal
place
engag
patient
antimicrobi
stewardship
initi
need
multi
prong
approach
although
tool
perceiv
use
awar
exist
experi
use
lack
train
around
antimicrobi
stewardship
also
identifi
discuss
andor
conclus
recommend
eaad
tool
materi
need
effect
dissemin
pharmacist
requir
opportun
specialis
train
antimicrobi
stewardship
role
commun
pharmacist
deliv
antimicrobi
resist
strategi
gill
hawksworth
phil
howard
jake
mill
bahareh
yazdani
sophi
devin
emili
clifford
univers
huddersfield
leed
teach
hospit
nh
trust
leed
background
studi
analys
approach
commun
pharmaci
current
undertak
adher
depart
health
antimicrobi
resist
strategi
aim
object
determin
deliveri
commun
pharmacist
antimicrobi
resist
strategi
pharmacist
view
challeng
gp
antibiot
prescrib
point
care
test
earli
detect
infect
method
studi
requir
receiv
ethic
approv
follow
consent
questionnair
sent
januari
particip
commun
pharmacist
across
calderdal
kirkle
result
questionnair
receiv
pharmacist
awar
local
antibiot
guidelin
monitor
local
antibiot
prescrib
gp
wherea
never
ask
patient
antibiot
qualit
data
studi
show
pharmacist
thought
question
sensit
would
discuss
written
prescript
antibiot
pharmacist
alway
check
allergi
explain
dose
explain
complet
cours
explain
avoid
share
antibiot
support
point
care
test
expans
vaccin
programm
emphasi
hand
wash
discuss
andor
conclus
potenti
practic
improv
commun
pharmacist
includ
indic
antibiot
prescript
checklist
includ
allergi
patient
counsel
avoid
share
gener
hygien
patient
selfhelp
guid
studi
also
suggest
diagnost
servic
someth
commun
pharmacist
would
develop
may
show
implement
antimicrobi
strategi
patient
view
commun
pharmacist
deliv
antimicrobi
resist
strategi
gill
hawksworth
phil
howard
jake
mill
bahareh
yazdani
sophi
devin
emili
clifford
univers
huddersfield
leed
teach
hospit
nh
trust
leed
background
studi
analys
patient
view
effect
commun
pharmacist
deliv
antimicrobi
resist
strategi
aim
object
determin
view
specif
member
public
indic
antibiot
prescript
establish
patient
view
antimicrobi
resist
import
adher
use
left
antibiot
investig
patient
view
trust
healthcar
profession
give
advic
antibiot
view
nh
treat
infect
leaflet
method
studi
receiv
ethic
approv
consent
pharmaci
allow
data
collect
patient
obtain
prescript
antibiot
januari
patient
receiv
questionnair
particip
inform
leaflet
nh
treat
infect
leaflet
result
questionnair
patient
saw
commun
pharmacist
gp
coldflu
stop
antibiot
complet
cours
felt
better
side
effect
flush
leftov
toilet
one
hundr
patient
support
indic
prescript
eg
hiv
chlamydia
chang
mind
say
knew
antimicrobi
resist
via
media
howev
patient
trust
sourc
nh
selfhelp
guid
favour
support
commun
pharmaci
access
record
discuss
andor
conclus
check
list
commun
pharmaci
antibiot
counsel
point
would
improv
adher
antimicrobi
strategi
ensur
relev
inform
trust
sourc
indic
antibiot
prescript
patient
discret
would
help
improv
antibiot
monitor
counsel
background
june
follow
secondari
care
reorganis
nh
greater
glasgow
clyde
nhsggc
infect
consult
servic
previous
provid
four
separ
hospit
site
amalgam
move
new
bed
queen
elizabeth
univers
hospit
aim
object
consult
offer
wardbas
infect
educ
promot
prudent
antimicrobi
prescrib
support
clinic
colleagu
optimis
infect
investig
manag
support
wider
antimicrobi
stewardship
agenda
nhsggc
combin
persuas
restrict
strategi
promot
safe
effect
prudent
antimicrobi
use
method
background
rrna
pcr
pcr
utilis
clinic
microbiolog
identifi
organ
cultur
neg
clinic
specimen
potenti
optimis
empir
antimicrobi
manag
select
critic
specimen
refer
uk
laboratori
pcr
casebycas
basi
review
local
cultur
result
method
investig
pcr
influenc
antimicrobi
manag
one
year
period
conduct
retrospect
review
specimen
sent
pcr
specimen
type
result
turnaround
time
tat
clinic
impact
posit
result
evalu
result
seventyeight
specimen
sent
patient
averag
tat
five
day
rang
larg
proport
neurosurg
patient
includ
csf
bone
flap
intracrani
materi
overal
posit
result
receiv
specimen
patient
treatment
inform
avail
deescal
narrow
spectrum
agent
upon
receipt
posit
pcr
possibl
five
patient
specimen
sent
dna
detect
treatment
inform
avail
two
patient
antimicrobi
discontinu
upon
receipt
neg
result
discuss
andor
conclus
rrna
pcr
role
antimicrobi
stewardship
complex
infect
requir
lengthi
treatment
cours
wherebi
provid
evid
presenc
microbi
dna
may
support
deescal
decis
absenc
microbi
dna
may
support
decis
discontinu
empir
treatment
select
patient
younger
gener
viewscommun
pharmacist
deliv
antimicrobi
resist
strategi
gill
hawksworth
phil
howard
jake
mill
bahareh
yazdani
sophi
devin
emili
clifford
univers
huddersfield
leed
teach
hospit
nh
trust
leed
background
studi
determin
univers
student
current
understand
antimicrobi
resist
issu
relat
work
commun
pharmacist
implement
nh
england
antimicrobi
resist
strategi
aim
object
determin
student
view
reason
infect
prescript
import
handwash
knowledg
antimicrobi
resist
import
adher
use
left
medicin
extent
trust
health
care
profession
advis
antibiot
use
method
studi
receiv
ethic
approv
questionnair
hand
univers
huddersfield
student
stand
promot
awar
antimicrobi
resist
antibiot
awar
day
novemb
result
questionnair
n
student
miss
andor
stop
antibiot
cours
end
n
correctli
identifi
antibiot
sole
effect
bacteri
infect
chisquar
test
determin
healthcareappli
scienc
student
like
correctli
identifi
show
statist
signific
result
p
small
effect
phi
coldflu
symptom
n
student
saw
pharmacist
gp
howev
n
support
caus
infect
prescript
feel
uncomfort
person
condit
chlamydia
hiv
thrush
handwash
import
n
use
good
hand
wash
techniqu
discuss
andor
conclus
student
knowledg
antimicrobi
resist
need
improv
mani
student
take
antibiot
correctli
commun
pharmacist
could
increas
complianc
antibiot
use
counsel
signpost
inform
websit
provis
leaflet
hand
wash
techniqu
howev
mani
student
unwil
see
pharmacist
gp
id
impact
pharmacyl
stewardship
round
london
teach
hospit
laura
whitney
ghadeer
muqbil
matthew
laundi
st
georg
univers
hospit
nh
foundat
trust
background
requir
reduc
hospitalacquir
clostridium
difficil
infect
cdi
year
began
case
week
significantli
trajectori
root
caus
analys
rca
complet
alongsid
review
wardbas
antibiot
prescrib
identifi
scope
optimis
prescrib
particularli
treatment
review
aim
object
intervent
requir
reduc
hacdi
improv
stewardship
rais
stewardship
pharmaci
agenda
provid
addit
junior
pharmacist
supervis
extern
scrutini
prescrib
increas
document
antimicrobi
review
improv
document
relat
stewardship
pharmacist
method
may
educ
stewardship
recent
rca
provid
pharmacist
senior
pharmacist
task
perform
monthli
ward
stewardship
visit
support
educ
referr
complex
case
stewardship
mdt
activ
review
collat
discuss
pharmaci
director
meet
approach
support
comprehens
stewardship
strategi
within
trust
result
intervent
significantli
increas
number
stewardship
encount
patient
review
monthli
pharmaci
mdt
pharmacistl
round
lower
intervent
rate
made
differ
intervent
type
commonli
improv
prescript
document
dose
adjust
similar
rate
iv
po
switch
cdi
rate
significantli
reduc
remain
trajectori
document
clinic
review
increas
discuss
andor
conclus
round
posit
contribut
stewardship
within
trust
work
focu
understand
clinic
variat
stewardship
round
number
patient
review
intervent
rate
background
slow
implement
electron
prescrib
medicin
administr
epma
identifi
barrier
stewardship
uk
aim
object
identifi
electron
prescrib
facilit
stewardship
larg
london
teach
hospit
method
epma
introduc
sequenti
trust
first
paediatr
cardiolog
neurosci
use
cerner
system
kansa
us
delay
role
lead
epma
use
alongsid
paper
medic
record
year
offer
us
uniqu
opportun
analys
effect
implement
stewardship
metric
activ
result
report
effect
implement
epma
adher
uk
antimicrobi
stewardship
guidelin
start
smart
focu
complianc
trust
guidelin
polici
describ
effect
mdt
stewardship
round
use
protect
antimicrobi
audit
feedback
programm
within
trust
also
discuss
stewardship
enabl
built
system
identifi
futur
work
requir
improv
util
system
discuss
andor
conclus
implement
epma
signific
affect
stewardship
activ
within
hospit
work
requir
optimis
use
investig
util
icnet
ng
clinic
surveil
softwar
record
intervent
made
hospit
antimicrobi
stewardship
wardround
ann
duguid
edward
jame
nh
border
background
benefit
multidisciplinari
wardround
promot
good
antimicrobi
stewardship
previous
describ
antimicrobi
stewardship
am
wardround
requir
access
current
data
patient
review
secur
system
record
activ
futur
report
regard
use
icnet
ng
system
surveil
hospit
infect
control
prevent
team
well
establish
aim
object
studi
investig
potenti
extend
use
system
hospit
am
wardround
method
data
patient
refer
am
wardround
gener
hospit
record
use
icnet
ng
live
stage
system
reason
referr
classifi
one
three
categori
alert
antimicrobi
aminoglycosid
cours
clinic
pharmacist
request
outcom
am
wardround
classifi
one
five
categori
continu
chang
stop
iv
oral
switch
referr
outpati
antibiot
therapi
opat
system
qualit
compar
previou
paperbas
method
user
result
data
patient
refer
am
ward
round
period
month
review
user
experi
use
icnet
softwar
suggest
benefit
electron
system
term
access
relev
patient
data
eas
activ
report
discuss
andor
conclus
icnet
ng
clinic
surveil
softwar
use
patient
monitor
record
tool
am
wardround
evalu
prescrib
carbapenem
piperacillin
tazobactam
acut
hospit
nh
scotland
jacquelin
sneddon
alison
cockburn
abdulrhman
mohana
robson
alex
mullen
marion
benni
william
malcolm
r
andrew
seaton
healthcar
improv
scotland
nh
lothian
univers
strathclyd
nh
nation
servic
scotland
nh
greater
glasgow
clyde
background
guidanc
scottish
antimicrobi
prescrib
group
use
carbapenem
piperacillintazobactam
piptaz
implement
incorpor
local
guidanc
aim
object
aim
establish
extent
local
guidanc
translat
clinic
practic
method
bespok
point
preval
studi
pp
perform
acut
hospit
octob
use
valid
webbas
tool
determin
whether
prescrib
compli
local
guidanc
anonymis
data
patient
prescrib
antibiot
collect
input
pp
websit
local
report
gener
data
board
aggreg
creat
nation
report
result
pp
complet
health
board
prescript
analys
result
show
complianc
prescrib
polici
use
meropenem
frequent
use
carbapenem
high
complianc
vari
consider
piptaz
document
indic
use
record
meropenem
prescript
less
well
document
piptaz
use
document
review
stop
date
meropenem
piptaz
vari
greatli
gener
low
boardlevel
data
allow
identif
board
high
complianc
measur
share
good
practic
discuss
andor
conclus
studi
demonstr
variat
practic
across
scotland
second
stage
improv
programm
optimis
use
meropenem
piptaz
qualit
work
ongo
evalu
clinician
behaviour
use
antibiot
inform
nation
improv
plan
id
develop
pharmaceut
care
part
antimicrobi
stewardship
intraven
oral
switch
ivo
wardround
alison
cockburn
esperanza
palenzuela
jenni
carson
nh
lothian
background
ivo
wardround
implement
nh
lothian
acut
hospit
mean
improv
antimicrobi
stewardship
contribut
antimicrobi
pharmacist
wardround
achiev
improv
antimicrobi
prescrib
formal
assess
aim
object
aim
studi
assess
effect
antimicrobi
pharmacist
contribut
achiev
improv
antimicrobi
stewardship
part
ivo
wardround
programm
nh
lothian
method
pharmaceut
care
intervent
record
antimicrobi
pharmacist
eight
ivo
round
intervent
review
nh
lothian
antimicrobi
team
amt
risk
assess
possibl
advers
outcom
patient
result
feedback
medic
staff
part
antimicrobi
stewardship
educ
programm
help
improv
safe
antimicrobi
prescrib
result
total
patient
review
eight
ivo
round
addit
intervent
referr
medic
staff
made
pharmacist
major
pharmaceut
care
intervent
assess
moder
high
risk
possibl
advers
patient
outcom
intervent
use
inform
antimicrobi
stewardship
educ
programm
deliv
ward
ivo
studi
undertaken
discuss
andor
conclus
document
assess
pharmaceut
care
intervent
ivo
wardround
novel
approach
improv
antimicrobi
stewardship
medic
staff
review
antimicrobi
pharmacist
intervent
subsequ
develop
educ
programm
junior
medic
staff
antimicrobi
stewardship
facilit
achiev
improv
antimicrobi
prescrib
antimicrobi
stewardship
assess
knowledg
attitud
percept
futur
prescrib
moham
altalib
eben
jone
martin
llewelyn
brighton
sussex
univers
hospit
trust
brighton
sussex
medic
school
background
antimicrobi
resist
recognis
major
threat
global
health
inappropri
prescrib
identifi
key
factor
promot
resist
threat
postantibiot
era
loom
next
gener
doctor
forefront
battl
antimicrobi
resist
aim
object
sought
explor
knowledg
attitud
percept
among
fourth
year
medic
student
brighton
sussex
medic
school
uk
regard
antimicrobi
stewardship
method
distribut
knowledg
attitud
percept
survey
fourth
year
medic
student
complet
formal
infecti
diseas
modul
survey
complet
teach
session
form
basi
discuss
result
total
respond
five
separ
session
april
march
student
familiar
term
antimicrobi
stewardship
student
strongli
agre
antibiot
overus
uk
resist
problem
uk
neutral
regard
resist
problem
hospit
felt
confid
prescrib
antibiot
specif
area
weak
includ
deescal
antibiot
dose
transit
iv
oral
antibiot
well
appropri
prescrib
context
known
resist
discuss
andor
conclus
find
suggest
student
perceiv
resist
nationalintern
problem
rather
local
problem
futur
prescrib
lack
knowledg
understand
antimicrobi
stewardship
requir
counter
spread
resist
studi
requir
clarifi
generalisabilti
find
guid
futur
medic
school
curricula
audit
assess
influenc
procalcitonin
patient
manag
provid
cover
procalcitonin
test
chandani
mendi
ramasundara
kordo
saeed
bruce
wake
background
bacteri
sepsi
major
cours
morbid
mortal
procalcitonin
pct
ia
use
guid
clinician
take
correct
decis
antibiot
prescrib
improv
patient
outcom
reduc
emerg
resist
health
care
cost
aim
object
assess
indic
earli
provis
pct
result
influenc
patient
manag
outcom
method
detail
pct
episod
collect
patient
admit
basingstok
north
hampshir
hospit
bnhh
patient
follow
prospect
day
assess
outcom
result
major
patient
year
male
main
indic
pct
support
diagnosi
exclus
bacteri
infect
assess
respons
treatment
pct
done
earlier
stop
antibiot
cours
alreadi
start
episod
clinician
continu
antibiot
episod
antibiot
withheld
stop
deescal
episod
two
patient
start
antibiot
die
improv
patient
die
result
infect
deescal
patient
improv
pct
episod
impact
patient
manag
accord
bnhh
micro
guid
pct
result
interpret
criteria
discuss
andor
conclus
higher
percentag
pct
episod
impact
patient
manag
major
patient
improv
within
day
earli
regular
provis
pct
result
help
clinician
take
appropri
decis
regard
antibiot
prescrib
wound
infect
incis
skin
soft
tissu
oper
common
incid
reduc
use
antibiot
surgic
prophylaxi
use
inappropri
detriment
carri
audit
area
provid
indic
qualiti
antibiot
prescrib
practic
would
highlight
area
potenti
improv
new
audit
follow
introduct
protocol
neurosurg
spinal
surgeri
aim
object
studi
qualiti
adher
hospit
protocol
antimicrobi
prophylaxi
explor
reason
nonadher
promot
good
record
keep
awar
good
prescrib
practic
object
evalu
antimicrobi
prescrib
qualiti
suitabl
ongo
prescrib
feedback
method
standard
compar
audit
newcastl
upon
tyne
neurosurg
spinal
surgeri
prophylaxi
protocol
develop
base
current
best
evid
audit
conduct
period
data
obtain
theatr
list
audit
data
obtain
case
note
review
erecord
patholog
softwar
system
result
choic
antimicrobi
prophylaxi
per
guidelin
patient
receiv
antibiot
right
time
small
proport
patient
receiv
inappropri
addit
dose
antibiot
discuss
andor
conclus
inappropri
administr
antibiot
increas
preval
antibioticresist
bacteria
predispos
patient
infect
organ
like
c
difficil
hope
find
audit
emphas
import
adher
trust
antimicrobi
prophylaxi
protocol
feedback
audit
might
encourag
surgeon
undertak
data
collect
roll
programm
basi
help
evalu
improv
prophylact
antibiot
prescript
emphasis
import
adher
time
antibiot
instil
evalu
role
antimicrobi
manag
team
nurs
achiev
improv
antimicrobi
stewardship
background
within
antimicrobi
manag
team
amt
nh
lothian
nurs
appoint
perform
clinic
audit
antimicrobi
use
educ
nurs
prescrib
new
antimicrobi
prescrib
guidelin
implement
within
board
april
reduc
broad
spectrum
antibiot
usag
reduc
clostridium
difficil
infect
cdi
routin
audit
cycl
issu
inaccuraci
gentamicin
prescrib
procedur
identifi
audit
undertaken
amt
nurs
investig
situat
aim
object
aim
studi
evalu
role
amt
nurs
achiev
improv
antimicrobi
stewardship
relat
gentamicin
administr
prescrib
method
antibiot
prescrib
medic
surgic
ward
audit
assess
adher
antibiot
prescrib
guidelin
procedur
gentamicin
prescrib
educ
subsequ
provid
nurs
staff
gentamicin
administr
prescrib
addit
gentamicin
dose
wheel
creat
implement
assist
nurs
calcul
blood
sampl
time
staff
survey
audit
perform
result
audit
show
prescript
contain
error
involv
document
sampl
administr
gentamicin
follow
implement
educ
programm
error
rate
drop
improv
nurs
level
knowledg
regard
gentamicin
prescrib
administr
also
achiev
discuss
andor
conclus
studi
show
amt
nurs
effect
role
within
amt
assist
implement
polici
guidelin
monitor
practic
enabl
knowledg
share
provid
educ
antimicrobi
stewardship
background
support
reduct
clostridium
difficil
infect
cdi
scottish
antimicrobi
prescrib
group
recommend
nh
board
scotland
restrict
antibiot
associ
high
risk
cdi
june
nh
grampian
chang
polici
antibiot
prophylaxi
orthopaed
surgeri
includ
flucloxacillin
gentamicin
recent
studi
found
increas
postop
acut
kidney
injuri
aki
follow
similar
chang
aim
object
use
individu
level
link
data
examin
rate
postop
aki
polici
chang
nh
grampian
patient
underw
orthopaed
surgic
procedur
prophylaxi
recommend
select
case
link
local
creatinin
data
nation
patient
level
hospit
activ
commun
prescrib
scottish
renal
registri
data
segment
regress
analys
interrupt
time
seri
use
evalu
chang
level
trend
aki
rate
associ
intervent
estim
effect
size
result
signific
increas
aki
rate
trend
follow
polici
chang
ci
p
trauma
patient
equat
increas
case
procedur
month
rel
intervent
effect
month
ci
signific
chang
aki
rate
among
elect
patient
discuss
andor
conclus
found
chang
orthopaed
antibiot
prophylaxi
polici
nh
grampian
associ
increas
postop
aki
consist
observ
board
support
new
recommend
away
polici
made
sapg
key
featur
epic
intervent
report
modul
ivent
allow
pharmacist
commun
intervent
recommend
made
investig
use
ivent
specif
document
am
intervent
aim
object
investig
type
am
intervent
classifi
type
clinic
impact
intervent
assess
whether
differ
am
intervent
made
clinic
area
pharmacist
grade
method
report
gener
collat
am
ivent
record
pharmacist
one
year
period
peerreview
group
compris
antimicrobi
pharmacist
consult
microbiologist
consult
decid
suitabl
categori
data
analysi
ivent
sort
accord
categori
assign
valu
potenti
clinic
impact
group
also
review
random
sampl
intervent
assess
agreement
categori
sever
whether
intervent
made
clinic
appropri
categori
intervent
includ
administr
advic
dose
optimis
cours
length
optimis
patient
counsel
therapeut
drug
monitor
tdm
choic
agent
advic
vaccin
referr
iv
oral
switch
suppli
issu
stop
unnecessari
prescript
result
preliminari
data
onemonth
period
april
demonstr
intervent
made
common
am
intervent
antimicrobi
requir
tdm
least
common
patient
counsel
iv
oral
switch
intervent
made
intens
care
ward
fewest
neurolog
ward
number
intervent
made
increas
grade
pharmacist
intervent
medium
clinic
impact
id
personalis
feedback
antibiot
prescrib
data
primari
care
team
jacquelin
sneddon
william
malcolm
marion
benni
helen
storkey
terri
mclaughlin
jame
smith
chari
marwick
bruce
guthri
sean
macbridestewart
dilip
nathwani
healthcar
improv
scotland
nh
nation
servic
scotland
nh
nation
servic
scotland
nh
taysid
univers
dunde
nh
greater
glasgow
clyde
background
scotland
feedback
prescrib
data
prove
success
gp
high
risk
medicin
dental
practition
antimicrobi
similar
approach
design
complement
intervent
reduc
unnecessari
antibiot
use
gp
aim
object
studi
aim
establish
programm
provid
gp
practic
quarterli
report
antibiot
prescrib
data
along
benchmark
inform
method
studi
steer
group
establish
fund
secur
creation
data
report
pilot
phase
involv
practic
four
health
board
area
randomli
select
use
stratifi
sampl
frame
receiv
report
detail
practic
obtain
autom
email
messag
set
result
practic
receiv
quarterli
report
contain
rate
antibiot
prescrib
compar
local
nation
benchmark
along
suggest
action
detail
support
resourc
first
report
focuss
total
antibiot
use
includ
key
messag
improv
use
antibiot
respiratori
tract
infect
report
email
directli
gp
practic
along
letter
chief
medic
offic
next
three
report
focu
urinari
tract
infect
risk
clostridium
difficil
infect
skin
soft
tissu
infect
follow
time
seri
analysi
chang
prescrib
rate
intervent
practic
compar
control
practic
plan
implement
intervent
across
gp
practic
scotland
discuss
andor
conclus
autom
feedback
intervent
attract
addit
stewardship
programm
support
good
evid
implement
nation
rel
low
cost
nurs
influenc
antimicrobi
stewardship
commun
hospit
jo
mcewen
chari
marwick
dilip
nathwani
nh
taysid
dunde
univers
background
multidisciplinari
antimicrobi
stewardship
programm
essenti
optimis
antimicrobi
use
minimis
associ
collater
damag
mani
antimicrobi
stewardship
initi
primarili
target
doctor
pharmacist
howev
potenti
contribut
nurs
could
make
area
yet
fulli
explor
aim
object
primari
aim
initi
enhanc
nurs
knowledg
around
antimicrobi
stewardship
focus
key
area
nurs
influenc
secondari
focu
encourag
appropri
urin
sampl
older
adult
popul
indwel
urinari
cathet
promot
scottish
antimicrobi
prescrib
group
uti
manag
resourc
method
educ
programm
deliv
commun
hospit
nurs
team
nh
taysid
month
period
questionnair
issu
pre
post
intervent
assess
impact
intervent
result
comparison
preintervent
postintervent
questionnair
demonstr
improv
nurs
knowledg
relat
antimicrobi
stewardship
infect
manag
statist
signific
six
fourteen
question
p
statist
signific
reduct
urin
sampl
submit
cultur
intervent
mean
per
obd
per
month
differ
ttest
p
discuss
andor
conclus
nurs
constant
deliveri
patient
care
therefor
profess
ideal
place
enhanc
antimicrobi
manag
within
multidisciplinari
team
educ
awar
nurs
significantli
impact
infect
outcom
contribut
optimis
antimicrobi
treatment
whilst
deliv
high
qualiti
safe
patient
focuss
care
background
reduct
use
broadspectrum
antibiot
import
prioriti
antimicrobi
stewardship
nh
lothian
slower
reduc
use
one
factor
may
recommend
prolong
cours
broadspectrum
antibiot
secondari
care
aim
object
studi
look
prescrib
data
identifi
whether
extend
cours
broadspectrum
antibiot
signific
contributori
factor
overal
use
method
prescrib
inform
system
scotland
provid
six
year
time
seri
analysi
compar
nh
lothian
nh
board
overal
antibiot
broadspectum
use
prescrib
inform
system
identifi
prescrib
prolong
cours
broadspectrum
antibiot
current
lothian
joint
formulari
ljf
clinic
indic
review
expect
result
preval
calcul
compar
current
use
amount
antibiot
prescrib
longer
durat
ljf
recommend
analys
result
nh
lothian
remain
lowest
total
user
antibiot
primari
care
much
slower
reduct
broadspectrum
use
scottish
averag
prescript
longer
day
recommend
longest
durat
ljf
major
prescript
day
coamoxiclav
prescript
longer
day
discuss
andor
conclus
analysi
pi
data
confirm
prescrib
prolong
cours
broadspectrum
antibiot
signific
level
prescrib
durat
coamoxiclav
mostli
line
ljf
expect
level
clinic
condit
indic
treatment
antimicrobi
stewardship
ward
round
make
differ
hala
kandil
hala
kandil
tejal
vaghela
west
hertfordshir
hospit
nh
trust
background
antibiot
stewardship
ward
round
key
promot
appropri
antibiot
use
aim
object
aim
studi
evalu
impact
intervent
made
antimicrobi
stewardship
team
ast
ward
round
antimicrobi
consumpt
clinic
outcom
larg
district
hospit
method
twice
weekli
antibiot
stewardship
ward
round
asw
introduc
april
inform
patient
antibiot
collect
pharmaci
record
outcom
ast
intervent
two
month
period
analys
monthli
antibiot
consumpt
per
admiss
monitor
complianc
ng
qualiti
standard
statement
audit
data
clinic
outcom
readmiss
within
day
also
collect
result
review
cours
antibiot
commonli
prescrib
antibiot
period
tazocin
follow
augmentin
approxim
prescrib
antibiot
compliant
trust
antimicrobi
guidelin
ast
stop
antibiot
cours
specifi
stop
date
optimis
dose
switch
po
deescal
escal
one
previou
intervent
recommend
cours
antibiot
cours
audit
met
ng
qs
applic
case
total
antibiot
tazocin
consumpt
significantli
reduc
baselin
admiss
respect
prior
intervent
admiss
post
intervent
discuss
andor
conclus
asw
prove
effect
optimis
antibiot
therapi
significantli
reduc
antibiot
consumpt
short
period
without
compromis
patient
care
amikacin
concentr
target
rang
mycobacteria
infect
tamara
cairney
alison
thomson
lock
xu
bao
fiona
robb
univers
strathclyd
nh
greater
glasgow
clyde
background
guidelin
amikacin
use
multidrug
resist
mycobacteri
infect
recommend
mgkg
daili
od
mgkg
thrice
weekli
tw
aim
object
determin
whether
guidelin
dose
achiev
peak
od
mgl
tw
trough
mgl
method
follow
data
extract
patient
mycobacteri
infect
least
one
amikacin
dose
peak
concentr
age
weight
height
creatinin
concentr
amikacin
dose
concentr
time
map
bayesian
pharmacokinet
analysi
provid
individu
estim
amikacin
volum
distribut
v
clearanc
cl
use
predict
end
infus
h
trough
amikacin
concentr
use
guidelin
dosag
regimen
result
data
avail
patient
male
receiv
od
tw
dose
age
rang
year
weight
kg
estim
creatinin
clearanc
ml
min
dose
rang
od
mg
tw
cl
v
estim
rang
lh
l
respect
use
paramet
od
dosag
regimen
predict
achiev
concentr
within
target
peak
tw
regimen
within
target
peak
predict
predos
trough
mgl
od
dose
tw
dose
h
post
dose
high
trough
observ
patient
poor
renal
function
discuss
andor
conclus
amikacin
guidelin
mycobacteri
infect
achiev
high
peak
concentr
patient
renal
impair
requir
longer
dosag
interv
rapid
project
clinic
decis
tool
support
antibiot
stewardship
acut
respiratori
infect
background
antimicrobi
resist
major
public
health
risk
excess
antibiot
use
recognis
major
driver
resist
uk
antimicrobi
stewardship
guidanc
start
smart
focu
encourag
clinician
undertak
activ
review
revis
prescrib
antibiot
hour
initi
aim
object
develop
pilot
intervent
support
review
revis
prescrib
decis
acut
respiratori
infect
ari
remain
commonest
indic
antibiot
method
option
simpl
evidencebas
rapid
reduc
unnecessari
antibiot
prescrib
dyspnoea
decis
tool
develop
iter
review
refin
multidisciplinari
work
group
stop
criteria
incorpor
clinic
observ
biomark
radiolog
antibiot
prescrib
review
baselin
day
admiss
unselect
patient
day
day
intervent
clinic
team
respons
appli
defin
stop
criteria
result
across
timepoint
patient
prescrib
ari
antibiot
criteria
stop
antibiot
hr
defin
normal
chest
radiograph
averag
news
score
crp
antibiot
prescrib
unnecessarili
patient
preintervent
phase
intervent
phase
prescript
stop
accord
rapid
criteria
one
fifth
actual
stop
discuss
andor
conclus
even
good
stakehold
engag
use
standalon
clinic
decis
tool
reduc
antibiot
prescrib
acut
medic
set
safe
reduc
unnecessari
antibiot
prescrib
like
requir
resourc
intens
intervent
dedic
stewardship
wardround
background
inappropri
prescrib
matter
salient
concern
china
recruit
cirrhot
patient
primari
spontan
bacteri
periton
sbp
accord
use
administr
data
tertiari
hospit
januari
decemb
asp
integr
nosocomi
infect
control
nic
implement
institut
time
ascit
polymorphonuclear
leukocyt
pmn
count
cellsmm
clinic
laboratori
data
suggest
secondari
periton
infect
antimicrobi
use
week
treatment
sbp
hepatocellular
carcinoma
discharg
day
treatment
without
ascet
fluid
test
antimicrobi
use
sbp
exclud
clinic
outcom
evalu
result
episod
cirrhot
sbp
collect
administr
data
investig
percentag
patient
whose
pmn
count
cellsmm
ascit
fluid
recruit
sbp
increas
first
triennium
second
third
episod
sbp
identifi
major
initi
prescrib
antibiot
fluoroquinolon
gener
cephalosporin
first
triennium
respect
betalactam
antibacterialsenzym
inhibitor
last
one
p
antimicrobi
treatment
longer
day
decreas
respect
p
mortal
slightli
lower
p
discuss
andor
conclus
adopt
asp
nic
combin
model
china
slow
promis
diagnosi
manag
urinari
tract
infect
uti
adult
year
age
larg
district
hospit
eleni
mavrogiorg
hala
kandil
prema
singh
tejal
vaghela
west
hertfordshir
nh
trust
background
obtain
microbiolog
sampl
patient
prescrib
antibiot
review
treatment
result
becom
avail
one
qualiti
standard
qs
recommend
nice
antimicrobi
stewardship
guidelin
aim
object
aim
studi
audit
complianc
nice
qs
statement
relat
presumpt
diagnosi
uti
find
whether
microbiolog
sampl
taken
start
antimicrobi
therapi
method
studi
carri
care
elderli
ward
larg
district
hospit
two
week
period
patient
prescrib
antimicrobi
urinari
tract
infect
identifi
daili
ward
base
pharmacist
studi
period
microbiolog
result
collect
interpret
microbiologist
clinic
note
review
data
analys
result
identifi
patient
antimicrobi
uti
median
patient
age
year
old
studi
show
urin
dip
patient
urin
cultur
done
seventi
nine
appropri
antimicrobi
treatment
base
current
cultur
result
creactiv
protein
crp
rais
mgl
patient
discuss
andor
conclus
result
show
complianc
trust
antimicrobi
guidelin
nq
standard
achiev
major
case
rais
awar
staff
import
microbiolog
investig
key
ensur
appropri
antibiot
use
background
serum
procalcitonin
pct
specif
sensit
biomark
detect
bacteri
infect
compar
crp
white
cell
count
report
use
pct
measur
diagnost
tool
support
clinic
decis
make
around
antibiot
use
patient
suspect
infect
aim
object
aim
studi
audit
use
serum
pct
measur
relat
antibiot
prescrib
hospit
set
method
patient
medic
surgic
ward
exclud
icu
hdu
undergon
pct
test
audit
week
clinic
attach
microbiolog
antibiot
prescrib
decis
review
note
within
hour
pct
result
accord
hampshir
hospit
guidelin
result
use
threshold
mcgl
pct
result
elev
neg
elev
result
clinic
diagnosi
bacteri
infect
support
patient
start
continu
escal
antibiot
neg
pct
result
antibiot
appropri
either
withheld
stop
discuss
andor
conclus
believ
find
clinic
import
pct
result
aid
clinician
decis
make
regard
withhold
cessat
antibiot
turn
reduc
unnecessari
prescript
case
antibiot
serum
pct
measur
help
achiev
hospit
antibiot
cquin
target
importantli
reduc
select
pressur
antimicrobi
misus
rise
era
antibiot
resist
unit
kingdom
antibiot
cquin
challeng
clinician
alan
abid
yann
gelist
natali
parker
taryn
keyser
kordo
saeed
matthew
dryden
sophi
lewi
univers
portsmouth
univers
southampton
hampshir
hospit
foundat
trust
background
mani
patient
admit
hospit
develop
life
threaten
infect
requir
antibiot
acut
set
clinician
may
alway
consid
consequ
prescrib
broad
spectrum
antibiot
lead
potenti
antibiot
resist
increas
pressur
hospit
reduc
use
broad
spectrum
antibiot
well
antibiot
whole
especi
follow
new
financi
implic
creat
cquin
framework
aim
object
aim
assess
use
piperacillintazobactam
tazocin
within
royal
hampshir
counti
hospit
complianc
clinician
expert
advic
andor
prescrib
guidelin
method
real
life
audit
carri
identifi
patient
prescrib
tazocin
use
electron
prescrib
softwar
jac
day
period
patient
found
case
note
review
perform
assess
reason
circumst
antibiot
prescript
result
patient
prescrib
tazocin
accord
trust
guidelin
follow
advic
microbiolog
deem
compliant
within
sampl
major
diagnos
intraabdomin
respiratori
natur
case
respect
prescript
stop
date
discuss
andor
conclus
clinician
follow
local
protocol
case
irrespect
clinic
appropri
stop
date
includ
small
proport
prescript
although
cquin
challeng
find
suggest
potenti
achiev
improv
complianc
local
guidelin
expert
microbiolog
advic
orla
geoghegan
traci
lyon
mark
gilchrist
bo
ye
imperi
colleg
nh
healthcar
trust
background
point
preval
survey
pp
demonstr
strength
area
improv
within
antimicrobi
stewardship
asp
programm
inher
labourintens
imperi
colleg
healthcar
nh
trust
undertaken
pp
sinc
electron
prescrib
eprescrib
introduc
provid
opportun
reassess
deliveri
pp
aim
object
aim
evalu
introduct
eprescrib
affect
pp
term
eas
data
collect
human
resourc
method
inpati
schedul
receiv
antiinfect
day
data
collect
includ
februari
studi
antimicrobi
pharmacist
note
time
taken
audit
clinic
area
signific
asp
intervent
made
analysi
result
result
ward
patient
review
retain
paperbas
system
utilis
specialist
intens
care
prescrib
programm
move
eprescrib
whilst
overal
antimicrobi
prescrib
indic
remain
similar
previou
year
averag
pp
time
taken
per
ward
hh
mm
reduc
paperbas
area
eprescrib
locat
intens
care
area
paperbas
ward
intervent
identifi
around
dose
optimis
wherea
identifi
via
electron
system
mainli
concern
cours
durat
discuss
andor
conclus
electron
record
prescript
system
dramat
reduc
time
taken
undertak
pp
even
greater
effici
improv
anticip
futur
follow
trustwid
adopt
electron
prescrib
intervent
identifi
paper
system
involv
dose
optimis
wherea
seen
within
eprescrib
area
hypothes
inbuilt
eprescrib
user
support
influenc
intervent
identifi
background
nh
grampian
antimicrobi
manag
team
coordin
annual
antibiot
point
preval
audit
across
acut
hospit
recommend
scottish
antimicrobi
prescrib
group
aim
object
monitor
complianc
local
antimicrobi
guidelin
agre
audit
standard
method
data
collect
pharmacist
use
standard
data
collect
form
day
novemberdecemb
year
antibiot
pharmacist
liaison
medic
microbiologist
assess
whether
antibiot
prescrib
appropri
complianc
audit
standard
calcul
report
summaris
result
medic
ward
dissemin
clinic
staff
year
individualis
report
sent
ward
lowest
rate
complianc
audit
standard
method
part
antimicrobi
stewardship
strategi
review
daili
pharmaci
request
protect
antibiot
ie
meropenem
ertapenem
linezolid
trust
review
case
note
drug
chart
laboratori
inform
system
evalu
rational
start
protect
antibiot
whether
prescript
appropri
appropri
prescript
discuss
daili
clinic
meet
attend
medic
microbiolog
doctor
antibiot
pharmacist
possibl
outcom
multidisciplinari
discuss
stop
protect
antibiot
without
start
new
antibiot
substitut
switch
protect
antibiot
nonprotect
altern
continu
protect
antibiot
result
commonli
use
protect
antibiot
meropenem
follow
linezolid
ertapenem
protect
antibiot
start
escal
patient
discuss
microbiolog
document
half
case
common
indic
start
protect
antibiot
recent
isol
mdr
organ
cover
nonprotect
option
whilst
allergi
penicillin
contribut
factor
choos
carbapenem
around
patient
prescript
judg
appropri
approxim
case
treatment
deescal
stop
whole
antibiot
therapi
recommend
patient
receiv
inappropri
prescript
patient
receiv
appropri
prescript
discuss
andor
conclus
studi
show
proactiv
multidisciplinari
strategi
review
everi
prescript
protect
antibiot
lead
mark
reduct
use
preciou
option
stewardship
opportun
treatment
urinari
tract
infect
use
oral
fosfomycin
much
learnt
helmi
sulaiman
aqtab
mazhar
alia
shu
jiun
khoo
saufi
irzat
che
yusoff
univers
malaya
background
fosfomycin
fm
first
introduc
follow
ferment
streptomyc
strain
follow
uniqu
posit
uncompl
uti
appropri
use
paramount
import
mitig
emerg
resist
aim
object
aim
look
current
practic
prescript
larg
outpati
clinic
method
retrospect
studi
carri
april
may
primari
care
clinic
affili
univers
malaya
medic
centr
malaysia
recruit
patient
year
old
receiv
singl
dose
oral
fm
divid
patient
guidelin
compliant
gc
nonguidelin
compliant
ngc
group
base
avail
consensu
result
patient
recruit
list
median
age
iqr
femal
predomin
subject
least
one
comorbid
hypertens
predomin
ngc
occurr
reason
ngc
asymptomat
bacteriuriaabu
acut
pyelonephr
complic
uti
inappropri
investig
urin
cultur
ultrasound
kidney
urin
analysi
commonest
test
perform
fmt
prescrib
wrongli
subject
wrong
indic
discuss
andor
conclus
data
illustr
dire
need
educ
term
uti
manag
primari
care
physician
misus
fm
common
accord
guidelin
addit
investig
may
reflect
nonuncompl
natur
uti
addit
lack
suscept
data
fm
local
contemporari
urinari
isol
address
id
measur
qualiti
antimicrobi
stewardship
andrew
berrington
rachel
bruce
ami
penni
citi
hospit
sunderland
nh
ft
citi
hospit
sunderland
nhsft
background
straightforward
measur
good
antimicrobi
stewardship
real
outcom
measur
like
infect
cure
resist
pressur
elus
surrog
outcom
measur
like
antibiot
consumpt
metric
tendenti
confound
factor
usual
measur
process
typic
audit
antimicrobi
prescrib
audit
easi
badli
difficult
well
decis
spread
time
place
new
inform
emerg
object
standard
difficult
set
need
care
audit
stewardship
specif
rather
medic
practic
gener
typic
complianc
audit
unlik
captur
complex
develop
audit
tool
assign
score
decis
made
initi
start
score
decis
made
treatment
continu
refin
sever
year
pilot
use
systemat
programm
audit
feedback
integr
assess
unit
backofhous
medic
ward
aim
object
describ
deploy
tool
pilot
systemat
audit
programm
design
assess
feasibl
approach
measur
qualiti
antimicrobi
prescrib
medic
unit
method
key
aspect
tool
result
summari
chart
describ
initi
audit
continu
audit
data
time
taken
perform
audit
discuss
andor
conclus
use
feasibl
approach
though
time
consum
accept
clinic
teamsgood
engag
import
defin
constitut
cours
develop
clinic
decis
support
cd
mobil
app
antimicrobi
prescrib
jacquelin
sneddon
ann
wale
dilip
nathwani
healthcar
improv
scotland
nh
educ
scotland
background
develop
clinic
decis
support
cd
prioriti
scottish
govern
give
clinician
easi
access
decis
support
tool
relev
guidanc
point
care
antimicrobi
prescrib
identifi
quick
win
demonstr
cd
nation
evidencebas
guidanc
treatment
algorithm
robust
clinic
network
alreadi
avail
aim
object
develop
nation
antimicrobi
app
collabor
scottish
antimicrobi
prescrib
group
nh
educ
scotland
method
propos
develop
fund
secur
scottish
govern
develop
appoint
via
tender
process
multiprofession
clinic
refer
group
establish
result
app
launch
august
avail
download
free
via
app
store
use
mobil
devic
app
includ
dosag
calcul
gentamicin
vancomycin
regist
medicin
healthcar
product
regulatori
agenc
antibiot
guidanc
primari
care
hospit
customis
health
board
decis
aid
support
manag
urinari
tract
infect
older
peopl
audit
tool
support
data
gather
report
local
nation
improv
work
discuss
andor
conclus
bespok
nation
app
provid
customis
local
guidanc
cd
tool
enabl
clinician
use
antibiot
safe
effect
across
care
set
uniqu
audit
compon
support
improv
practic
time
audit
feedback
key
prescrib
measur
evalu
impact
underway
use
outcom
chain
model
contribut
analysi
background
excess
broadspectrum
antibiot
use
associ
advers
outcom
includ
clostridium
difficil
antibioticresist
infect
oncolog
inpati
suscept
infect
due
cancer
chemotherapyassoci
immunocompromis
use
broadspectrum
antibiot
alway
warrant
aim
object
project
aim
identifi
tackl
barrier
appropri
antibiot
prescrib
oncolog
inpati
southampton
gener
hospit
hope
reduc
inappropri
use
broadspectrum
antibiot
method
one
week
twenti
oncolog
inpati
receiv
least
hour
antibiot
identifi
exclud
haematolog
cancer
patient
receiv
stem
cell
transplant
audit
antibiot
choic
durat
investig
identifi
infect
sourc
sever
complianc
local
guidelin
outcom
antibiot
review
result
dissemin
good
practic
guidelin
produc
incorpor
trust
applicationbas
antibiot
polici
result
tazocin
use
patient
clear
justif
nearli
patient
receiv
long
antibiot
cours
day
chang
made
antibiot
review
inadequ
use
document
cultur
guid
antibiot
prescrib
tool
assess
infect
risk
eg
mascc
score
use
patient
febril
neutropenia
sever
eg
blood
lactat
measur
patient
discuss
andor
conclus
inappropri
broadspectrum
antibiot
use
associ
inadequ
assess
infect
risk
sourc
sever
educ
empow
clinician
improv
domain
hope
reduc
inappropri
antibiot
use
reaudit
pend
time
write
evalu
behaviour
chang
part
antimicrobi
stewardship
intervent
review
uk
stateoftheart
confer
adam
tsao
ann
tivey
timothi
rawson
esmita
charani
mark
gilchrist
luke
moor
alison
holm
imperi
colleg
school
medicin
imperi
colleg
london
background
improv
qualiti
antimicrobi
stewardship
am
intervent
applic
behaviour
scienc
support
multidisciplinari
collabor
recommend
analys
major
uk
scientif
research
confer
investig
level
am
behaviour
chang
intervent
report
method
lead
uk
scientif
confer
abstract
clinic
specialti
identifi
interrog
four
research
am
andor
antimicrobi
resist
amr
abstract
identifi
use
valid
search
criteria
abstract
independ
review
three
research
report
behaviour
intervent
categoris
use
behaviour
chang
wheel
framework
describ
michi
colleagu
result
overal
confer
ran
day
deleg
amsamr
abstract
oral
poster
identifi
present
uk
infecti
diseas
microbiolog
confer
amsamr
abstract
describ
behaviour
chang
intervent
commonest
abstract
report
behaviour
chang
intervent
qualiti
improv
project
total
uniqu
behaviour
chang
function
identifi
polici
categori
guidelin
servic
provis
frequent
report
intervent
function
educ
persuas
enabl
also
common
intervent
categori
incentivis
coercion
polici
categori
fiscal
legisl
report
identifi
abstract
discuss
andor
conclus
despit
benefit
behaviour
chang
intervent
antimicrobi
prescrib
amsamr
studi
uk
stateoftheart
confer
report
implement
am
intervent
must
focu
promot
behaviour
chang
toward
antimicrobi
prescrib
greater
emphasi
must
place
noninfect
specialti
engag
issu
behaviour
chang
toward
antimicrobi
use
audit
appropri
sampl
cultur
prior
start
intraven
antibiot
acut
admiss
st
jame
univers
hospit
leed
background
frequent
opportun
obtain
critic
microbiolog
specimen
appear
miss
prior
start
intraven
antibiot
acut
admiss
hospit
aim
object
gain
accur
pictur
current
practic
strategi
improv
practic
might
develop
method
patient
intraven
antibiot
review
medic
surgic
admiss
ward
st
jame
univers
hospit
seri
spot
check
period
three
week
data
analys
primarili
see
mani
patient
blood
cultur
obtain
prior
intraven
antibiot
commenc
secondari
analys
carri
identifi
demograph
diagnost
featur
advers
treatment
outcom
associ
sampl
taken
result
patient
blood
cultur
taken
prior
first
dose
antibiot
patient
cultur
taken
apyrexi
admiss
associ
failur
take
cultur
present
biliari
sepsi
also
admit
surgic
ward
blood
cultur
taken
antibiot
posit
compar
blood
cultur
taken
antibiot
length
stay
increas
cultur
taken
antibiot
given
rel
cultur
taken
first
four
patient
die
none
cultur
taken
antibiot
discuss
andor
conclus
current
practic
fall
far
short
standard
audit
help
identifi
area
focu
intervent
educ
also
demonstr
neg
impact
patient
outcom
failur
sampl
appropri
caus
foundat
doctorl
audit
educ
effect
intervent
promot
antimicrobi
stewardship
royal
bolton
hospit
c
subudhi
aideen
carrol
jonathan
evan
emma
clare
hugh
rhian
proffitt
alex
smith
andrew
steel
samim
patel
royal
bolton
hospit
bolton
nh
foundat
trust
background
view
rapidli
emerg
antibioticresist
bacteria
grow
need
antibiot
stewardship
programm
import
intervent
improv
stewardship
target
foundat
doctor
compris
signific
proport
antibiot
prescrib
aim
object
studi
aim
evalu
improv
qualiti
antibiot
prescrib
follow
foundat
doctorl
educ
intervent
royal
bolton
hospit
method
royal
bolton
hospit
quarterli
audit
carri
conjunct
microbiolog
depart
audit
standard
base
public
health
england
guidanc
follow
standard
complianc
trust
guidelin
standard
indic
treatment
written
patient
case
note
hour
use
data
collect
audit
foundat
doctorl
teach
session
design
deliv
improv
safe
prescrib
antibiot
fellow
foundat
traine
result
four
quarterli
audit
complet
cours
academ
year
averag
complianc
across
five
standard
quarter
respect
overal
annual
complianc
standard
follow
deliveri
teach
session
standard
reaudit
target
set
complianc
respect
discuss
andor
conclus
despit
previou
intervent
complianc
prescrib
standard
remain
rel
static
follow
formal
educ
peertop
teach
improv
expect
suffici
meet
desir
target
background
acuiti
complex
patient
treat
commun
health
servic
increas
dramat
pressur
nh
servic
escal
rural
somerset
high
risk
patient
present
suspect
sepsi
may
requir
initi
treatment
geograph
dispers
potenti
isol
minor
injuri
unit
commun
hospit
transfer
acut
trust
could
result
unaccept
delay
treatment
initi
principl
patientcentr
care
support
appropri
avoid
unnecessari
hospit
transfer
aim
object
develop
sepsi
treatment
pathway
rural
commun
health
servic
set
provid
prompt
safe
care
septic
patient
optimis
outcom
within
confin
commiss
servic
model
implement
maintain
good
medicin
govern
initi
unfamiliar
high
risk
medicin
promot
appropri
antibiot
stewardship
line
local
strategi
local
resist
method
prospect
review
process
undertaken
lesson
learnt
develop
antibiot
guidanc
sepsi
multidisciplinari
clinic
team
result
develop
robust
uniform
pathway
across
geograph
dispers
sometim
dispar
servic
set
prove
challeng
safe
time
treatment
sepsi
use
high
risk
drug
tradit
administ
commun
health
servic
eg
gentamicin
teicoplanin
vancomycin
requir
novel
approach
consider
discuss
andor
conclus
legaci
histor
nh
commun
health
servic
oper
model
includ
limit
access
medic
prescrib
clinic
pharmaci
servic
consult
microbiolog
support
rapid
diagnost
test
infrastructur
routin
avail
acut
hospit
set
resourc
develop
local
nation
antibiot
guidelin
requir
review
ensur
current
gap
identifi
process
acknowledg
mitig
barrier
facilit
antimicrobi
guidelin
adher
dentistri
knowledg
attitud
assess
tool
noha
seoudi
zhang
xu
qmul
background
antimicrobi
stewardship
one
import
strategi
tackl
increasingli
seriou
threat
antimicrobi
resist
global
faculti
gener
dental
practition
fgdp
public
health
england
phe
issu
guidelin
regul
use
antimicrobi
primari
dental
care
howev
poor
adher
report
literatur
barrier
guidelin
adher
expect
differ
accord
local
set
therefor
analys
barrier
import
step
develop
antimicrobi
stewardship
intervent
aim
develop
valid
knowledg
attitud
assess
tool
assess
barrier
facilit
guidelin
adher
method
questionnair
develop
base
mitchi
behaviour
chang
wheel
assess
capabl
motiv
opportun
relat
dental
antimicrobi
prescrib
habit
knowledg
part
questionnair
modifi
previous
publish
tool
palmer
et
al
peer
review
consult
stage
pilot
audit
conduct
valid
tool
result
pilot
compar
result
prospect
antimicrobi
prescrib
pattern
audit
set
result
particip
took
part
questionnair
antimicrobi
prescript
episod
also
audit
statist
signific
differ
concord
rate
nation
local
guidelin
compar
questionnair
prospect
audit
conclus
aim
present
newli
develop
knowledg
attitud
assess
tool
use
audit
antimicrobi
prescrib
pattern
identifi
best
local
antimicrobi
stewardship
intervent
dentistri
background
despit
recent
advanc
diagnost
therapeut
strategi
infect
endocard
remain
challeng
treat
thu
associ
bad
prognosi
term
morbid
mortal
particularli
uncommon
microorgan
involv
report
first
case
infect
endocard
caus
paenibacillu
provencensi
rare
gramneg
sporeform
rod
result
mitral
valv
veget
incident
discov
intraop
transoesophag
echocardiographi
old
ladi
undergo
aortic
valv
replac
empir
antibiot
treatment
infect
endocard
gentamicin
teicoplanin
start
precis
identif
caus
agent
reli
genotyp
characteris
rdna
gene
sequenc
microbiolog
cultur
subsequ
perform
obtain
antimicrobi
suscept
profil
adjust
antibiot
regimen
accordingli
patient
treat
cours
vancomycin
meropenem
follow
week
daptomycin
due
identif
vancomycinresist
enterococci
rectal
swab
long
inhospit
stay
patient
eventu
recov
clinic
biochem
transthorac
echocardiogram
demonstr
well
function
mitral
valv
without
residu
lesion
endocard
discuss
andor
conclus
best
knowledg
first
report
show
paenibacillu
provencensi
pathogen
human
member
genu
paenibacillu
may
involv
nativ
valv
endocard
case
also
emphasi
import
rdna
gene
sequenc
realtim
polymeras
chain
reaction
rapid
accur
method
identifi
microorgan
like
paenibacillu
miss
convent
microbiolog
investig
background
year
old
woman
admit
hospit
octob
symptom
fever
intermitt
diarrhoea
hepat
encephalopathi
histori
cirrhosi
secondari
autoimmun
hepat
initi
thought
ill
secondari
decompens
would
necessit
liver
transplant
born
pakistan
live
uk
sinc
last
visit
pakistan
may
juli
result
routin
laboratori
result
demonstr
worsen
liver
function
pancytopenia
hyponatremia
blood
cultur
posit
final
prove
brucella
abortu
serolog
posit
brucella
igmigg
sampl
august
retrospect
test
neg
discuss
andor
conclus
follow
confirm
brucellosi
treat
week
ciprofloxacin
week
gentamicin
good
respons
month
later
remain
well
mild
encephalopathi
time
human
brucellosi
remain
rare
uk
case
highlight
need
consid
patient
present
pyrexia
unknown
origin
travel
endem
area
due
liver
condit
treatment
regimen
chosen
avoid
rifampicin
initi
concern
might
requir
liver
transplant
abat
background
viscer
leishmaniasi
rare
ill
present
uk
although
consid
differenti
appropri
travel
histori
year
old
male
retir
civil
engin
haematologist
investig
pancytopenia
sinc
novemb
present
symptom
weight
loss
night
sweat
loss
appetit
lethargi
background
psoriat
arthriti
took
methotrex
travel
histori
includ
holiday
north
america
morocco
recent
spain
lymphoma
consid
like
diagnosi
evid
splenomegali
imag
list
splenectomi
repeat
splenic
biopsi
came
back
show
reactiv
chang
result
leishmania
serolog
came
back
strongli
posit
leishmania
dat
posit
titr
leishmania
test
antibodi
leishmania
antigen
posit
day
prior
plan
splenectomi
discuss
andor
conclus
viscer
leismaniasi
consid
like
diagnosi
treat
standard
liposom
amphotericin
b
mgkg
day
latest
follow
made
good
recoveri
platelet
count
normal
haemoglobin
white
cell
count
improv
leishmania
consid
initi
differenti
month
serolog
perform
although
major
case
occur
countri
bangladesh
brazil
india
sudan
also
endem
mediterranean
area
consider
given
diagnosi
appropri
travel
histori
especi
immunosuppress
individu
background
year
old
australasian
holidaymak
brought
ambul
e
complain
sever
abrupt
onset
abdomin
pain
present
hour
sore
throat
day
examin
febril
hold
neck
throat
appear
normal
cervic
lymphadenopathi
anterior
neck
tender
tachyopn
satur
air
hr
bp
central
right
upper
quadrant
abdomin
tender
cxr
show
small
right
pleural
effus
also
seen
ct
abdomen
also
demonstr
consolid
caus
pain
three
hour
becam
hoars
complain
frog
throat
nebulis
adrenalin
intraven
ceftriaxon
dexamethason
administ
ct
neck
reveal
signific
soft
tissu
swell
thicken
epiglotti
airway
immedi
secur
transfer
intens
care
blood
cultur
posit
follow
day
gramneg
diplococci
later
identifi
neisseria
meningitidi
extub
within
hour
complet
day
iv
ceftriaxon
discharg
scottish
refer
laboratori
confirm
n
meningitidi
serogroup
rare
mlst
type
scotland
sinc
scottish
figur
show
serogroup
account
n
meningitidi
isol
invas
case
csf
eye
blood
cultur
affect
older
adult
mean
year
age
rang
femal
male
serogroup
rare
implic
epiglott
hand
case
previous
report
unusu
pneumonia
road
traffic
accid
amelia
joseph
shiu
soo
nottingham
univers
hospitalshealth
educ
east
midland
nottingham
univers
hospit
background
year
old
male
admit
trap
car
crash
rural
ditch
whilst
emerg
servic
work
free
becam
submerg
underwat
aim
object
arriv
hospit
sever
respiratori
compromis
requir
endotrach
intub
comput
tomographi
reveal
bilater
alveolar
opac
air
bronchogram
suggest
aspir
bronchial
wash
obtain
piperacillintazobactam
commenc
empir
betahaemolyt
oxidaseposit
gramneg
organ
grew
blood
agar
hour
biochem
identif
confirm
organ
aeromona
hydrophilia
isol
test
resist
piperacillintazobactam
sensit
ciprofloxacin
meropenem
method
review
intens
care
microbiologist
piperacillintazobactam
switch
intraven
ciprofloxacin
patient
deterior
respiratori
failur
sepsi
diarrhoea
meropenem
ad
repeat
bronchial
wash
mould
grew
blood
sabouraud
agar
identifi
microscopi
aspergillu
fumigatu
result
voriconazol
commenc
within
hour
significantli
improv
howev
profus
wateri
diarrhoea
continu
auramin
stain
stool
sampl
reveal
cryptosporidium
cyst
later
identifi
cryptosporidium
homini
follow
continu
improv
complet
fourteen
day
cours
meropenem
ciprofloxacin
voriconazol
diarrhoea
slowli
settl
discharg
home
week
later
discuss
andor
conclus
mechan
trauma
case
led
sever
waterborn
infect
report
literatur
neardrown
aeromona
speci
commonest
caus
earlyonset
pneumonia
pseudoallescheria
boydii
commonest
fungal
infect
usual
delay
present
aspergillu
infect
report
small
number
case
usual
poor
prognosi
background
year
old
man
present
progress
weight
loss
lymphadenopathi
back
pain
visual
disturb
myoclonu
poor
memori
aim
object
due
progress
physic
deterior
patient
admit
investig
number
differenti
consid
includ
malign
lymphoma
sarcoidosi
examin
cachect
palpabl
inguin
lymph
node
neurolog
examin
reveal
myoclon
jerk
arm
reduc
upward
gaze
normal
power
reflex
patient
complain
ocular
pain
photophobia
floater
vision
examin
eye
reveal
nondescript
intermedi
uveiti
method
numer
investig
perform
includ
upper
gastrointestin
endoscopi
biopsi
histolog
duoden
biopsi
show
featur
highli
suggest
whippl
diseas
fix
paraffin
curl
duoden
biopsi
posit
tropheryma
whipplei
rrna
pcr
pcr
csf
also
weakli
posit
result
patient
treat
week
intraven
cotrimoxazol
due
penicillin
allergi
oral
cotrimoxazol
plan
least
year
symptom
start
improv
weight
increas
day
treatment
discuss
andor
conclus
whippl
diseas
extrem
rare
difficult
recognis
patient
fit
characterist
demograph
middleag
caucasian
male
complain
diarrhoea
common
featur
whippl
diseas
may
mask
opioid
taken
back
pain
neurolog
ocular
symptom
recognis
rarer
featur
whippl
diseas
case
highlight
import
take
appropri
biopsi
sampl
clinic
awar
whippl
diseas
identifi
pathognomon
featur
histolog
aneeka
chavda
poonam
kapila
abhinav
kumar
sherwood
forest
hospit
nh
foundat
trust
king
mill
hospit
background
report
case
year
old
turkish
male
background
ulcer
coliti
present
two
week
histori
increas
short
breath
progress
deterior
despit
treat
broad
spectrum
antibiot
unfortun
die
evid
phagocytosi
blood
film
along
high
serum
ferritin
microgramml
multi
organ
failur
led
diagnosi
haemophagocyt
syndrom
hp
four
day
death
respiratori
sampl
test
posit
mycobacterium
tuberculosi
hp
due
mycobacterium
tuberculosi
uncommon
hand
case
report
predominantli
immunocompromis
hp
aggress
lifethreaten
syndrom
excess
immun
activ
excess
inflamm
thought
caus
lack
normal
regul
activ
macrophag
lymphocyt
infect
common
trigger
genet
predisposit
sporad
case
prompt
initi
treatment
essenti
surviv
affect
patient
often
greatest
barrier
success
outcom
delay
diagnosi
difficult
rariti
syndrom
variabl
clinic
present
lack
specif
clinic
laboratori
find
malaria
case
report
year
uk
although
estim
repres
total
number
case
post
malaria
neurolog
syndrom
pmn
rare
complic
sever
malaria
preval
per
treat
plasmodium
falciparum
malaria
pfm
common
sever
malaria
uncompl
malaria
associ
use
mefloquin
malaria
treatment
discuss
andor
conclus
present
year
old
caucasian
male
return
gambia
sever
pfm
taken
antimalari
chemoprophylaxi
treat
intraven
artesun
tertiari
referr
centr
requir
intub
ventil
haemofiltr
follow
primari
treatment
improv
subsequ
deterior
develop
generalis
weak
increasingli
confus
reduc
glasgow
coma
score
gc
extens
investig
exclus
altern
caus
pmn
diagnos
treat
iv
hydrocortison
due
depress
gc
absenc
contraind
made
rapid
clinic
improv
discharg
without
neurolog
impair
explor
decis
lead
use
corticosteroid
case
similar
present
report
literatur
background
man
develop
symptom
system
infect
generalis
bodi
ach
five
week
follow
transurethr
resect
prostat
turp
previou
retent
urin
blood
urin
cultur
morganella
speci
treat
accordingli
piperacillintazobactam
one
week
good
clinic
respons
observ
ongo
symptom
predominantli
lower
back
pain
necessit
second
admiss
although
system
sepsi
inflammatori
marker
remain
normal
magnet
reson
imag
spine
confirm
disciti
level
vertebra
biopsyaspir
spine
pursu
avoid
delay
initi
antimicrobi
treatment
patient
made
full
recoveri
symptom
ertapenem
week
repeat
mri
nine
month
follow
onset
confirm
complet
resolut
disciti
discuss
andor
conclus
bacteraemia
follow
urolog
intervent
unusu
especi
previou
instrument
indwel
cathet
predispos
colonis
bacteria
lower
urotheli
tract
patient
present
urosepsi
associ
nonspecif
symptom
follow
urolog
procedur
need
prompt
symptom
specif
investig
diagnos
uncommon
manifest
bacteraemia
order
avoid
delay
treatment
improv
prognosi
would
also
reason
monitor
patient
symptom
unusu
linger
era
age
popul
need
urolog
intervent
alongsid
increas
antibiot
resist
like
see
greater
incid
gram
neg
sepsi
follow
urolog
intervent
clinician
need
vigil
diagnosi
treatment
complic
result
lactat
mmoll
admiss
blood
cultur
grew
gram
neg
bacilli
ct
scan
ultra
sound
scan
suggest
suspici
lesion
went
develop
multi
organ
failur
dissemin
intra
vascular
coagul
acut
liver
failur
atrial
fibril
note
intens
care
unit
right
index
finger
abras
black
margin
confirm
patient
dog
bite
injuri
onset
ill
discuss
andor
conclus
overwhelm
post
splenectomi
infect
opsi
rare
associ
high
mortal
rate
common
organ
encapsul
organ
streptococcu
pneumonia
nisseria
meningitid
hemophiliu
influenza
streptococcu
pyogen
capnocytophaga
canimorsu
commens
gram
neg
bacterium
present
saliva
dog
case
inform
us
consid
capnocytophaga
canimorsu
infect
organ
associ
dog
bite
injuri
diagnosi
made
septic
shock
possibl
capnocytophaga
canimori
organ
luci
li
sanjay
cheema
nupur
goel
west
middlesex
univers
hospit
background
group
b
streptococcu
gb
infrequ
caus
mening
adult
usual
affect
elderli
patient
seriou
underli
diseas
recognis
one
lead
aetiolog
agent
neonat
mening
case
present
report
case
previous
healthi
year
old
male
builder
initi
present
hour
histori
worsen
sever
headach
photophobia
confus
lumbar
punctur
result
consist
bacteri
mening
blood
cultur
grew
gb
patient
initi
treat
intraven
aciclovir
ceftriaxon
dexamethason
complet
two
week
cours
ceftriaxon
make
rapid
improv
within
hour
knowledg
patient
repres
one
report
case
gb
mening
previous
healthi
young
male
discuss
genet
factor
may
predispos
certain
peopl
develop
mening
normal
harmless
microorgan
gb
key
messag
gb
infrequ
caus
adult
mening
carri
high
case
fatal
gb
mening
must
consid
exclus
peripartum
infecti
period
patient
comorbid
ill
research
requir
characteris
genet
predisposit
bacteri
viral
cn
infect
refer
background
case
year
old
pakistani
ladi
present
week
gestat
week
histori
acut
fever
unknown
origin
pv
bleed
initi
diagnos
chorioamnion
deliv
prematur
week
via
caesarian
section
foetal
distress
two
day
later
deterior
hypoxia
respiratori
distress
ground
glass
chang
ct
chest
confus
high
protein
low
glucos
lymphocyt
csf
analysi
transfer
itu
babi
neonat
unit
discuss
empir
treatment
start
listeria
tb
bacteri
viral
cn
infect
tb
later
identifi
csf
pcr
eventu
cultur
sputum
urin
csf
consist
miliari
tb
defin
progress
wide
dissemin
haematogen
tb
tb
one
great
chameleon
id
world
notori
difficult
diagnos
uniqu
diagnost
challeng
present
pregnanc
neonat
diagnosi
pregnanc
afford
opportun
specif
test
birth
determin
risk
vertic
transmiss
congenit
tb
commonli
present
approxim
day
deliveri
suggest
follow
prophylaxi
initi
birth
full
investig
exclud
neonat
tb
avail
sampl
cultur
includ
gastric
lavag
mother
placenta
endometri
sampl
tb
confirm
babi
fulli
treat
tb
deadli
zoonos
cat
dog
two
case
report
describ
occult
transmiss
common
pet
commens
vulner
elderli
popul
jame
wilson
shermayn
ng
dougla
fink
imperi
colleg
healthcar
nh
trust
hammersmith
hospit
chare
cross
hospit
hospit
tropic
diseas
background
bacteraemia
secondari
c
canimorsu
p
multocida
disproportion
affect
elderli
associ
mortal
rate
aim
object
present
two
elderli
patient
treat
sepsi
organ
typic
associ
cat
dog
bite
case
highlight
occult
mode
transmiss
rel
vulner
elderli
patient
potenti
deadli
zoonos
method
retrospect
review
case
note
literatur
review
import
zoonos
agerel
immun
dysfunct
result
first
case
describ
yearold
ladi
background
epilepsi
live
italian
greyhound
patient
report
frequent
dog
lick
although
deni
bite
broken
skin
initi
present
seizur
secondari
hyponatraemia
day
admiss
becom
acut
unwel
fulmin
sepsi
multiorgan
dysfunct
capnocytophaga
canimorsu
septicaemia
isol
pcr
blood
cultur
coloni
make
full
recoveri
iv
piperacillin
tazobactam
c
canimorsu
remain
rare
caus
fulmin
sepsi
case
previous
describ
uk
second
case
describ
yearold
ladi
present
rapid
onset
cellul
sepsi
associ
shin
lacer
fall
scaffold
pasteurella
multocida
isol
blood
cultur
treat
iv
ceftriaxon
sever
sepsi
make
full
recoveri
p
multocida
common
isol
dog
cat
bite
wound
howev
seldom
caus
bacteraemia
conclud
brief
review
import
pet
zoonos
explor
link
age
immun
dysfunct
case
unexpect
diabet
foot
background
corynebacterium
ulceran
rare
lead
caus
toxigen
diphtheria
uk
increas
incid
report
cutan
diphtheria
infect
first
describ
case
toxigen
c
ulceran
associ
anim
contact
patient
diabet
foot
infect
aim
object
present
indigen
case
toxigen
cutan
c
ulceran
infect
highlight
import
laboratori
advanc
identif
corynebacterium
speci
discuss
issu
regard
manag
context
recent
revis
public
health
england
guidanc
method
case
descript
year
old
woman
present
outpati
evid
infect
hallux
ulcer
discuss
includ
summari
exist
literatur
result
swab
isol
corynebacterium
speci
identifi
c
ulceran
malditof
ms
subsequ
refer
laboratori
test
pcr
elek
test
confirm
presenc
tox
gene
toxin
product
patient
system
well
manag
oral
antibiot
commun
like
sourc
domest
pet
dogcat
despit
test
neg
c
ulceran
case
carrier
identifi
discuss
andor
conclus
present
unusu
case
cutan
toxigen
c
ulceran
associ
diabet
foot
infect
use
malditof
ms
enabl
rapid
accur
identif
c
ulceran
technolog
becom
avail
clinic
laboratori
like
increas
case
ascertain
difficulti
delay
test
suspect
sourc
anim
encount
due
issu
surround
cost
like
remain
problemat
c
ulceran
notifi
diseas
anim
rare
case
primari
cervic
spondylodisc
due
streptococcu
pneumonia
immunocompet
patient
harri
theron
alic
bradley
daniel
chan
marina
morgan
univers
exet
medic
school
exet
spine
unit
peninsula
medic
school
discuss
andor
conclus
present
rare
case
primari
spondylodisc
due
streptococcu
pneumonia
affect
cervic
spine
femal
patient
immunosuppress
predispos
risk
factor
present
spinalclin
complain
midcerv
spinal
pain
flexion
deform
ataxia
bilater
arm
pain
suggest
nerv
root
irrit
apart
report
sever
anaphylact
allergi
penicillin
past
medic
histori
unremark
mri
show
destruct
well
partial
liquefi
prevertebr
soft
tissu
mass
compress
cord
emerg
anterior
cervic
decompress
reconstruct
surgeri
due
penicillin
allergi
need
penetr
biofilm
empir
combin
intraven
vancomycin
clindamycin
oral
rifampicin
commenc
later
chang
clindamycin
rifampicin
pneumonia
isol
tissu
remov
oper
isol
sensit
penicillin
clindamycin
rifampicin
daptomycin
shortli
afterward
develop
maculopapular
rash
attribut
clindamycin
necessit
chang
oral
rifampicin
intraven
daptomycin
continu
month
outpati
recov
well
pneumococcu
serotyp
serotyp
current
cover
avail
conjug
vaccin
recognit
emerg
serotyp
rais
question
whether
current
pneumococc
vaccin
need
develop
includ
emerg
strain
would
appear
first
report
case
pneumococc
osteomyel
treat
daptomycin
jo
quinn
adrian
kennedi
phil
stanley
paul
mcwhinney
sulman
hasni
riccardo
guintini
ben
jeff
bradford
royal
infirmari
bradford
teach
hospit
background
streptococcu
pneumonia
rare
caus
infect
endocard
high
morbid
mortal
yearold
previous
fit
well
gentleman
admit
gener
unwel
pyrexi
aortic
murmur
visual
loss
secondari
panuv
result
transoesophag
echocardiogram
show
evid
aortic
valv
endocard
five
set
blood
cultur
grew
streptococcu
pneumonia
vitreou
humour
cultur
show
growth
discuss
andor
conclus
treat
intraven
vancomycin
gentamicin
chang
intraven
benzylpenicillin
day
sensit
requir
valv
replac
day
admiss
endophthalm
empir
treat
intravitr
ceftazidim
benzylpenicillin
plu
oral
steroid
teicoplanin
mgkg
daili
start
day
facilit
outpati
administr
patient
treat
total
four
week
intraven
antibiot
made
good
clinic
recoveri
infect
endocard
due
streptococcu
pneumonia
mainli
affect
individu
without
previou
cardiac
histori
predominantli
affect
aortic
valv
case
pneumococc
endocard
often
associ
endophthalm
mening
austrian
syndrom
patient
develop
endophthalm
sign
symptom
mening
thu
lumbar
punctur
perform
often
high
rate
valv
destruct
need
valv
replac
surgeri
case
rel
high
mortal
rate
pneumococc
endocard
particularli
associ
mening
chloe
walsh
kavita
sethi
jane
minton
leed
teach
hospit
nh
trust
background
year
old
man
inject
drug
present
e
pain
thigh
doubl
vision
admit
surgeri
incis
drainag
thigh
abscess
receiv
flucloxacillin
underw
ct
head
assess
doubl
vision
normal
next
hour
continu
complain
doubl
vision
haemodynam
stabl
apyrexi
went
develop
dysphonia
dysphagia
stridor
refer
infecti
diseas
review
bilater
ptosi
ophthalmoparesi
nonreact
pupil
dysarthria
flaccid
paralysi
neck
facial
muscl
tongu
result
clinic
diagnosi
wound
botul
made
patient
transfer
intens
care
receiv
antitoxin
intub
debrid
receiv
penicillin
metronidazol
made
good
neurolog
recoveri
mild
diplopia
discharg
day
cultur
pu
tissu
debrid
confirm
clostridium
botulinum
type
b
discuss
andor
conclus
wound
botul
rare
diagnosi
well
recognis
peopl
inject
drug
pwid
case
uk
case
one
cluster
three
recent
report
public
health
england
patient
present
classic
afebril
descend
flaccid
paralysi
antitoxin
debrid
key
manag
essenti
maintain
high
index
suspicion
wound
botul
pwid
due
potenti
fatal
consequ
recognis
facilit
coordin
public
health
respons
wijitha
weerakoon
milind
khare
annmari
omeara
david
pickard
background
erysepelothrix
rhusiopathia
ubiquit
organ
found
decay
nitrogen
wast
infect
human
occup
relat
occur
result
contact
anim
product
wast
human
infect
mild
cutan
infect
known
erysepeloid
diffus
cutan
form
seriou
although
rare
complic
septicaemia
endocard
report
aim
object
clinic
case
review
method
report
year
old
femal
patient
diagnos
infect
endocard
caus
erysepelothrix
rhusiopathia
present
histori
unwel
febril
letharg
week
anaem
temperatur
pan
systol
mumur
examin
result
echocardiographi
show
abnorm
mitral
valv
leaflet
veget
possibl
perfor
anterior
leaflet
veget
aortic
valv
empir
start
intraven
amoxicillin
gentamicin
take
blood
cultur
blood
cultur
isol
gram
posit
bacilli
resist
vancomycin
organ
identifi
erysepelothrix
rhusiopathia
vitek
confirm
refer
laboratori
treat
high
dose
intraven
benzyl
penicillin
week
good
outcom
valv
replac
epidemiolog
risk
factor
found
patient
histori
penicillin
allergi
discuss
andor
conclus
rapid
identif
erysepelothrix
rhusiopathia
gram
posit
organ
critic
appropri
manag
infect
endocard
especi
patient
histori
penicillin
allergi
background
neisseria
meningitidi
rare
import
caus
mening
septicaemia
invas
meningococc
diseas
associ
signific
morbid
mortal
highest
incid
infect
seen
children
age
year
younger
adult
age
year
nausea
vomit
diarrhoea
welldocu
symptom
meningococc
infect
howev
present
predominantli
gastrointestin
symptom
rare
recent
describ
uk
outbreak
unusu
present
diarrhoea
associ
group
w
n
meningitidi
teenag
progress
sever
diseas
date
one
case
fulmin
meningococcemia
associ
primari
present
gastroenter
report
elderli
patient
aim
object
report
two
case
group
b
invas
meningococc
diseas
elderli
patient
present
primarili
gastrointestin
symptom
result
case
patient
present
acut
histori
vomit
diarrhoea
fever
one
patient
remain
haemodynam
stabl
requir
minim
support
multipl
comorbid
present
septic
shock
requir
itu
support
neither
patient
exhibit
focu
infect
evid
cn
infect
patient
blood
cultur
taken
admiss
posit
n
meningitidi
later
identifi
group
b
molecular
test
patient
treat
iv
ceftriaxon
g
bd
day
made
good
recoveri
discharg
home
discuss
andor
conclus
clinic
manifest
invas
meningococc
diseas
vari
import
clinician
awar
atyp
present
ensur
prompt
diagnosi
effect
treatment
diagnost
conundrum
role
rapid
molecular
test
mycobacterium
tuberculosi
detect
mix
infect
nontubercul
mycobacteria
rosalind
saunder
hemu
patel
nelun
perera
univers
hospit
leicest
nh
trust
background
coinfect
mycobacterium
tuberculosi
mtb
nontubercul
mycobacteria
ntm
rare
frequent
encount
among
patient
human
immunodefici
viru
infect
hiv
detect
mix
mtb
ntm
clinic
specimen
cultur
challeng
may
pose
difficulti
result
present
rare
case
mix
mtb
ntm
infect
rapid
cepheid
genexpert
mtbrif
polymeras
chain
reaction
pcr
primari
sputum
sampl
help
confirm
clinic
diagnosi
pulmonari
tuberculosi
infect
direct
laboratori
care
examin
cultur
isol
ultim
confirm
presenc
mtb
ntm
discuss
andor
conclus
case
illustr
util
rapid
molecular
test
mtb
primari
clinic
sampl
benefit
clinician
laboratori
resolv
diagnost
conundrum
elan
tsarfati
olga
lucia
moncayo
donald
inverar
christoph
jone
hilal
bahia
nh
lothian
old
male
refer
plastic
neighbour
trust
emerg
room
sustain
avuls
injuri
left
later
thigh
ziplin
forest
wound
skin
fat
necrosi
underli
infect
haematoma
immedi
washout
debrid
undertaken
sampl
tissu
swab
fluid
sent
microbiolog
lab
microscopi
cultur
sensit
vacuum
pump
appli
sampl
isol
staphylococcu
aureu
well
two
clostridiaon
identifi
c
sordellii
c
botulinum
use
sensit
metronidazol
coamoxiclav
public
health
england
refer
laboratori
detect
clostridium
botulinum
neurotoxin
b
e
f
malditof
pcr
confirm
isol
c
sporogen
nontoxin
form
clostridium
speci
identifi
c
botulinum
use
patient
improv
skin
graft
sent
home
within
day
clostridi
wound
infect
penetr
trauma
potenti
deadli
immedi
debrid
appropri
antibiot
given
initi
manag
must
includ
surgic
debrid
antibiot
therapi
neurolog
symptom
develop
crucial
suppli
antitoxin
intens
care
facil
avail
also
vital
engag
refer
laboratori
identif
clinic
signific
isol
case
fulmin
sepsi
due
capnocytophaga
canimorsu
immunocompet
patient
ami
bond
katrina
blackmor
york
teach
hospit
background
capnocytophaga
canimorsu
slow
grow
gram
neg
bacillu
normal
commens
dog
oral
caviti
human
infect
uncommon
may
sever
even
immunocompet
individu
strongli
associ
dog
exposur
bite
aim
object
report
case
fulmin
sepsi
due
c
canimorsu
immunocompet
patient
aim
increas
awar
potenti
fatal
pathogen
method
previous
well
male
arriv
e
ambul
histori
diarrhoea
vomit
sweat
arriv
tachypno
tachycard
hypotens
petechialpupur
rash
upper
bodi
lactat
mmoll
receiv
cefotaxim
potenti
meningococc
sepsi
within
minut
arriv
subsequ
dose
piperacillintazobactam
linezolid
gentamicin
human
normal
immunoglobulin
despit
intens
support
treatment
die
hour
arriv
hospit
result
anaerob
bottl
admiss
blood
cultur
signal
posit
hour
incub
gram
neg
bacilli
seen
organ
fail
grow
c
canimorsu
dna
detect
pcr
review
hospit
record
reveal
e
attend
bite
dog
discuss
andor
conclus
infect
c
canimorsu
commonli
manifest
system
sepsi
indistinguish
meningococc
diseas
usual
suscept
firstlin
antimicrobi
sever
sepsi
includ
thirdgener
cephalosporin
piperacillintazobactam
may
produc
extend
spectrum
betalactamas
like
empir
antimicrobi
therapi
adequ
case
patient
succumb
irrevers
multiorgan
failur
dissemin
intravascular
coagul
vivek
nayak
kavita
sethi
leed
teach
hospit
nh
trust
leed
gener
infirmari
leed
teach
hospit
nh
trust
background
femal
past
medicalsurg
histori
present
pleurit
chest
pain
progress
worsen
dyspnoea
last
hr
deni
fever
symptom
ho
recent
travel
contact
examin
afebril
stabl
haemodynam
normal
jvp
audibl
murmur
pericardi
rub
blood
test
reveal
rais
inflammatori
marker
evid
aki
rais
cardiac
enzym
ecg
show
diffus
st
elev
chest
lead
chest
xday
show
clear
lung
field
minim
enlarg
cardiac
silhouett
patient
treat
stemi
transfer
pci
method
arriv
tertiari
care
hospit
dyspnoea
significantli
worsen
haemodynam
instabl
blood
biochemistri
reveal
worsen
lft
cardiac
enzym
aki
auscult
chest
reveal
muffl
heart
sound
tachycardia
murmur
coronari
angiogram
normal
echocardiogram
show
cm
thick
collect
pericardi
sac
patient
symptomat
pericardiocentesi
perform
ml
pu
aspir
via
pig
tail
drain
iv
piperacillintazobactam
g
bd
commenc
collect
blood
cultur
result
biochem
analysi
pericardi
fluid
reveal
normal
protein
low
glucos
rais
ldh
microscopi
pericardi
fluid
show
polymorph
gram
stain
show
gramneg
cocci
henc
antibiot
switch
g
iv
ceftriaxon
patient
clinic
stabl
day
blood
paramet
improv
gradual
next
day
blood
cultur
isol
organ
patient
underw
surgic
pericardiectomi
discharg
home
complet
total
week
antibiot
therapi
someth
airdiagnosi
outcom
luke
bedford
sani
aliyu
ruth
kappel
papworth
nh
foundat
hospit
trust
addenbrook
hospit
background
year
old
caucasian
male
present
day
increas
back
pain
past
medic
histori
bladder
calculi
excess
alcohol
intak
report
foreign
travel
histori
signific
anim
occup
exposur
admiss
patient
becam
confus
feverish
treat
day
coamoxiclav
escal
piperacillintazobactam
due
persist
fever
mri
spine
show
multilevel
lumbar
disciti
psoa
abscess
transthorac
echocardiogram
demonstr
mitral
valv
lesion
sever
mitral
regurgit
blood
cultur
admiss
neg
taken
antibiot
treatment
urin
microscopi
indic
infect
serolog
coxiella
brucella
eventu
neg
patient
switch
treatment
iv
vancomycin
iv
gentamicin
transfer
local
cardiothorac
surgeri
unit
assess
patient
underw
valv
replac
excis
valv
sent
microscopi
cultur
gram
stain
show
gram
posit
cocci
staphylococcu
epidermidi
grown
broth
cultur
direct
cultur
neg
felt
consist
patient
present
valv
refer
pcr
posit
aerococcu
urina
aerococci
rare
caus
endocard
endocard
spinal
infect
report
one
case
awar
provid
unifi
diagnosi
patient
given
risk
factor
bladder
calculi
male
gender
age
patient
respond
week
treatment
benzypenicillin
gentamicin
purpos
studi
review
incid
uti
spc
insert
note
common
msu
result
patient
uti
notic
relat
rate
uti
demograph
factor
length
time
injuri
spc
insert
method
retrospect
studi
sci
patient
supra
pubic
cathet
insert
conduct
nation
spinal
injuri
centr
data
collect
electron
medic
record
statist
analysi
minitab
use
result
patient
identifi
mean
age
incid
uti
patient
prophylact
antibiot
patient
uti
midstream
specimen
urin
msu
collect
patient
msu
sent
antibiot
commenc
mix
growth
common
msu
result
procedur
done
first
admiss
spinal
centr
time
injuri
averag
month
statist
associ
occurr
uti
age
sex
time
injuri
discuss
andor
conclus
msu
collect
pre
antibiot
treatment
good
practic
rule
limit
use
wide
spectrum
antibiot
cultur
test
futil
taken
antibiot
therapi
uti
common
popul
examin
even
use
prophylact
antibiot
treatment
futur
research
look
prophylact
antibiot
use
effect
background
enteropathogen
escherichia
coli
epec
lead
caus
infantil
diarrhea
present
e
coli
popul
structur
seven
major
phylogenet
group
strain
respons
extraintestin
infect
belong
phylogroup
phylogroup
e
f
contain
strain
best
known
member
form
sister
group
phylogroup
respect
phylogroup
c
close
relat
distinct
phylogroup
aim
object
aim
studi
gain
insight
distribut
phylotyp
enteropathogen
escherichia
coli
virul
gene
associ
clinic
characterist
children
five
year
age
suffer
diarrhea
delhi
india
method
diarrheagen
e
coli
strain
isol
children
diarrhea
examin
presenc
enteropathogen
e
coli
real
time
pcr
perform
antibiot
suscept
test
quadruplex
pcr
perform
distribut
isol
among
seven
phylogroup
describ
clermont
et
al
statist
analysi
use
comparison
categor
data
result
found
epec
predomin
phylogenet
group
follow
phylogenet
group
f
c
e
one
isol
remain
unclassifi
silico
studi
perform
understand
relationship
background
littl
known
use
antibiot
extent
antibiot
associ
diarrhoea
aad
spinal
cord
injuri
sci
patient
aim
object
studi
aim
record
use
antibiot
ii
establish
preval
aad
iii
assess
season
variat
respect
antibiot
use
incid
aad
method
retrospect
studi
conduct
three
british
sci
centr
octob
june
data
collect
use
standardis
questionnair
defin
aad
wateri
stool
type
bristol
stool
scale
hour
result
sixhundredandtwentyf
adult
median
age
year
femal
sci
tetraplegia
complet
sci
includ
patient
antibiot
top
three
indic
antibiot
urinarytract
infect
skininfect
pressur
ulcer
infect
twentyon
develop
aad
statist
differ
observ
number
antibiot
sever
sci
use
protonpumpinhibitor
h
blocker
use
lax
group
aad
common
summer
season
compar
spring
autumn
winter
p
aad
associ
older
adult
p
tetraplegia
p
hypoalbuminaemia
p
elev
bodymassindex
p
urinarytractinfect
common
autumn
season
p
multicentr
studi
found
aad
common
sci
patient
mayb
risk
factor
poorer
outcom
increas
hospit
cost
studi
test
whether
probiot
reduc
incid
aad
warrant
especi
summer
season
background
staphylococcu
aureu
aureu
known
form
biofilm
colon
damag
skin
hand
aim
object
investig
chang
quantiti
aureu
hand
chang
skin
damag
use
handcleans
formul
potassium
oleat
without
sanit
formul
highli
effect
remov
aureu
biofilm
caus
minim
skin
damag
design
prospect
crossov
doubleblind
commiss
test
set
particip
studi
includ
medic
staff
member
geriatr
health
servic
facil
cosmo
intervent
particip
use
two
type
handcleans
formul
formul
b
week
aureu
hand
cultur
swab
sampl
agar
plate
surfac
evalu
scali
sesc
indic
scali
dryness
keratin
measur
use
uvmicroscop
marker
skin
damag
result
quantiti
aureu
use
formul
week
colonyform
unit
cfu
ml
statist
signific
decreas
quantiti
aureu
cfuml
use
p
addit
sesc
use
formul
week
significantli
lower
sesc
week
use
p
formul
b
quantiti
aureu
sesc
significantli
chang
use
p
conclus
formul
remov
aureu
hand
particip
skin
damag
hand
improv
presum
occur
formul
gentli
remov
aureu
biofilm
evalu
clinic
util
posit
pneumocysti
pneumonia
pcr
larg
teach
hospit
isobel
ramsay
huina
yang
vanessa
wong
jumok
sule
addenbrook
hospit
background
pneumocysti
pneumonia
pcp
therapi
cover
empir
broad
spectrum
antibiot
use
treatment
pneumonia
posit
pcppcr
result
alon
diagnost
infect
may
repres
colonis
aim
object
determin
clinic
util
posit
pcr
result
guid
pcp
therapi
method
pcp
pcr
perform
respiratori
sampl
includ
sputum
request
use
inhous
assay
ct
valu
deem
posit
laboratori
databas
search
patient
posit
result
period
end
septemb
demograph
clinic
diagnost
therapeut
data
contribut
therapeut
decis
make
collect
hospit
inform
system
result
identifi
patient
posit
result
immunosuppress
unknown
abnorm
chest
radiolog
ct
chest
radiograph
mention
pcp
sampl
four
patient
sent
grocott
stain
posit
twelv
patient
start
treatment
sampl
collect
median
day
rang
day
prophylaxi
two
treat
sampl
collect
result
follow
posit
result
continu
treatment
start
treatment
one
prophylaxi
twenti
patient
receiv
day
treatment
three
treat
patient
die
hospit
admiss
discharg
die
within
day
admiss
remain
treat
patient
untreat
patient
surviv
day
admiss
discuss
andor
conclus
posit
pcr
help
clinic
decis
make
patient
start
continu
pcp
treatment
creatin
kinas
monitor
patient
receiv
daptomycin
background
clinic
studi
increas
plasma
creatin
phosphokinas
ck
level
associ
muscular
pain
andor
weak
report
therapi
daptomycin
product
licens
state
plasma
ck
level
measur
baselin
least
weekli
therapi
aim
object
primari
outcom
complianc
recommend
measur
baselin
weekli
ck
level
ii
signific
elev
time
baselin
ck
lead
cessat
therapi
method
conduct
retrospect
studi
tertiari
hospit
england
use
pharmaci
system
identifi
patient
receiv
daptomycin
three
year
baselin
ck
level
defin
measur
point
either
previou
six
month
day
first
dose
patient
receiv
dose
subsequ
level
would
expect
around
day
margin
error
day
result
total
patient
identifi
differ
patientepisod
baselin
ck
level
measur
case
patient
baselin
level
sixteen
patient
ck
level
measur
eightyon
patient
receiv
seven
dose
daptomycin
repeat
ck
level
taken
appropri
time
around
week
start
daptomycin
therapi
four
patient
high
level
daptomycin
treatment
discuss
andor
conclus
import
monitor
ck
level
although
elev
level
rare
daptomycin
therapi
may
return
normal
despit
continu
clare
murphi
hannah
soulsbi
sarah
macalisterhal
ronald
andrew
seaton
teresa
inkster
greater
glasgow
clyde
nh
trust
nh
greater
glasgow
clyde
nh
trust
background
aggregatibact
aphrophilu
part
normal
oropharyng
flora
fastidi
slow
grow
gram
neg
coccobacillu
part
hacek
group
organ
associ
endocard
case
report
report
liver
brain
epidur
abcess
along
bone
joint
infect
pneumonia
empyema
adhesin
virul
factor
produc
organ
enabl
intracrani
abscess
format
aphrophilu
found
normal
canin
flora
brain
abscess
report
patient
close
contact
dog
year
old
ladi
present
week
vomit
diarrhoea
abdomin
pain
comput
tomographi
ct
magnet
reson
imag
scan
mri
abdomen
demonstr
multipl
liver
lesion
blood
cultur
grew
aphrophilu
follow
deterior
day
thirteen
brain
ct
demonstr
multipl
brain
abscess
result
ladi
treat
three
month
ceftriaxon
six
week
metronidazol
switch
oral
amoxicillin
td
complet
year
antibiot
total
repeat
imag
six
month
end
treatment
show
tini
fleck
persist
enhanc
new
lesion
remain
well
sinc
complet
therapi
discuss
andor
conclus
case
illustr
import
take
blood
cultur
prior
antibiot
administr
commun
clinic
inform
microbiolog
laboratori
good
commun
improv
likelihood
isol
fastidi
organ
aphrophilu
thu
optimis
patient
manag
jenna
gilli
mairi
macleod
nh
greater
glasgow
clyde
background
sinc
rise
case
invas
group
streptoocci
streptococcu
pyogen
associ
morbid
mortal
aim
object
aim
review
case
group
streptococc
bacteraemia
greater
glasgow
clyde
determin
sourc
treatment
plan
type
mortal
rate
method
blood
cultur
isol
patient
detail
collect
use
local
laboratori
system
telepath
patient
one
posit
blood
cultur
within
day
period
class
singl
episod
electron
record
patient
record
review
result
episod
identifi
adult
paediatr
common
sourc
identifi
adult
cohort
cellul
follow
sourc
identifi
septic
arthriti
pneumonia
paediatr
cohort
common
sourc
skin
infect
associ
chickenpox
follow
septic
arthriti
port
mortem
find
tonsil
adult
paeditr
cohort
isol
penicillin
sensit
adult
isol
resist
macrolid
clindamycin
adult
isol
test
doxycylin
resist
paediatr
isol
sensit
macrolid
clindamycin
common
antibiot
regim
iv
benzylpenicillin
clindamycin
adult
children
day
mortal
adult
paediatr
emm
type
commonest
emm
type
group
discuss
andor
conclus
find
show
wide
varieti
sourc
typingmort
rate
keep
rest
europ
charlott
brookfield
summya
fatima
emma
bradley
ivor
cartmil
background
clostridium
difficil
infect
associ
high
morbid
mortal
nation
guidanc
avail
inform
manag
translat
local
guidelin
within
pennin
acut
hospit
nh
trust
aim
object
aim
project
evalu
local
complianc
nation
local
standard
improv
servic
highlight
method
audit
conduct
hospit
acquir
toxin
posit
c
difficil
case
hour
post
admiss
januari
decemb
total
patient
audit
standard
evalu
sever
assess
mdt
involv
appropri
treatment
monitor
escal
stop
inappropri
antibioticsproton
pump
inhibitor
therapi
data
taken
patient
note
infect
control
note
electron
prescrib
system
microbiolog
document
result
audit
demonstr
mdt
approach
place
good
commun
result
infect
control
liaison
also
evid
support
patient
regularli
reassess
concomit
use
broad
spectrum
antibiot
review
vast
major
patient
commenc
oral
vancomycin
mortal
outcom
audit
compar
nation
standard
area
improv
includ
document
initi
assess
sever
stratif
clinic
microbiolog
note
patient
could
assess
sever
could
potenti
led
treatment
discuss
andor
conclus
action
audit
focus
increas
educ
clinician
involv
around
initi
assess
therapi
choic
document
new
guidelin
initi
support
assess
tool
develop
ahead
plan
reaudit
vital
role
microbiologist
enhanc
diagnosi
infect
endocard
follow
posit
blood
cultur
manag
wijitha
weerakoon
milind
khare
deborah
gnanarajah
rebecca
turner
derbi
teach
hospit
nh
trust
derbi
teach
hospit
nh
trust
background
consult
microbiologist
note
high
incid
infect
endocard
recent
posit
blood
cultur
result
key
made
microbiologist
initi
investig
case
aim
object
evalu
complianc
trust
guidelin
blood
cultur
collect
suspect
infect
endocard
evalu
adher
bsac
guidelin
empir
select
treatment
method
forti
patient
infect
endocard
review
period
year
result
blood
cultur
time
could
comment
patient
due
delay
suspicion
infect
endocard
group
echocardiographi
advis
microbiologist
follow
posit
blood
cultur
patient
found
streptococc
speci
caus
endocard
enterococc
speci
found
patient
six
patient
staphylococcu
aureu
patient
mrsa
staph
epidermidi
one
patient
candida
albican
patient
found
unusu
pathogen
erysephalothix
rusipathia
haemphilu
parainfluenza
eschericia
coli
citrobact
spp
patient
found
cultur
neg
infect
endocard
prior
antibiot
therapi
inappropri
time
blood
cultur
probabl
reason
case
cultur
neg
endocard
discuss
andor
conclus
good
clinic
assess
consider
risk
factor
take
set
blood
cultur
appropri
time
key
diagnosi
infect
endocard
appropri
manag
background
previou
audit
show
patient
present
chare
cross
adult
e
diagnos
urinari
tract
infect
uti
criteria
diagnosi
vari
patient
urin
cultur
sent
without
clear
clinic
indic
public
health
england
provid
primari
care
guidanc
uti
diagnosi
studi
look
use
guidanc
addit
fever
confus
symptom
may
also
present
patient
attend
hospit
ensur
sampl
sent
appropri
aim
object
improv
investig
diagnosi
uti
e
number
sampl
sent
cultur
month
pre
post
introduct
guidanc
record
laboratori
system
symptom
antimicrobi
therapi
record
patient
sampl
sent
two
week
pre
post
introduct
electron
medic
record
result
number
sampl
sent
decreas
follow
introduct
guidanc
proport
patient
urin
sent
one
symptom
uti
fell
proport
sampl
growth
signific
growth
fell
preintervent
patient
symptom
growth
urin
asymptomat
bacteriuria
commenc
antibiot
decreas
patient
asymptomat
bacteriuria
receiv
antibiot
discuss
andor
conclus
introduct
guidanc
led
fewer
sampl
sent
cultur
decreas
proport
growth
also
decreas
number
patient
receiv
inappropri
antibiot
asymptomat
bacteriuria
result
schaalii
isol
identifi
patient
mean
age
year
rang
commonest
sourc
infect
urinari
patient
bacteraemia
secondari
urosepsi
posit
kidney
urin
bladder
biopsi
cultur
four
present
scrotal
abscess
breast
abscess
necrotis
otiti
externa
pacemak
pocket
infect
isol
assess
clinic
insignific
patient
given
antibiot
receiv
empir
piperacillin
tazobactam
coamoxiclav
isol
suscept
patient
discharg
patient
bacteraemia
receiv
piperacillintazobactam
die
shortli
afterward
discuss
andor
conclus
find
support
role
schaalii
urinari
infect
bacteraemia
particularli
elderli
patient
urolog
abnorm
clinic
signific
less
clear
infect
formal
identif
advis
prevent
misclassif
contamin
blood
urin
cultur
improv
understand
pathogen
potenti
echocardiographi
practic
staphylococcu
aureu
bacteraemia
sab
retrospect
review
univers
teach
hospit
emma
mcguir
aqtab
mazhar
alia
rachel
herbert
eoghan
de
barra
background
sab
frequent
complic
metastat
deposit
carri
high
mortal
rate
bsac
guidelin
recommend
echocardiographi
within
seven
day
treatment
commenc
assess
cardiac
involv
aim
object
purpos
studi
assess
level
adher
guidelin
trust
method
sab
case
april
march
identifi
laboratori
system
conduct
retrospect
analysi
clinic
echocardiographi
data
data
collect
time
indic
outcom
echocardiographi
well
clinic
inform
result
nineti
four
patient
identifi
methicillinsensit
aureu
mssa
methicillinresist
aureu
mrsa
bacteraemia
fifti
four
echocardiogram
either
transthorac
echocardiogram
tte
transoesophag
echocardiogram
toe
vs
respect
median
time
tte
day
rang
day
forti
three
tte
report
evid
infect
endocard
ie
tte
found
equivoc
featur
tte
report
found
patient
forti
case
aureu
bacteraemia
evid
echocardiographi
eighti
five
patient
sab
complic
infect
appropri
indic
echocardiographi
request
document
case
discuss
andor
conclus
low
incid
sab
ie
seri
concern
publish
rate
reason
low
echocardiographi
rate
need
assess
time
echo
limit
use
toe
lack
document
indic
may
reduc
sensit
granulicatella
speci
underrecognis
emerg
pathogen
orthopaed
infect
paulin
jumaa
nia
reev
sarah
mimmack
michael
parri
method
demograph
clinic
microbiolog
data
patient
granulicatella
speci
isol
extract
bone
infect
unit
databas
septemb
april
result
six
patient
granulicatella
speci
isol
identifi
isol
granulicatella
adiacen
granulicatella
elegan
infect
associ
orthopaed
implant
total
hip
replac
total
knee
replac
femor
endoprosthesi
case
compris
infect
follow
hemipelvectomi
knee
amput
excis
liposarcoma
patient
malign
case
report
dental
treatment
prior
infect
patient
implant
twostag
revis
granulicatella
cultur
deep
tissu
sampl
taken
surgeri
case
median
time
isol
granulicatella
speci
day
rang
day
one
case
rrna
pcr
identifi
g
adiacen
addit
cultur
three
patient
polymicrobi
infect
case
treatment
success
erad
infect
one
patient
die
caus
unrel
infect
discuss
andor
conclus
granulicatella
speci
rare
challeng
pathogen
orthopaed
infect
experi
suggest
may
associ
malign
prior
dental
treatment
jessica
johnson
jane
democrati
tae
lee
wexham
park
hospit
john
radcliff
hospit
background
capnocytopagia
canimorsu
infect
rare
nation
survey
done
netherland
identifi
case
per
million
year
case
fatal
rate
present
three
case
sever
sepsi
fatal
associ
anim
bite
present
last
month
blood
cultur
grew
gram
neg
rod
unabl
cultur
identifi
standard
laboratori
techniqu
identifi
capnocytophagia
canimorsu
refer
laboratori
capnocytophagia
rare
import
caus
sever
sepsi
difficult
identifi
laboratori
rawia
badr
rasha
hassan
ghada
mashali
ena
ham
amr
yassen
moham
wahab
faculti
medicin
mansoura
univers
faculti
medicin
liver
transplant
unit
gastroenterolog
surgic
center
background
liver
transplant
life
save
end
stage
liver
diseas
patient
infect
follow
liver
transplant
seriou
complic
data
report
regard
drug
resist
liver
transplant
egypt
aim
object
studi
carri
detect
frequenc
post
transplant
infect
common
site
infect
type
bacteri
isol
antibiot
sensit
pattern
drug
resist
bacteria
gastroenterolog
surgic
center
faculti
medicin
mansoura
univers
within
period
eight
month
april
novemb
method
studi
enrol
patient
experienc
live
donor
liver
transplant
ldlt
studi
period
result
bacteri
infect
rate
patient
within
first
thirti
day
postop
patient
one
infect
patient
experienc
multipl
infect
infect
respiratori
tract
commonest
site
infect
detect
studi
among
infect
patient
enrol
studi
twenti
seven
pathogen
detect
predomin
gram
neg
organ
drug
resist
among
isol
high
includ
isol
multi
extens
drug
resist
respect
discuss
andor
conclus
drug
resist
common
among
liver
transplant
patient
post
oper
gastroenterolog
surgic
center
mansoura
univers
therefor
comprehens
understand
common
pathogen
care
facil
resist
pattern
help
good
implement
infect
control
polici
impact
qualiti
life
liver
transplant
patient
royal
victoria
infirmari
ventil
associ
pneumonia
care
bundl
audit
katherin
watson
manjusha
narayanan
huw
mcconnel
phil
law
background
ventil
associ
pneumonia
vap
caus
increas
durat
ventil
itu
hospit
stay
increas
cost
depart
health
high
impact
intervent
care
bundl
provid
evid
base
approach
reduc
incid
vap
audit
prompt
period
increas
incid
vap
itu
aim
object
review
complianc
care
bundl
key
action
point
elev
head
bed
sedat
level
assess
oral
hygien
subglott
aspir
tracheal
tube
cuff
pressur
ventil
tube
manag
method
retrospect
audit
patient
intub
day
itu
day
period
result
patient
men
women
averag
age
year
ventil
total
day
overal
complianc
vap
care
bundl
action
point
high
audit
standard
greater
complianc
sedat
level
assess
lowest
complianc
patient
ventil
day
treat
ventil
associ
pneumonia
discuss
andor
conclus
result
present
itu
clinic
govern
meet
one
point
improv
emphasis
need
complet
document
plan
reaudit
complianc
check
standard
remain
high
audit
provid
opportun
look
cultur
result
respiratori
specimen
ventil
patient
organ
isol
suscept
cefuroxim
coamoxiclav
support
use
narrow
spectrum
antibiot
especi
pseudomona
aeruginosa
isol
sepsi
bleed
post
tru
biopsi
prostat
identifi
increas
risk
toma
austin
tracey
row
clair
higg
mari
park
senthooran
kanthasami
daniel
wilbi
helen
chesterfield
background
prostat
cancer
diagnosi
rapidli
evolv
diagnost
pathway
tru
transrect
ultrasound
biopsi
prostat
remain
one
main
diagnost
tool
associ
posttru
biopsi
sepsi
bleed
aim
object
predict
patient
higher
risk
develop
sepsi
signific
bleed
tru
biopsi
method
potenti
risk
factor
sepsi
bleed
prospect
record
consecut
patient
singl
institut
use
new
proforma
sheet
month
period
data
includ
previou
travel
antibiot
use
previou
uti
hospit
admiss
presenc
diabet
immunosuppress
indwel
intermitt
selfcatheteris
anticoagul
use
record
standard
antibiot
prophylaxi
ciprofloxacin
given
patient
result
patient
undergo
tru
biopsi
patient
develop
sir
defin
sepsi
requir
readmiss
rectal
bleed
develop
urinari
retent
readmiss
rate
patient
risk
factor
sepsi
previou
antibiot
use
note
patient
prior
travel
previou
uti
patient
readmit
sepsi
previou
risk
factor
sepsi
patient
take
form
anticoagul
medic
readmit
rectal
bleed
discuss
andor
conclus
risk
stratif
sepsi
risk
patient
undergo
tru
biopsi
remain
challeng
studi
fail
identifi
factor
increas
posttru
biopsi
sepsi
bleed
jennif
poyner
louis
wellington
dian
lindsay
robert
weir
kate
templeton
donald
inverar
ian
laurenson
nh
lothian
shlmprl
background
legionella
maceachernii
rare
identifi
caus
legionnair
diseas
six
previous
report
case
worldwid
knowledg
two
uk
case
mayb
largest
case
seri
l
maceachernii
ever
report
result
patient
one
present
septemb
sever
pneumonia
previous
undiagnos
underli
lymphoprolif
disord
patient
die
infect
eight
day
later
patient
two
present
novemb
renal
transplant
patient
cough
diarrhoea
ct
scan
show
right
basal
pneumonia
patient
die
eight
week
later
respiratori
failur
caus
infect
includ
legionella
neither
case
travel
typic
legionellosi
incub
period
case
legionella
spp
detect
inhous
qpcr
part
initi
respiratori
screen
thereaft
confirm
l
maceachernii
scottish
nation
refer
laboratori
levofloxacin
use
core
treatment
uk
legionellosi
notifi
diseas
lothian
health
protect
team
investig
case
clear
sourc
identifi
multipl
environment
sampl
household
member
develop
infect
discuss
andor
conclus
l
maceachernii
may
emerg
caus
legionellosi
diagnosi
depend
use
pcr
cultur
routin
urinari
antigen
test
serolog
detect
speci
clear
link
establish
two
case
despit
live
within
lothian
region
clear
environment
exposur
identifi
two
case
previou
case
report
suggest
l
maceachernii
associ
high
mortal
particularli
immunosuppress
normal
rang
csf
white
cell
count
children
background
mening
occur
children
normal
csf
microscopi
nevertheless
decis
treat
bacteri
mening
often
base
elev
csf
white
cell
count
wcc
respons
typic
normal
csf
wcc
consist
lymphocyt
neutrophil
csf
wcc
also
higher
normal
term
infant
compar
older
children
though
fall
rapidli
first
week
life
aim
object
establish
refer
rang
csf
cell
count
routin
report
microbiolog
depart
specialist
paediatr
hospit
method
review
interpret
guidanc
nice
phe
constitut
normal
csf
wcc
children
nice
clinic
guidanc
document
mening
bacteri
meningococc
speticaemia
uder
recognit
diagnosi
manag
updat
compar
contrast
phe
uk
standard
microbiolog
investig
investig
cerebrospin
fluid
issu
result
neonat
nice
suggest
treatment
bacteri
mening
csf
wcc
least
comment
expect
number
neutrophil
older
children
wccmm
neutrophilmm
consid
abnorm
phe
guidanc
use
follow
age
relat
csf
wcc
rangesmm
neonat
year
year
puberti
adult
make
comment
signific
neutrophil
count
result
total
patient
cpo
identifi
male
mean
age
inpati
hospit
stay
past
year
document
patient
abroad
n
uk
n
n
patient
posit
clinic
sampl
treat
infect
includ
urinari
tract
n
pneumonia
n
intraabdomin
n
intraabdomin
pneumonia
n
blood
stream
n
osteomyel
n
multivari
analysi
cpo
isol
clinic
sampl
associ
infect
ci
p
overal
mortal
rate
first
posit
sampl
treat
infect
start
treatment
eight
death
occur
patient
histori
hospitalis
within
previou
month
associ
reach
statist
signific
p
discuss
andor
conclus
patient
cpo
risk
infect
high
mortal
abil
predict
patient
increas
risk
cpo
infect
could
help
optimis
empir
antimicrobi
therapi
improv
outcom
unusu
case
erysipelothrix
rhusiopathia
bacteraemia
patient
shingl
overview
case
ggc
kirsti
keenan
ashutosh
deshpand
barbara
weinhardt
nh
gg
c
nh
ggc
background
describ
case
woman
admit
sepsi
exacerb
shingl
blood
unremark
except
rel
neutrophilia
crp
blood
cultur
admiss
grew
gram
posit
bacilli
turn
identifi
erysipelothrix
rhusiopathia
describ
clinic
histori
manag
case
well
present
overview
laboratori
report
case
health
board
faecal
carriag
resist
organ
commun
inpati
set
huan
hsin
cheng
manjusha
narayanan
carolin
william
john
perri
newcastl
univers
freeman
hospit
background
increas
preval
antibioticresist
organ
secondari
overus
inappropri
use
antibiot
becom
major
problem
worldwid
due
signific
impact
commun
hospit
bacteria
acquir
antimicrobi
resist
rang
antibiot
creat
seriou
concern
public
health
therefor
vital
health
profession
recogn
presenc
antibioticresist
organ
take
appropri
action
requir
aim
object
purpos
studi
estim
preval
antibioticresist
organ
esbl
extend
spectrum
betalactamas
produc
c
difficil
vre
vancomycinresist
enterococci
mrsa
methicillinresist
staphylococcu
aureu
isol
stool
sampl
inpati
commun
calcul
carriag
resist
organ
within
two
group
method
diarrheal
stool
sampl
inpati
commun
collect
cultur
bacteri
growth
cultur
sampl
identifi
record
hour
incub
result
sampl
posit
gram
neg
bacilli
resist
organ
posit
vre
posit
c
difficil
posit
mrsa
discuss
andor
conclus
preval
esbl
found
studi
show
increas
trend
compar
result
previou
studi
amount
vre
found
lower
carriag
c
difficil
found
higher
compar
valu
past
found
mrsa
posit
consist
decreas
trend
suggest
report
audit
microbiolog
sampl
antimicrobi
manag
patient
suspect
infect
immedi
assess
unit
iau
amrita
randhawa
beth
white
paulin
wright
queen
elizabeth
univers
hospit
qeuh
glasgow
background
suspect
infect
one
commonest
present
medic
receiv
use
antibiot
increas
across
nh
greater
glasgow
clyde
obtain
appropri
sampl
microbiolog
investig
antibiot
commenc
may
allow
switch
narrow
spectrum
altern
reveal
empir
coverag
inadequ
aim
object
aim
establish
whether
appropri
microbiolog
sampl
antimicrobi
manag
patient
achiev
acut
receiv
follow
diagnosi
infect
method
retrospect
singl
centr
studi
perform
medic
receiv
week
period
case
note
review
daili
follow
consult
review
result
studi
includ
patient
major
diagnos
respiratori
tract
infect
follow
genitourinari
tract
skin
soft
tissu
infect
patient
prescrib
antibiot
accord
local
guidelin
median
time
administr
antibiot
patient
sepsi
syndrom
hour
minut
patient
sepsi
syndrom
least
set
blood
cultur
taken
regard
microbiolog
sampl
patient
diagnos
sever
commun
acquir
pneumonia
sputum
sampl
sent
atyp
screen
perform
organ
isol
sampl
class
signific
pathogen
identifi
resist
empir
therapi
discuss
andor
conclus
studi
highlight
work
requir
improv
antimicrobi
sampl
acut
medic
receiv
set
could
achiev
could
influenc
futur
empir
antimicrobi
guidelin
effect
staphylococcu
aureu
toxin
human
platelet
sultan
alnomasi
univers
read
background
camrsa
seriou
human
pathogen
abil
resist
host
immun
defenc
camrsa
abil
caus
acut
infect
mening
endocard
due
product
toxin
phenolsolubl
modulin
psm
toxin
play
import
role
pathogenesi
aureu
aim
object
research
aim
studi
effect
aureu
toxin
human
platelet
activ
effect
aureu
platelet
function
identifi
mechan
interact
aureu
human
platelet
method
aggregomet
use
measur
effect
aureu
platelet
aggreg
flow
cytometri
use
measur
effect
aureu
affin
integrin
fibrinogen
exposur
pselectin
surfac
platelet
phosphovasp
phosphovasp
antibodi
use
determin
mechan
effect
result
aureu
show
abil
inhibit
platelet
aggreg
level
fibrinogen
bind
integrin
significantli
reduc
respons
thrombin
crpxl
due
presenc
aureu
exposur
pselectin
surfac
platelet
also
reduc
indic
platelet
fail
activ
recruit
platelet
aureu
induc
vasp
phosphoryl
human
platelet
residu
discuss
andor
conclus
experiment
data
studi
show
aureu
toxin
inhibitor
platelet
activ
inhibit
due
increas
level
camp
activ
pka
prevent
platelet
activ
result
adult
test
posit
mycoplasma
male
mean
age
year
underli
chest
comorbid
immunocompromis
commonest
present
symptom
cough
fever
sputum
product
short
breath
mean
peak
wbc
count
l
crp
mgl
alt
iul
patient
abnorm
chest
xray
receiv
initi
antibiot
effect
mycoplasma
pcr
result
use
betalactam
fell
whilst
tetracyclin
monotherapi
rose
patient
mean
length
hospit
stay
day
test
antibodi
titr
neg
serolog
test
within
day
symptom
onset
discuss
andor
conclus
cohort
predominantli
young
male
patient
present
lrti
symptom
includ
patient
erythema
multiform
major
myocard
acut
delirium
recognis
phenomena
associ
mycoplasma
patient
receiv
initi
antibiot
effect
mycoplasma
mani
treatment
rationalis
follow
pcr
result
suggest
test
chang
practic
introduct
streptococcu
bovi
group
associ
endocard
gastrointestin
tract
malign
associ
strongest
gallolyticu
subspeci
gallolyticu
previous
known
bovi
biotyp
review
clinic
present
antimicrobi
suscept
pattern
streptococcu
bovi
group
blood
cultur
isol
nh
greater
glasgow
clyde
method
use
list
gener
use
lim
system
tpath
review
electron
patient
record
patient
isol
streptococcu
gallolyticu
streptococcu
lutetiensi
streptococcu
infantariu
streptococcu
pasteurianu
blood
cultur
result
present
breakdown
special
patient
manag
whether
blood
cultur
monomicrobi
part
mix
cultur
whether
patient
prosthet
materi
penicillin
minimum
inhibitori
concentr
mic
whether
deep
sourc
identifi
mortal
date
conclus
result
guid
train
medic
staff
local
manag
infect
allow
us
give
local
accur
inform
clinic
team
advis
isol
organ
discuss
andor
conclus
four
main
pathogen
predomin
among
ophthalmolog
sampl
tertiari
referr
london
eye
hospit
among
pathogen
amr
commonli
use
agent
high
epidemiolog
must
integr
empir
antimicrobi
prescrib
decis
patient
cohort
furthermor
high
rate
amr
suggest
sampl
cultur
suscept
suspect
bacteri
eye
infect
undertaken
enabl
subsequ
target
antimicrobi
therapi
background
sexual
health
clinic
bart
health
current
perform
direct
nearpati
inocul
select
plate
neisseria
gonorrhoea
ng
suspect
case
gonorrhoea
use
dispos
inocul
loop
sigma
transwab
liquid
medium
transport
swab
compliant
compris
cellular
polyurethan
foam
effici
absorpt
releas
specimen
design
improv
recoveri
ng
allow
plate
inocul
occur
central
control
laboratori
condit
aim
object
evalu
compar
recoveri
ng
sigma
transwab
versu
convent
inocul
loop
symptomat
patient
sexual
health
clinic
bart
health
trust
method
patient
suspect
gonorrhoea
sampl
taken
sigma
transwab
routin
dispos
loop
loop
use
inocul
select
plate
peripher
clinic
transwab
transport
main
laboratori
inocul
plate
incub
parallel
plate
examin
hour
cultur
growth
result
total
patient
sampl
cultureposit
ng
dispos
loop
method
pick
posit
sampl
whilst
transwab
pick
posit
cultur
posit
ng
cultur
miss
transwab
grew
hour
discuss
andor
conclus
transwab
found
inferior
tradit
method
regard
abil
recov
viabl
gonoccocu
evalu
abl
assess
improv
evalu
current
provis
gonococc
cultur
highlight
unit
kingdom
accredit
servic
mycobacterium
mucogenicum
case
report
persist
rash
background
mycobacterium
mucogenicum
belong
rapidgrow
nontubercul
mycobacteria
commonli
found
contamin
water
pathogen
seem
mainli
caus
lineassoci
infect
case
skin
infect
caus
mucogenicum
publish
aim
object
would
like
present
case
persist
rash
mucogenicum
repeatedli
grown
tissu
sampl
method
patient
consent
obtain
result
patient
midsixti
seen
dermatolog
venou
eczema
bilater
lower
limb
oedema
known
rheumatoid
arthriti
physic
examin
papular
voilac
rash
left
lower
leg
note
report
slow
progress
rash
two
year
period
patient
immunosuppress
due
methotrex
treatment
rash
first
develop
histopatholog
tissu
taken
rash
appear
noncas
granulomat
inflamm
sampl
two
biopsi
rash
sent
refer
laboratori
mucogenicum
grew
day
incub
sampl
organ
test
suscept
amikacin
clarithromycin
doxycyclin
imipenem
linezolid
discuss
andor
conclus
find
interpret
clinic
relev
mucogenicum
found
two
biopsi
concur
clinic
histopatholog
pictur
prolong
cours
doxycyclin
plan
follow
patient
care
dermatolog
team
nontubercul
mycobacteria
mucogenicum
caus
wide
rang
infect
due
acidfast
natur
appropri
diagnost
method
chosen
infect
organ
possibl
background
solut
hai
germ
increas
antibiot
disinfect
resist
problem
requir
develop
implement
new
effect
approach
pathogen
destruct
aim
object
studi
effect
puls
xenon
ultraviolet
uv
radiat
continu
spectrum
gener
irradi
devic
clinic
strain
mdr
bacteria
mrsa
vre
p
aeruginosa
acinetobact
baumannii
k
pneumonia
difficil
spore
mycobacterium
terra
test
strain
method
plastic
metal
surfac
contamin
correspond
bacteria
difficil
spore
expos
radiat
initi
contamin
surfac
place
vertic
horizont
irradi
distanc
exposur
time
minut
bacteria
minut
mycobacteria
minut
c
difficil
spore
sheep
red
blood
cell
use
biolog
burden
result
treatment
horizont
vertic
align
plastic
metal
surfac
contamin
bacteri
strain
except
difficil
mycobacteria
effect
decreas
microbi
count
reach
lg
lg
mycobacteria
c
difficil
spore
surfac
place
vertic
distanc
irradi
elimin
microorgan
achiev
minut
distancein
minut
discuss
andor
conclus
high
effici
continu
spectrum
puls
uv
test
hai
pathogen
allow
recommend
irradi
devic
puls
xenon
lamp
wide
use
hospit
chlorhexidineimpregn
wipe
prevent
multiresist
bacteria
colon
intens
care
unit
jesu
ruiz
esther
villarr
monica
gordon
juan
frasquet
castellano
susana
cuesta
marcela
pieruccioni
paula
ramirez
hospit
universitario
la
fe
intens
care
unit
hospit
universitario
la
fe
aim
object
assess
efficaci
chlorhexidineimpregn
wipe
clinellwash
vesisminibersurg
prevent
multiresist
bacteria
mrb
colon
infect
intens
care
unit
icu
method
prospect
observ
studi
critic
care
unit
design
chlorhexidin
wipe
introduc
daili
wash
patient
undergo
mechan
ventil
patient
colon
mrb
assess
efficaci
chlorhexidin
wipe
evolut
number
patient
icustay
mrb
colon
analys
month
number
nosocomi
infect
compar
equival
period
last
year
analys
data
analysi
conduct
stata
softwar
use
jisquar
test
compar
proport
evolut
patient
colon
month
evalu
use
linear
regress
model
result
intervent
period
patient
admit
icu
mean
age
sd
year
apach
ii
median
iqr
follow
introduct
chlorhexidin
wipe
signific
reduct
incid
patient
mrb
colon
month
observ
p
signific
reduct
number
icustay
mrb
colon
found
p
signific
reduct
overal
incid
nosocomi
infect
intervent
period
compar
equival
period
last
year
observ
vs
p
contact
dermat
observ
treat
patient
discuss
andor
conclus
chlorhexidineimpregn
wipe
reduc
incid
colon
infect
mrb
appear
practic
tool
prevent
nosocomi
infect
critic
care
unit
valu
clean
monitor
endoscop
reprocess
hen
reuter
sabin
heiligtag
walter
popp
nina
parohl
germani
hykom
gmbh
background
recent
report
endoscopeassoci
outbreak
mdro
shown
reprocess
flexibl
endoscop
remain
challeng
improv
qualiti
control
close
monitor
clean
endoscop
contribut
identif
endoscop
risk
patient
patient
transmiss
aim
object
demonstr
contribut
clean
monitor
adenosinetriphosph
atp
bioluminesc
test
reprocess
flexibl
endoscop
overal
process
qualiti
method
bedsid
flush
manual
clean
autom
endoscop
reprocess
aer
process
step
routin
reprocess
clinic
use
gastroscop
monitor
six
nonconsecut
day
atp
test
german
teach
hospit
result
studi
show
unstabl
clean
outcom
reprocess
although
clean
perform
manual
clean
aer
rel
stabl
studi
suggest
endoscop
procedur
effect
bedsid
flush
drive
overal
outcom
endoscop
clean
influenc
condit
specif
endoscop
invas
procedur
shown
discuss
andor
conclus
clean
monitor
reprocess
flexibl
endoscop
rapid
sensit
quantit
atp
test
help
identifi
endoscop
risk
contribut
pathogen
transmiss
provid
immedi
feedback
oper
systemat
surveil
provid
improv
overal
qualiti
control
reprocess
endoscop
help
hospit
document
process
qualiti
water
water
everywher
ward
sink
demount
tap
mixer
assembl
process
washer
disinfector
background
infect
pseudomona
aeruginosa
link
hospit
water
suppli
sourc
belfast
outbreak
thought
handwash
basin
tap
ref
guidanc
given
htm
addendum
state
healthcar
premis
flush
regim
place
advis
discard
patientassoci
fluid
eg
bath
water
sink
howev
although
may
reduc
delay
format
biofilm
prevent
tap
capabl
easili
remov
plumb
system
dismantl
thermal
disinfect
develop
armitag
shank
studi
tap
assembl
artifici
contamin
biofilmproduc
strain
p
aeruginosa
process
valid
benchtop
thermal
washer
disinfector
wd
method
tap
dismantl
compon
contamin
immersionflush
suspens
test
organ
left
humid
environ
day
compon
process
wd
sampl
occur
disinfect
establish
pre
post
disinfect
count
test
perform
triplic
result
tap
effect
decontamin
compliant
thermal
washer
disinfector
accept
reduct
p
aeruginosa
achiev
ie
log
discuss
andor
conclus
test
demonstr
tap
assembl
effect
decontamin
wd
advantag
process
clean
part
wd
cycl
assist
remov
biofilm
studi
plan
support
use
tap
clinic
area
sort
fact
fiction
atp
testinga
new
algorithm
improv
sampl
cleanli
measur
use
atp
test
greg
whiteley
trevor
glasbey
western
sydney
univers
western
sydney
univers
whiteley
corpor
background
rapid
test
adenosin
triphosph
atp
becom
commonli
use
method
quantit
assess
surfac
devic
cleanli
atp
test
easi
use
broad
measur
cellular
contamin
provid
real
time
altern
visual
inspect
howev
atp
test
subject
variabl
problem
affect
interpret
use
result
variabl
includ
inher
variabl
aris
devic
perform
issu
caus
imprecis
difficulti
limit
quantit
aim
object
improv
valid
cleanli
measur
use
atp
test
method
seri
experi
defin
dynam
rang
sever
avail
atp
test
system
perform
characterist
indic
imprecis
due
variabl
limit
detect
limit
quantit
devic
test
statist
method
appli
develop
new
sampl
algorithm
overcom
risk
variabl
practic
atp
test
sampl
algorithm
use
three
tier
brand
specif
cleanli
threshold
cleanli
verif
step
ensur
surfac
cleanli
verifi
use
valid
clean
method
base
exist
asept
techniqu
result
result
algorithm
indic
method
easi
use
provid
user
quantifi
accur
measur
real
cleanli
statu
surfac
devic
result
indic
new
atp
sampl
algorithm
mitig
inher
variabl
use
applic
includ
cleanli
monitor
environment
surfac
medic
devic
import
implic
improv
cleanli
monitor
use
atp
test
background
outbreak
invas
aspergillosi
connect
ongo
build
work
hospit
moreov
construct
possibl
increas
number
opportunist
microorgan
besid
aspergillu
reduct
overal
bioburden
patient
environ
patient
equip
link
reduc
risk
hospit
acquir
infect
ultrav
system
hygien
solut
utilis
uvc
ray
rapidli
inactiv
dna
ventil
restrict
vapourimperm
requir
aim
object
aim
project
evalu
indic
snapshot
environment
air
contamin
uvc
decontamin
ongo
construct
gener
medic
word
royal
lancast
infirmari
total
room
test
test
includ
total
viabl
count
tvc
sampl
uv
decontamin
air
sampl
merck
air
sampler
perform
test
room
decontamin
immedi
hour
week
total
fungal
bacteri
count
air
determin
result
tvc
show
reduct
obtain
decontamin
highest
tvc
level
record
toilet
roll
holder
bin
lid
sink
air
sampl
show
highli
variabl
number
differ
mould
domin
penicillium
less
virul
mould
evid
reduct
follow
decontamin
discuss
andor
conclus
uvc
decontamin
achiev
signific
level
reduct
microorgan
detect
surfac
lower
environment
contamin
minimis
risk
infect
construct
improv
patient
safeti
object
studi
evalu
antimicrobi
properti
copper
select
copper
alloy
cn
highli
resist
antibiot
isol
touch
surfac
polish
hospit
unit
method
modif
japanes
standarda
method
test
antimicrobi
properti
surfac
made
nonpor
materi
use
studi
assess
antimicrobi
properti
perform
copper
alloy
cuetp
posit
control
stainless
steel
neg
control
bacteri
strain
use
studi
staphylococcu
haemolyticu
staphylococcu
epidermidisstrain
resist
betalactam
antibiot
aminoglycosid
fluoroquinolon
clindamycin
erythromycin
trimethoprimsulfamethoxazol
vs
strain
speci
form
biofilm
comparison
stapylococcu
aureu
result
strongest
antimicrobi
properti
test
strain
found
pure
coppertot
elimin
bacteria
level
cfuml
observ
approxim
min
faster
total
reduct
densiti
bacteri
suspens
also
observ
case
sa
compar
cn
strain
effect
compar
pure
copper
demonstr
tin
bronz
result
demonstr
copper
alloy
materi
exhibit
strong
antimicrobi
properti
studi
strain
mean
use
equip
made
materi
antimicrobi
properti
help
limit
spread
antibiot
resist
gene
hospit
environ
work
carri
framework
ncbir
project
background
report
decolon
mrsa
carrier
shown
low
success
rate
patient
colon
multipl
posit
site
risk
factor
intraven
line
indwel
cathet
wound
aim
object
want
evalu
whether
use
perform
decolon
attempt
patient
promot
univers
rather
target
decolon
center
method
octob
may
mrsa
carrier
decolon
use
day
treatment
protocol
includ
chlorhexidin
bodi
mouth
wash
mupirocin
nasal
ointment
data
collect
extent
colon
nose
throat
perineum
site
risk
factor
could
influenc
outcom
control
screen
sampl
taken
least
day
complet
protocol
result
mrsa
patient
treat
accord
day
protocol
patient
colon
one
locat
nose
throat
perineum
n
decolon
protocol
prove
effect
case
patient
colon
multipl
locat
n
andor
risk
factor
n
treatment
success
respect
patient
patient
becam
neg
one
attempt
overal
carrier
remain
neg
one
year
follow
discuss
andor
conclus
success
rate
mrsa
decolon
even
patient
estim
low
chanc
success
includ
therefor
univers
rather
target
mrsa
decolon
strategi
seem
justifi
method
six
orthopaed
flexibl
drill
bit
fdb
contamin
trypic
soya
broth
contain
sheep
blood
staphylococcu
aureu
cellsml
allow
dri
hour
subject
prerins
manual
autom
clean
atp
present
instrument
surfac
lumen
surfac
protein
test
bacteri
contamin
coloni
form
unit
determin
step
experi
repeat
five
time
result
protein
test
insensit
fail
detect
fdb
subject
prerins
requir
clean
present
clean
requir
rerins
despit
atp
read
rlu
atp
level
microbi
load
significantli
decreas
follow
either
manual
automat
clean
p
median
valu
surfac
atp
rlu
prerins
manual
clean
automat
clean
instrument
respect
similar
result
obtain
lumin
atp
microbi
load
prerins
instrument
log
decreas
log
manual
clean
automat
clean
remov
microbi
contamin
log
reduct
discuss
andor
conclus
protein
test
use
unsuit
pointofus
test
determin
instrument
clean
atp
demonstr
suitabl
pointofus
test
howev
analysi
rlu
variabl
need
valid
benchmark
aim
detect
improv
hidden
procedur
daili
hospit
routin
method
literatur
review
questionnair
compos
question
sent
italian
bmt
centr
februari
march
princip
bmt
nurs
centr
fill
questionnair
googl
drive
platform
main
domain
six
infect
control
screen
isol
decontamin
collabor
commun
result
seventytwo
centr
divid
adult
paediatr
mix
depart
answer
questionnair
fortyeight
unit
compos
bmt
centr
haematolog
divis
bmt
centr
patient
room
colonis
mdro
clean
twice
day
case
left
last
room
clean
unit
clean
personnel
get
centr
specif
educ
mdro
decontamin
unit
throughout
compos
cleaner
microbiolog
control
final
decontamin
take
place
bmt
depart
particl
count
plate
swab
common
procedur
control
effect
decontamin
discuss
andor
conclus
nation
survey
give
snapshot
current
situat
itali
mani
procedur
could
improv
standardis
order
enfeebl
mdro
bmt
unit
evalu
dispos
preimpregn
wipe
versu
standard
twostep
protocol
clean
disinfect
hightouch
surfac
intens
care
hightouch
surfac
intens
care
unit
clean
disinfect
either
daili
standard
twostep
protocol
applic
alcoholbas
deterg
keradet
kiehl
follow
chlorinebas
disinfect
antisapril
angelini
use
dispos
wipe
impregn
quaternari
ammonium
compoundsbiguanid
clinel
univers
wipe
gama
effect
reduc
microbi
burden
high
touch
nearpati
surfac
assess
contact
plate
method
five
site
immedi
preprocedur
postat
hour
studi
repeat
five
time
three
month
sampl
bed
protocol
sampl
site
result
preimpregn
wipe
demonstr
decreas
mean
total
bacteri
count
tbc
cm
hour
vs
reduct
cm
sp
subsequ
test
mean
tbc
decreas
respect
dispos
wipe
sp
method
tbc
show
increas
accord
italian
hygien
standard
ispesl
use
preimpregn
wipe
site
site
show
tbc
cfu
cm
hygien
failur
wherea
sp
site
class
fail
chi
squar
p
discuss
andor
conclus
dispos
wipe
use
nearpati
inanim
surfac
provid
effect
altern
usual
twostep
procedur
consid
potenti
residu
activ
jawal
said
tamara
perez
outeir
jeanyv
maillard
martin
kiernan
cardiff
universitygama
healthcar
ltd
cardiff
univers
background
clinic
surfac
may
becom
contamin
microorgan
clean
disinfect
crucial
intervent
minimis
spread
healthcar
associ
infect
viabl
organ
shown
persist
dri
biofilm
even
termin
clean
disinfect
work
demonstr
use
dri
biofilm
test
investig
efficaci
variou
disinfect
approach
method
staphylococcu
aureu
ncimb
biofilm
grown
trypton
soya
broth
mm
stainless
steel
disc
finish
day
rotat
wet
dri
phase
everi
h
dri
biofilm
expos
disinfect
solut
vari
exposur
time
wipe
disinfect
wipe
use
test
comparison
wet
biofilm
aureu
grown
h
dri
aureu
inoculum
en
use
disinfect
includ
chlorin
glutaraldehyd
peracet
acid
assess
efficaci
measur
biomass
reduct
crystal
violet
stain
biofilm
recoveri
indic
ph
indic
colour
chang
transfer
bacteria
surfac
surfac
result
treatment
dri
biofilm
wipe
show
reduct
biomass
biocid
solut
alon
show
littl
reduct
biomass
mode
treatment
achiev
ideal
log
reduct
cfu
biofilm
recoveri
seen
colorimetr
medium
h
wet
biofilm
grown
h
show
recoveri
colorimetr
medium
h
dri
biofilm
contrast
wet
biofilm
plankton
cell
found
persist
biocid
exposur
highlight
need
improv
antibiofilm
approach
background
necess
proper
disinfect
steril
overemphas
success
prevent
control
healthcar
associ
infect
hai
improp
steril
pose
seriou
threat
infect
patient
aim
object
assess
impact
multimod
intervent
program
improv
decontamin
practic
medic
instrument
among
healthcar
worker
hcw
secondari
level
healthcar
facil
bangladesh
method
yearlong
quasi
experiment
studi
conduct
two
secondari
level
healthcar
facil
bangladesh
total
hcw
particip
includ
physician
nurs
laboratori
technician
ward
boy
clean
staff
multimod
intervent
program
consist
educ
standard
decontamin
process
skill
enhanc
job
train
improv
decontamin
facil
complianc
standard
decontamin
practic
measur
direct
observ
intervent
result
continu
improv
complianc
standard
method
disinfect
steril
seen
intervent
remark
complianc
institut
child
mother
health
icmh
gener
hospit
sirajgonj
gh
p
indic
tape
steril
introduc
hospit
complianc
significantli
increas
icmh
gh
p
cleanli
steril
room
improv
icmh
gh
discuss
andor
conclus
studi
result
show
implement
multimod
intervent
improv
standard
decontamin
practic
among
hcw
turn
play
critic
role
prevent
control
healthcar
associ
infect
singleb
space
within
multibed
bay
safe
decontamin
uvc
without
pose
risk
patient
staff
background
decontamin
singl
bedspac
within
multibed
patient
bay
hpv
uvc
logist
difficult
achiev
empti
whole
bay
patient
put
much
oper
pressur
hospit
whole
uvc
easili
block
solid
object
includ
fabric
glass
aim
object
aim
studi
establish
whether
would
safe
use
uvc
sourc
decontamin
singleb
space
within
multibed
bay
screen
standard
hospit
privaci
curtain
studi
carri
clinic
simul
room
educ
centr
univers
hospit
coventri
fit
threebed
bay
found
elsewher
acut
hospit
bed
space
fit
standard
issu
flameretard
polyest
curtain
sunlight
uk
system
hygien
solut
king
lynn
uk
oper
within
bedspac
behind
close
privaci
curtain
uv
level
outsid
curtain
measur
use
bentham
doubl
monochrom
system
bentham
instrument
ltd
read
uk
spectrum
rang
nm
measur
head
abdomen
ankl
height
made
use
polystyren
bodi
shape
maniken
place
outsid
close
curtain
result
lowest
valu
effect
treatment
dose
equival
around
time
maximum
permiss
uv
exposur
maximum
treatment
dose
around
time
exposur
limit
discuss
andor
conclus
would
therefor
advis
oper
uvc
system
hospit
curtain
screen
bedspac
patient
staff
background
although
steam
steril
failur
report
due
failur
remov
air
load
classic
exampl
devonport
incid
still
widespread
denial
healthcar
group
presenc
air
contribut
steril
failur
aim
object
aim
studi
investig
steam
penetr
dental
handpiec
use
benchtop
nonvacuum
steril
commonli
use
dental
practic
method
three
differ
type
handpiec
investig
steam
penetr
handpiec
lumen
use
chemic
indic
ci
biolog
indic
bi
thermocouplesdata
logger
tc
nonvacuum
type
n
benchtop
steam
steril
investig
laboratori
gener
dental
practic
set
laboratori
test
differ
make
machin
model
make
gener
dental
practic
set
test
seven
nonvacuum
benchtop
steril
result
result
laboratori
demonstr
bi
failur
test
ci
failur
test
typic
delay
reach
steril
temperatur
rang
second
detect
use
tc
gener
dental
practic
detect
bi
failur
rate
test
ci
failur
rate
test
tc
failur
rate
defin
temperatur
delay
shtm
discuss
andor
conclus
conclus
demonstr
type
n
steril
dental
handpiec
unreli
due
trap
air
handpiec
lumen
minimum
recommend
dental
handpiec
use
invas
procedur
steam
steril
vacuum
benchtop
steam
steril
nicola
coltel
frank
van
laer
huckert
intern
uza
background
incub
could
sourc
contamin
could
affect
neonat
disinfect
procedur
key
element
fight
pathogen
crucial
point
control
aim
object
assess
perform
dm
dedicateddisinfect
mainten
incub
identifi
potenti
sourc
infect
evalu
sampl
materi
reliabl
accuraci
method
incub
sampl
rodac
plate
environment
swab
disinfet
rodac
plate
appli
mastress
swab
door
tranpsort
liquid
form
swab
spread
specif
chromogen
media
plate
identifi
blindcount
differ
oper
result
disinfect
door
free
contamin
mattress
present
residu
contamin
cfu
saprophyticu
pseudomona
aureu
oftenli
present
mattress
door
observ
anymor
disinfect
disinfect
sampl
perform
differ
oper
incub
appear
realli
posit
contamin
disinfect
inadequ
disinfect
rodac
plate
reliabl
swab
detect
potenti
contamin
swab
sampl
follow
spread
chromogen
media
allow
examin
complex
bacteri
flora
discuss
andor
conclus
neutrali
present
bactericid
activ
min
rodac
plate
power
indic
bacteri
contamin
mattress
contamin
door
bacteria
enterobacteria
andor
pseudomona
cluster
mattress
critic
item
disinfect
monitor
disinfect
control
could
reveal
possibl
lack
disinfecton
treatment
failur
orient
medium
suffici
detect
varieti
bacteria
carla
maria
zotti
savina
ditommaso
monica
giacomuzzi
elisa
ricciardi
depart
public
health
scienc
pediatr
torino
univers
depart
public
health
scienc
pediatr
torino
univers
background
duwl
becom
contamin
main
water
suppli
although
potabl
still
carri
bacteria
remov
inactiv
bacteria
requir
use
chemic
germicid
could
use
intermitt
shock
treatment
andor
continu
small
quantiti
aim
object
longitudin
studi
undertaken
find
efficaci
continu
use
icx
tablet
chemic
cleaner
combin
monthli
shock
disinfect
use
hydrogen
peroxid
method
duwl
effluent
sampl
determin
bacteria
total
viabl
count
tvc
two
dental
chair
treat
one
chair
never
receiv
treatment
efficaci
icx
also
assess
vitro
versu
collect
strain
staphilococcu
aureu
pseudomona
aeruginosa
accord
en
method
result
postintervent
monitor
achiev
level
tvc
conform
limit
italian
standard
drink
water
howev
six
month
surveil
day
shock
chair
show
increas
tvc
signific
differ
found
tvc
detect
dental
chair
receiv
treatment
versu
control
vitro
icx
caus
decim
log
reduct
aureu
respect
min
h
instead
product
less
effect
log
tripleemitt
nm
arrang
around
bed
triangular
format
surfacid
helio
b
singleemitt
nm
reloc
accord
sensor
room
hygien
solut
surfac
swab
taken
environment
site
terminaldisinfect
enhanceddisinfect
inocul
carrier
assay
determin
efficaci
logreduct
result
time
enhanceddisinfect
similar
devic
min
b
min
environment
site
contamin
terminaldisinfect
site
n
enhanceddisinfect
elimin
contamin
use
devic
b
respect
devic
reduc
mrsa
kp
log
reduct
regardless
soil
locat
effect
log
reduct
cd
low
soil
floorsurfac
difficulttoaccess
area
locat
highfrequencytouch
site
locat
less
effect
log
reduct
heavi
soil
devic
effect
reduc
log
cd
bedsid
tabl
despit
heavi
soil
conclus
enhanceddisinfect
uvirradi
effect
mrsa
kp
cd
spore
reduc
contamin
surfac
miss
termin
clean
inus
efficacytest
consid
assur
correct
posit
devic
access
shadow
area
floor
surfac
improv
hospit
decontamin
protocol
vitro
efficaci
disinfect
utilis
skin
decolon
environment
decontamin
hospit
outbreak
candida
auri
silk
schelenz
alireza
abdolrasouli
dariu
armstrongjam
royal
brompton
hospit
imperi
colleg
school
public
health
background
recent
c
auri
outbreak
led
implement
extens
infectionpreventionandcontrolmeasur
c
auri
skin
environment
decontamin
challeng
publish
inform
efficaci
c
auri
aim
object
establish
invitro
efficaci
disinfect
utilis
skin
environment
decontamin
c
auri
outbreak
invitro
suscept
c
auri
atcc
control
test
chlorhexidin
iodinatedpovidon
sodiumdichloroisocyanur
use
microdilutionmethod
howev
comparison
ofa
significantli
fewer
organ
recov
ofb
c
h
respect
p
aeruginosa
recov
water
deliv
ofa
level
augment
care
alert
level
ie
ml
contamin
persist
despit
continu
flush
contrast
water
deliv
ofb
contain
p
aeruginosa
beyond
first
flush
discuss
andor
conclus
contamin
of
via
clean
cloth
occur
design
whilst
remov
potenti
retrograd
contamin
may
combin
flush
regimen
prevent
waterborn
pathogen
contamin
water
deliv
outlet
vitro
studi
biofilm
prevent
use
antibioticload
bead
implic
prosthet
infect
manag
bead
place
well
plate
beadswel
ml
bacteri
strain
cellsml
ad
well
day
h
postinocul
viabl
cell
count
confoc
laser
scan
microscopi
scan
electron
microscopi
bead
surfac
perform
assess
extent
surfac
colonis
biofilm
format
result
follow
two
bacteri
challeng
hr
incub
strain
cshag
csccg
show
extens
bacteri
colon
scsvt
remain
clear
poster
figur
mrsa
scsvt
maintain
log
log
reduct
day
respect
epidermidi
cscvt
maintain
log
reduct
day
respect
discuss
andor
conclus
presenc
broad
spectrum
combin
vancomycin
tobramycin
high
puriti
calcium
sulfat
bone
void
filler
superior
gentamicin
alon
cshag
csccg
respect
biofilm
prevent
bacteri
colonis
challeng
invitro
model
new
makemodel
hcu
fill
filter
tap
water
high
number
pful
ad
tank
allglass
imping
use
sampl
air
hcu
circul
circul
water
sampler
oper
min
imping
fluid
transfer
steril
contain
cultur
result
similar
number
p
recov
air
hcu
circul
pfum
circul
pfum
water
filler
inlet
identifi
princip
area
aerosol
releas
aerosol
releas
affect
posit
inlet
cover
could
minimis
crude
modif
filler
unit
discuss
andor
conclus
specialist
aerobiolog
use
biolog
tracer
determin
level
aerosol
releas
hcu
locat
result
obtain
rapidli
could
use
manufactur
nh
trust
inform
design
purchas
decis
alik
impact
multifacet
intervent
strategi
devic
associ
infect
indian
trauma
center
method
airwat
channel
work
channel
includ
gastroscop
colonoscop
examin
surfac
rough
analys
compar
never
use
channel
live
bacteria
isol
identifi
rdna
sequenc
quantit
realtim
pcr
rrna
gene
use
quantifi
total
number
bacteria
present
livedead
viabil
stain
conjunct
confoc
laser
scan
microscopi
scan
electron
microscopi
use
visual
confirm
bacteri
viabil
biofilm
presenc
respect
result
airwat
channel
work
channel
bacteri
cultur
posit
pcr
demonstr
averag
bacteriacm
contamin
airwat
channel
whilst
averag
bacteriacm
contamin
work
channel
bacteria
sampl
visual
confirm
present
biofilm
sem
bacteria
within
biofilm
shown
viabl
livedead
stain
clsm
use
endoscop
channel
present
higher
rough
valu
compar
new
channel
discuss
andor
conclus
despit
improv
disinfect
process
show
decreas
contamin
endoscop
channel
viabl
biofilm
contain
pathogen
speci
still
found
process
endoscop
channel
aim
provid
preliminari
evalu
diagnost
accuraci
test
detect
candidaemia
nh
servic
context
method
twelv
consecut
adult
candidaemia
identifi
prospect
patient
serum
taken
contemporan
blood
cultur
avail
store
batch
analysi
possibl
serum
obtain
preced
andor
follow
day
also
collect
serum
thirtynin
adult
pair
neg
blood
cultur
also
collect
similar
manner
neg
control
staff
perform
pcr
test
blind
cultur
result
sensit
specif
calcul
express
confid
interv
result
primari
analysi
comparison
pair
blood
cultur
contemporan
serum
undertaken
candidaem
patient
pair
serum
pcrposit
gener
sensit
control
sera
pcrposit
gener
specif
sensit
increas
secondari
analysi
serum
sampl
day
beforeaft
posit
blood
cultur
includ
detect
discuss
andor
conclus
overal
sensit
rendx
fungiplex
test
lower
previous
report
may
relat
low
copynumb
candidaemia
retrospect
pcr
test
furthermor
sampl
size
small
lead
uncertainti
accuraci
metric
diagnost
accuraci
assess
requir
guid
optim
adopt
test
routin
nh
practic
perform
test
evalu
compar
alongsid
select
cultur
screen
method
current
use
institut
test
perform
routin
rectal
screen
sampl
collect
prospect
adult
patient
part
local
cpe
screen
protocol
intend
collect
rectal
swab
report
sensit
specif
turnaround
time
result
c
difficil
gdh
antigen
detect
n
stool
sampl
n
also
posit
cdt
b
cultur
chromagar
c
difficil
fluoresc
coloni
grown
gdh
posit
sampl
absenc
flouresc
coloni
sampl
either
fail
grow
non
flouresc
coloni
howev
sampl
neg
gdh
toxin
flouresc
coloni
discuss
andor
conclus
find
support
use
chromagar
c
difficl
test
found
sensit
specif
easi
perform
sensit
specif
method
detect
presenc
c
difficil
stool
sampl
studi
almost
third
posit
stool
sampl
nondiarrho
unfortun
due
limit
avail
clinic
data
could
ascertain
full
clinicalpubl
health
signific
posit
howev
organ
isol
gener
regard
signific
human
pathogen
conclus
would
advis
extend
polici
test
unform
stool
encompass
enter
pathogen
c
difficil
michael
rist
jame
scriven
background
cn
infect
result
signific
morbid
mortal
manag
complex
difficult
anecdot
evid
suggest
area
suboptim
trust
object
evid
lack
part
wider
cn
audit
look
specif
tb
mening
diagnosi
manag
compar
nation
guidelin
determin
whether
patient
presum
tubercul
mening
investig
appropri
specif
audit
target
follow
bia
guidelin
tb
central
nervou
system
method
patient
identifi
use
birmingham
tb
databas
propos
look
lymphocyt
csf
data
avail
time
audit
electron
paper
record
assess
audit
proforma
complet
detail
demograph
clinic
present
investig
manag
result
headach
fever
common
present
symptom
signific
delay
perform
lumbar
punctur
patient
csf
volum
poorli
document
assess
current
laboratori
report
method
patient
posit
csf
tb
cultur
grew
tb
sputum
bal
remaind
treat
probabl
tbm
patient
form
imag
look
extrapulmonari
tb
background
rapid
pointofcar
test
poct
avail
mani
format
particularli
respiratori
virus
howev
user
need
consid
balanc
turnaround
time
tat
sensitivityspecif
eas
use
cost
test
aim
object
evalu
new
enigma
minilab
pcrbase
poct
test
rsv
influenza
b
without
subtyp
inhous
respiratori
pcr
assay
adult
bone
marrow
transplantoncolog
unit
influenza
season
method
symptomat
consent
patient
requir
treatment
isol
influenzalik
ill
test
take
two
swab
one
enigma
poct
tat
minut
inhous
assay
tat
hour
result
total
sampl
test
rsv
influenza
b
respect
sampl
neg
assay
sampl
po
assay
sampl
po
inhous
assay
neg
poct
wherea
sampl
found
po
poct
neg
inhous
assay
po
poct
inhous
assay
respect
rsv
background
year
old
asylum
seeker
travel
eritrea
uk
overland
libya
mediterranean
europ
present
month
histori
fever
weight
loss
malais
abdomin
pain
initi
investig
includ
chest
xray
routin
blood
abdomin
ultrasound
malaria
film
hiv
test
blood
urin
cultur
unremark
apart
rais
inflammatori
marker
sputum
cultur
grew
haemophiliu
influenza
despit
cours
amoxicillin
fever
continu
wide
differenti
consid
view
ongo
fever
travel
histori
lack
organ
focu
extens
investig
perform
includ
ct
chest
abdomen
pelvi
brucella
leishmania
coxiella
serolog
bone
marrow
biopsi
stool
cultur
microscopi
vascul
screen
caus
found
pet
scan
perform
local
presum
infect
malign
lesion
allow
target
biopsi
multipl
metabol
activ
abdomin
thorac
lymph
node
appar
ct
seen
ebu
collect
insuffici
sampl
definit
histolog
given
countri
origin
clinic
pictur
posit
tspot
test
diagnosi
occult
tubercul
lymphaden
made
antitubercul
therapi
start
patient
defevresc
put
weight
subsequ
stool
cultur
lymph
node
biopsi
sampl
grew
mycobacterium
bovi
case
demonstr
util
pet
scan
new
test
localis
diseas
provid
target
biopsi
also
old
test
stool
cultur
mycobacteria
reach
diagnosi
cryptic
mycobacterium
bovi
lymphadenopathi
direct
identif
blood
cultur
isolatesa
key
improv
antibiot
stewardship
emili
goldstein
aleksandra
marek
mairi
macleod
nh
greater
glasgow
clyde
background
identif
isol
directli
blood
cultur
fluid
use
malditof
permit
preliminari
result
report
pathogen
around
minut
rapid
turnaround
time
allow
target
antibiot
therapi
result
improv
patient
manag
antibiot
stewardship
result
studi
perform
direct
identif
isol
blood
cultur
bottl
flag
posit
use
centrifug
method
compar
result
identif
obtain
use
tradit
cultur
identif
method
correct
identif
achiev
monomicrobi
infect
compar
tradit
method
greater
proport
gram
neg
organ
correctli
identifi
gram
posit
organ
ten
blood
cultur
bottl
investig
studi
polymicrobi
direct
identif
method
correctli
identifi
one
organ
sampl
case
like
pathogen
identifi
eg
staphylococcu
aureu
enterococcu
spp
wherea
probabl
contamin
also
perform
retrospect
analysi
antibiot
prescrib
patient
includ
studi
determin
whether
correct
identif
blood
cultur
isol
use
direct
identif
method
improv
turnaround
time
least
one
day
would
improv
antibiot
prescrib
practic
could
turn
improv
patient
outcom
katharin
relph
jenni
crane
nh
lothian
aim
object
assess
current
practic
investig
suspect
mening
view
newli
publish
uk
joint
specialist
guidelin
establish
area
practic
requir
improv
method
retrospect
audit
patient
present
suspect
mening
lumbar
punctur
lp
suspect
mening
eighteen
month
period
perform
case
identif
undertaken
review
csf
sampl
receiv
laboratori
data
collect
case
note
use
proforma
adapt
recent
guidelin
result
patient
includ
patient
lp
hour
mean
time
lp
hour
rang
present
patient
neuroimag
prior
lp
patient
indic
reason
delay
lp
includ
uncontrol
seizur
deterior
gc
agit
patient
refus
technic
challeng
lp
patient
blood
cultur
sent
patient
blood
sent
bacteri
pcr
discuss
andor
conclus
signific
major
patient
wait
hour
lp
common
factor
delay
wait
neuroimag
improv
investig
patient
follow
intervent
implement
reduc
unnecessari
request
intracrani
imag
educ
medic
staff
simul
lp
teach
medic
traine
improv
access
equip
eg
lp
pack
facilit
time
lp
use
electron
order
bundl
blood
cultur
bacteri
pcr
prospect
analysi
undertaken
assess
propos
background
order
find
strength
weak
health
system
point
patient
safeti
whole
detail
mani
help
factor
likewis
failur
commun
perform
research
patient
care
use
prospect
observ
techniqu
consid
failur
critic
patient
life
resolv
happen
creat
safer
environ
ongo
surgeri
oper
room
draw
attent
staff
potenti
fault
first
one
survey
creat
evalu
staff
knowledg
patient
safeti
consid
method
prevent
error
onepag
form
prepar
collect
fault
near
miss
case
error
durat
research
prefer
research
method
correl
method
differ
aspect
research
durat
one
month
start
point
main
particip
staff
oper
room
iranian
hospit
dubai
next
step
analyz
done
base
lotic
score
result
recommend
solut
remov
problem
like
wise
result
base
collect
data
found
mani
import
negoti
problem
patient
safeti
oper
room
first
miscommun
import
issu
also
found
gap
train
educ
ot
background
hand
hygien
complianc
amongst
medic
staff
poor
perform
project
determin
knowledg
hand
hygien
practic
initi
result
show
good
understand
hand
hygien
practic
poor
understand
core
scienc
behind
current
guidelin
educ
event
administ
local
infect
control
team
address
shortcom
aim
object
follow
educ
event
questionnair
administ
reassess
staff
knowledg
hand
hygien
practic
attitud
toward
hand
hygien
educ
result
result
show
basic
principl
hand
hygien
well
understood
understand
core
scienc
lack
particip
indic
strong
tendenc
toward
evid
base
practic
wish
opportun
evalu
evid
enact
chang
clinic
practic
particip
indic
unhappi
current
format
hand
hygien
educ
thought
overli
dogmat
studi
show
poor
understand
core
scienc
underpin
current
hand
hygien
practic
amongst
medic
staff
contend
learn
style
medic
staff
mandat
greater
focu
evid
scienc
behind
current
hand
hygien
guidelin
current
educ
theori
suggest
better
knowledg
like
translat
higher
complianc
hand
hygien
guidelin
suggest
hand
hygien
educ
chang
reflect
particular
need
medic
staff
parallel
program
run
medic
staff
hand
hygien
practic
among
anesthiologist
palestin
result
guidesmanu
publish
sinc
first
public
field
japan
one
ongo
lectur
citi
healthcar
center
lead
decreas
number
influenza
outbreak
nation
center
hospit
children
first
build
design
consid
infect
prevent
ichg
member
particip
design
hospit
guidemanu
hospit
architectur
publish
ichg
influenc
design
hospit
japan
taught
infect
prevent
measur
compil
inspect
tour
eu
hospit
eu
medic
profession
knowledg
believ
intellig
superior
sourc
result
japanes
infect
prevent
measur
chang
due
introduct
eu
practic
would
like
continu
studi
abroad
translat
knowledg
acquir
japan
improv
infect
prevent
disadvantag
health
care
worker
hand
hygien
educ
background
health
careassoci
infect
hospit
major
caus
morbid
mortal
effect
hand
hygien
best
way
prevent
aim
present
studi
show
chang
health
care
worker
behaviour
increas
hand
hygien
questionnairebas
survey
carri
anonym
among
nurs
physician
latvia
identifi
quantifi
factor
affect
hand
wash
behaviour
group
ask
answer
free
form
regard
fail
neglect
wash
hand
done
questionnair
includ
detail
situat
physician
nurs
neglect
wash
hand
classifi
five
categori
describ
japan
studi
result
nurs
physician
neglect
wash
hand
done
among
busi
nurs
physician
forgot
nurs
physician
recogn
necess
nurs
physician
find
facil
wash
hand
nurs
physician
use
glove
instead
wash
hand
nurs
physician
discuss
andor
conclus
signific
differ
found
among
staff
group
improv
hand
hygien
psycholog
factor
must
consid
includ
motiv
recognit
behaviour
urgent
condit
hospit
need
develop
implement
innov
educ
motiv
programm
tailor
physician
background
patient
safeti
hai
prevent
control
pillar
profession
level
compet
start
first
approach
health
care
organ
undergradu
level
base
also
activ
involv
student
anniversari
adopt
clean
care
safer
care
project
itali
provid
opportun
univers
member
gisios
studi
group
hai
tri
new
way
encourag
student
creativ
aim
object
activ
involv
student
nurs
medic
degre
healthcar
profession
creativ
contest
hand
hygien
order
increas
awar
topic
gener
hai
univers
member
gisio
network
promot
local
level
contest
previous
defin
aim
method
framework
evalu
result
student
invit
prepar
may
product
video
poster
present
leaflet
screensav
best
work
repres
univers
nation
contest
held
novemb
result
student
italian
univers
albania
involv
project
present
evalu
local
committe
judg
accord
common
framework
follow
item
scientif
accuraci
creativ
product
technic
qualiti
use
campaign
nation
committe
charg
appli
criteria
nation
contest
discuss
andor
conclus
given
encourag
achiev
steer
group
consid
whether
extend
particip
next
futur
result
day
met
expect
divers
audienc
particip
report
follow
knowledg
learnt
confer
inform
futur
practic
number
respons
bracket
websit
resourc
sign
post
eg
phe
fingertip
becom
promot
antibiot
guardian
risk
foreign
hospitalis
cpe
carriag
infect
control
key
tackl
amr
threat
cpe
health
secur
implement
cpe
toolkit
import
screen
patient
review
antibiot
hour
particip
enjoy
divers
speaker
broad
global
overview
current
amr
environment
dimens
amr
farm
vet
approach
tackl
amrantibiot
stewardship
human
travel
spread
resist
complex
amr
complex
amr
success
deliv
rang
amr
specialist
simultan
wide
rang
profession
inform
studi
finnish
infect
control
nurs
n
respons
data
collect
use
electron
questionnair
summer
data
analyz
use
induct
content
analysi
two
categori
form
result
analysi
describ
infect
control
nurs
educ
need
form
categori
profession
educ
educ
support
execut
assign
result
infect
control
nurs
describ
need
wide
educ
background
made
especi
nurseeduc
good
foundat
job
although
nurs
remark
educ
univers
give
better
start
point
understand
write
scientif
public
educ
staff
import
part
infect
control
nurs
job
rare
formal
educ
human
resourc
manag
inform
manag
project
manag
pedagog
compet
import
skill
infect
control
nurs
educ
contain
substanc
knowledg
skill
would
support
best
perform
infect
control
nurs
educ
univers
would
also
give
opportun
use
clinic
expert
tittl
result
particip
age
group
year
work
experi
year
good
knowledg
posit
attitud
associ
socio
demograph
variabl
variabl
viz
knowledg
attitud
p
posit
correl
knowledg
attitud
r
p
base
find
signific
portion
staff
nurs
poor
knowledg
attitud
apart
attitud
relat
knowledg
emphasi
inservic
educ
program
seminar
train
etc
requir
nosocomi
infect
increas
knowledg
reduc
incid
hospit
nepal
ann
thomson
background
complex
hospit
made
organis
structur
well
technic
system
within
build
process
owner
act
within
highli
interdisciplinari
field
recognis
regul
organis
barrier
activ
regard
risk
manag
requir
interdisciplinari
work
literatur
mere
report
legionella
prevent
seen
clinic
perspect
rather
technic
one
technic
servic
oper
system
may
deeper
knowledg
system
potenti
threat
come
system
consid
aim
object
ongo
research
project
address
peopl
hospit
respons
servic
built
environ
aim
project
systemat
uncov
present
situat
legionella
prevent
water
system
select
health
care
hc
organis
differ
countri
project
contribut
work
refer
system
guid
peopl
respons
identifi
understand
properli
take
action
prevent
stakehold
theori
provid
suitabl
theoret
framework
analys
relat
polici
issu
respons
activ
peopl
particip
process
serv
water
system
contribut
prevent
hygien
theoret
drive
research
induct
base
qualit
approach
data
collect
divid
two
consecut
phase
result
preliminari
result
exemplarili
present
organis
structur
legisl
frame
regard
water
safeti
legionella
prevent
type
water
system
relat
servic
process
seen
fmf
perspect
technic
focu
discuss
andor
conclus
hospit
repres
case
studi
work
endeavour
manag
risk
properli
accord
organis
specif
necess
handheld
devic
decontamin
within
healthcar
environ
background
use
mobil
phone
tablet
comput
becom
widespread
clinic
environ
handheld
devic
may
contamin
microorgan
becom
potenti
reservoir
crosstransmiss
pathogen
healthcar
worker
patient
determin
efficaci
codon
uvc
disinfect
technolog
decontamin
handheld
mobil
devic
use
hospit
set
method
introduc
two
ward
tablet
disinfect
control
ward
month
use
crossov
perform
washout
one
week
surfac
sampl
use
blood
contact
plate
cm
taken
tablet
screen
disinfect
also
tablet
case
predisinfect
result
decreas
overal
number
isol
episod
patient
second
timefram
epidemiolog
shift
c
glabrata
c
lusitana
calcul
pvalu
speci
predomin
reveal
signific
possibl
influenc
small
sampl
number
isol
timefram
suscept
amphotericin
b
fluconazol
suscept
earlier
timefram
isol
sensit
dosedepend
later
timefram
sensit
dosedepend
resist
isol
sensit
voriconazol
caspofungin
first
timefram
reduc
suscept
voriconazol
caspofungin
later
group
discuss
andor
conclus
c
parapsilosi
remain
preval
speci
paediatr
popul
note
increas
incid
reduc
suscept
certain
antifung
agent
continu
vigil
requir
detect
chang
suscept
speci
distribut
voriconazol
therapeut
drug
monitor
tdm
background
voriconazol
triazol
broadspectrum
antifung
activ
yeast
dimorph
filament
fungi
lack
activ
zygomycet
nonlinear
pharmacokinet
cytochrom
polymorph
oral
bioavail
rang
children
sick
explain
extens
variat
serum
voriconazol
concentr
therapeut
drug
monitor
tdm
recommend
prophylaxi
treatment
aim
object
assum
audit
standard
describ
trustwid
assess
voriconazol
tdm
method
pharmaci
record
voriconazol
dispens
june
june
retrospect
review
adult
children
receiv
voriconazol
twoweek
prophylaxi
treatment
includ
patient
demograph
treatment
indic
tdm
result
recov
trust
inform
manag
system
result
eight
patient
identifi
median
age
year
rang
gender
differ
three
patient
receiv
voriconazol
prophylaxi
treatment
haematolog
malign
remain
five
receiv
treatment
three
invas
aspergillosi
one
allerg
bronchopulmonari
aspergillosi
one
endophthalm
one
episod
voriconazol
tdm
eight
case
insuffici
voriconazol
tdm
patient
popul
better
outcom
demonstr
patient
receiv
voriconazol
tdm
versu
tdm
supratherapeut
trough
associ
toxic
crucial
patient
receiv
either
prophylaxi
treatment
voriconazol
tdm
respons
audit
principl
good
antimicrobi
stewardship
specialityspecif
seminar
clinic
practic
guidelin
introduc
subsequ
prospect
audit
feedback
improv
utilis
tdm
voriconazol
use
use
test
bronchoalveolar
lavag
sampl
diagnosi
invas
fungal
diseas
pneumocysti
pneumonia
result
although
c
albican
prove
frequent
speci
isol
preval
substanti
lower
current
report
remain
organ
consist
c
glabrata
c
dubliniensi
isol
show
differenti
sensit
fluconazol
major
isol
requir
mgl
kill
plankton
sessil
commun
biofilm
format
shown
highli
variabl
across
isol
test
observ
shift
preval
candida
spp
increas
isol
nonc
albican
speci
reduc
suscept
frequent
use
vvc
antifung
fluconazol
observ
demonstr
vvc
isol
could
form
biofilm
vitro
implic
antifung
azol
notori
resist
biofilm
candida
auri
highli
virul
resist
capabl
form
biofilm
chlorhexidin
effect
c
auri
biofilm
unlik
antifung
mgl
requir
kill
biofilm
although
c
albican
c
auri
similar
kill
kinet
vivo
c
auri
infect
achiev
mortal
rate
rapidli
c
albican
discuss
andor
conclus
c
auri
abl
form
biofilm
resist
antifung
activ
plankton
counterpart
featur
contribut
virul
also
surviv
hospit
environ
increas
abil
caus
outbreak
result
vivo
model
mimic
clinic
experi
highlight
c
auri
highli
virul
speci
equival
c
albican
background
patient
highrisk
neutropenia
administ
antifung
prophylaxi
prevent
breakthrough
invas
fungal
infect
bifi
bifi
associ
high
morbid
mortal
rate
within
patient
group
rate
bifi
hospit
trust
unclear
fungal
servic
evalu
tool
fset
aid
provid
optim
patient
manag
august
current
regist
nh
trust
use
tool
determin
proport
highrisk
patient
develop
bifi
analys
manag
highrisk
patient
develop
bifi
analys
subsequ
impact
healthcar
resourc
use
fset
computerbas
tool
host
secur
uk
nh
network
fset
collect
data
nonidentifi
patient
characterist
underli
diseas
detail
diagnost
test
antifung
manag
hospit
visit
defin
patient
group
amalgam
pool
data
gener
simpl
visual
report
summaris
key
output
result
fset
allow
hospit
trust
extens
analys
patient
cohort
undertak
prophylaxi
antifung
captur
holist
resourc
usag
incur
overal
patient
manag
pathway
fset
produc
number
report
incorpor
varieti
data
input
everi
patient
cover
number
topic
rang
patient
demograph
servic
cost
associ
manag
patient
may
may
develop
bifi
fset
establish
indic
level
resourc
utilis
help
trust
review
antifung
patient
manag
estim
futur
budgetari
resourc
background
scopulariopsi
speci
common
soil
saprophyt
wide
distribut
natur
previous
isol
plant
debri
air
moist
indoor
environ
brevicauli
appear
commonli
isol
speci
gracili
second
common
ocular
involv
rare
report
remain
pauciti
case
scopulariopsi
kerat
within
literatur
aim
object
case
highli
unusu
scopulariopsi
gracili
fungal
kerat
occur
interfac
graft
host
follow
descemet
strip
endotheli
keratoplasti
contamin
graft
transplant
best
knowledg
first
time
scopulariopsi
gracili
fungal
kerat
report
given
incid
follow
implant
contamin
endotheli
keratoplasti
method
infect
like
occur
secondari
contamin
dextran
transport
medium
human
cornea
transfer
eye
bank
scopulariopsi
gracili
subsequ
isol
refer
laboratori
result
slow
growth
fungu
detect
day
cultur
sampl
howev
releas
prior
implant
day
subconjunctiv
dexamethason
postop
may
encourag
rapid
growth
fungu
occular
fungal
infiltr
first
enlarg
despit
therapi
later
clear
chang
antifung
regim
discuss
andor
conclus
patient
good
treatment
respons
complet
resolut
fungal
kerat
diagnosi
made
promptli
treatment
initi
earli
topic
g
voriconazol
amphotericin
well
oral
voriconazol
itraconazol
infect
graft
remov
promptli
repeat
intracamer
inject
antifung
agent
background
aspergillu
fumigatu
major
fungal
pathogen
transmit
airborn
rout
excav
soil
construct
renov
thought
increas
spore
burden
risk
nosocomi
acquisit
air
sampl
perform
hospit
surveil
particularli
major
construct
ensur
engin
control
effect
aim
object
prospect
collect
data
one
year
fumigatu
count
order
obtain
baselin
level
advanc
major
build
air
sampl
perform
twicemonthli
hospit
locat
indoor
locat
includ
intens
care
unit
icu
stem
cell
transplant
unit
cardiothorac
icu
respiratori
ward
differ
air
handl
arrang
dual
head
sa
air
sampler
use
sampl
air
sabouraud
dextros
agar
use
select
fumigatu
coloni
roswel
park
memori
institut
agar
contain
itraconazolevoriconazol
screen
triazol
resist
fumigatu
result
area
control
ventil
seal
window
gener
satisfactori
count
two
ward
without
control
ventil
repeatedli
show
high
aspergillu
count
address
instal
portabl
hepa
filter
stem
cell
transplant
unit
consist
satisfactori
result
fumigatu
cfu
count
outdoor
gener
higher
indoor
find
confirm
adequ
environment
control
depend
unitsward
air
handl
system
address
patient
risk
develop
nosocomi
aspergillosi
healthwork
involv
awar
talk
done
ensur
updat
manag
possibl
hepat
b
afflict
academ
level
awar
done
medic
student
healthcar
worker
major
hepat
egypt
b
c
surveyor
method
clinic
level
survey
needl
stick
injuri
given
healthwork
ensur
confidenti
awar
hepat
b
academ
level
presurvey
given
medic
student
healthwork
assess
hisher
knowledg
hepat
b
c
gener
talk
target
certain
basic
info
need
known
student
clinician
given
post
survey
given
assess
talk
result
healthwork
got
injur
needl
stick
past
month
nt
file
incid
report
vaccin
hep
b
nt
receiv
train
manag
needl
stick
injuri
surveyor
gener
info
hep
answer
question
right
presurvey
answer
right
postsurvey
discuss
andor
conclus
focu
need
put
inform
healthwork
medic
student
prevent
needl
stick
injuri
gener
need
awar
common
type
hepat
enriqu
castrosanchez
michiyo
iwami
raheelah
ahmad
alison
holm
nation
centr
infect
prevent
manag
imperi
colleg
london
imperi
colleg
london
background
social
market
intervent
valuabl
address
communic
diseas
outcom
evalu
critic
yet
often
exclud
compon
intervent
aim
object
appli
novel
set
evalu
criteria
uk
social
market
campaign
focus
infect
method
campaign
activ
identifi
literatur
internet
search
two
research
score
campaign
area
includ
understand
problem
stakehold
clear
definit
outcom
priori
indic
requir
chang
longterm
effect
clear
theoryplaus
intervent
mode
action
outcom
measur
meet
stakehold
need
impact
measur
accept
sustain
link
intervent
outcom
compet
factor
unpredict
effect
intervent
evalu
strategi
econom
analysi
peerreview
public
campaign
receiv
point
depend
well
conduct
report
indic
present
result
campaign
focus
vaccin
sexual
health
hand
hygien
other
identifi
median
score
campaign
point
maximum
possibl
indic
best
describ
score
point
maximum
possibl
lowest
score
achiev
indic
link
intervent
outcom
indic
insuffici
inadequ
report
campaign
discuss
andor
conclus
uk
social
market
campaign
could
improv
report
key
outcom
evalu
aspect
sustain
econom
evalu
unintend
effect
campaign
requir
increas
attent
background
basal
skull
osteomyel
challeng
condit
surgeri
risk
seriou
morbid
mortal
optimum
durat
antibiot
unknown
seen
case
refer
outpati
parenter
antimicrobi
therapi
opat
servic
conserv
treatment
aim
object
wish
determin
complic
opat
durat
intraven
antibiot
overal
treatment
success
method
retrospect
analysi
clinic
opat
databas
individu
review
case
note
result
found
six
case
basal
skull
osteomyel
treat
opat
servic
complic
requir
admiss
antibiot
side
effect
line
thrombosi
relat
worsen
condit
subsequ
discharg
back
opat
mean
durat
antibiot
opat
day
mean
total
iv
antibiot
durat
day
mean
overal
treatment
durat
includ
oral
antibiot
day
opat
treatment
success
defin
complet
intend
intraven
antibiot
whilst
opat
overal
treatment
success
defin
complet
intend
intraven
opat
inpati
subsequ
oral
antibiot
note
one
case
fail
twelv
week
cours
antibiot
achiev
success
follow
repeat
twelv
week
cours
iv
follow
twelv
week
oral
antibiot
although
patient
finish
intend
cours
antibiot
ongo
morbid
includ
hear
loss
ear
discharg
need
surgeri
opat
servic
effect
support
conserv
manag
basal
skull
osteomyel
despit
high
complic
readmiss
rate
michael
addidl
vani
sathyendran
tim
taylor
yvonn
peckov
background
baselin
audit
demonstr
provis
clinic
detail
microbiolog
laboratori
poor
despit
variou
educ
effort
decid
trial
mandatori
clinic
detail
polici
start
infecti
serolog
extend
area
clinic
microbiolog
sampl
arriv
laboratori
without
clinic
detail
store
certain
time
period
depend
type
sampl
messag
sent
back
requestor
process
proceed
clinic
detail
receiv
aim
object
aim
clinic
detail
present
samp
come
microbiolog
laboratori
follow
reason
ensur
correct
test
perform
facilit
interpret
borderlin
result
result
uncertain
signific
allow
test
perform
laboratori
recommend
requestor
consider
ensur
test
perform
diagnost
reason
method
thorough
consult
process
carri
laboratori
stakehold
follow
leadin
period
go
live
polici
detail
except
pitfal
polici
describ
result
far
neg
feedback
limit
clinic
detail
receiv
vast
major
request
unnecessari
test
reduc
post
implement
audit
perform
discuss
andor
conclus
import
qualiti
initi
initi
implement
difficult
long
term
qualiti
benefit
signific
result
timelin
show
summari
mileston
demonstr
ongo
collabor
improv
work
sinc
graph
display
oper
room
hand
hygien
audit
result
date
averag
discuss
andor
conclus
sustain
complianc
world
health
organis
five
moment
hand
hygien
oper
theatr
achiev
multimod
strategi
continu
improv
educ
audit
rapid
feedback
help
maintain
focu
import
hand
hygien
use
care
bundl
low
lowmiddl
incom
countri
systemat
review
metaanalysi
background
sepsi
global
problem
increas
incid
mortal
number
sepsi
care
bundl
produc
highincom
countri
introduct
bundl
shown
doubl
surviv
howev
major
seen
unsuit
use
low
lowmiddl
incom
countri
lmic
due
resourc
limit
aim
object
review
effect
use
variou
care
bundl
comparison
usual
care
lmic
perform
systemat
review
studi
includ
adult
patient
lmic
compar
use
bundl
care
usual
care
bundl
includ
sepsi
ventilatorassoci
pneumonia
catheterassoci
uti
outcom
includ
improv
care
use
bundl
reduc
incid
infect
mortal
process
outcom
result
identifi
one
randomis
control
trial
n
nine
nonrandomis
beforeandaft
studi
n
metaanalysi
five
studi
show
overal
signific
reduct
incid
infect
bundl
care
rate
ratio
ci
p
three
studi
includ
metaanalys
show
decreas
mortal
rate
signific
reduct
sever
score
apach
ii
discuss
andor
conclus
use
care
bundl
lmic
significantli
reduc
incid
infect
signific
effect
mortal
result
may
use
consid
develop
care
bundl
specif
use
lmic
accord
selfevalu
doctor
nurs
disinfect
hand
patient
contact
patient
answer
questionnair
consid
doctor
nurs
alway
disinfect
hand
treat
base
real
life
observ
proper
hd
patient
contact
perform
doctor
nurs
occas
rang
success
perform
hd
five
moment
n
observ
doctor
n
observ
nurs
respect
discuss
andor
conclus
doctor
nurs
overestim
hh
practic
patient
consid
hcw
hh
practic
better
real
life
observ
hcw
especi
doctor
hand
hygien
practic
need
improv
hospit
result
enterobacteriaceas
respons
posit
blood
cultur
eschericia
coli
commonest
individu
organ
follow
klebsiella
pneumonia
pseudomona
aeruginosa
urinari
tract
implic
sourc
bacteraemia
half
patient
gastrointestin
tractb
second
commonest
sourc
among
enterobacteriacea
isol
found
sensit
carbapenem
amikacin
colistin
fosfomycin
isol
found
sensit
piperacillin
tazobactam
gentamicin
isol
sensit
temocillin
greater
isol
resist
ciprofloxacin
ceftriaxon
resist
rate
amoxicillinclavulan
acid
trimethoprim
trimethoprimsulfamethoxazol
amoxicillin
respect
discuss
andor
conclus
studi
confirm
find
previous
describ
elsewher
regard
common
caus
organ
sourc
bacteraemia
among
renal
transplant
recipi
studi
demonstr
grow
problem
antibiot
resist
almost
fifti
percent
isol
resist
previous
commonli
use
antibiot
amoxicillinclavulan
acid
ciprofloxacin
give
us
import
inform
inform
empir
treatment
renal
transplant
patient
present
sepsi
new
method
treat
patient
diabet
foot
ulcer
osteomyel
use
antibiot
impregn
calcium
sulphat
benjamin
kapur
tarek
el
gamel
gillian
jackson
simon
platt
method
mrsa
colonis
patient
recruit
mgh
mupirocin
appli
intranas
two
cours
either
treatment
td
five
day
administ
three
consecut
neg
mrsa
screen
result
confirm
success
decolonis
result
mean
age
femal
studi
particip
previous
known
mrsa
histori
attempt
decolonis
receiv
two
cours
nasal
mupirocin
concomit
mdro
colonis
nonnas
site
mrsa
total
isol
either
singl
room
cohort
contact
precaut
particip
complet
studi
protocol
intervent
group
control
group
decolonis
p
c
itt
analysi
success
rate
mgh
mupirocin
respect
accord
pp
analysi
fourteen
particip
lost
follow
withdrawn
deviat
alloc
protocol
discuss
andor
conclus
first
type
rcto
result
confirm
potenti
mgh
howev
work
requir
replic
find
optimis
concentr
mgh
observ
studi
klebsiella
pneumonia
bacteraemia
univers
malaya
medic
center
shaharudeen
kamaludeen
helmi
sulaiman
nadia
atiya
adeeba
kamarulzaman
univers
malaya
medic
centr
univers
malaya
medic
center
background
klebsiella
pneumonia
common
gram
neg
bacteria
caus
infect
associ
high
mortal
incid
klebsiella
pneumonia
bacteraemia
kpb
increas
trend
although
mani
region
studi
conduct
kpb
data
malaysia
limit
method
retrospect
studi
may
april
analys
patient
kpb
identifi
demograph
factor
risk
factor
outcom
associ
infect
case
identifi
microbiolog
laboratori
databas
organ
identif
antimicrobi
suscept
test
perform
use
vitek
autom
system
result
kpb
occur
predominantli
elderli
age
group
commun
onset
co
nosocomialonset
infect
year
old
respect
diabet
predomin
group
co
nokpb
show
significantli
higher
icu
admiss
rate
longer
hospit
icu
stay
commonest
identifi
site
infect
pneumonia
co
rate
liver
abscess
co
nokpb
respect
antibiot
exposur
one
month
prior
current
infect
p
presenc
foreign
bodi
p
associ
resist
phenotyp
esblcr
apach
ii
score
ci
p
time
appropri
antibiot
therapi
ci
p
associ
day
mortal
discuss
andor
conclus
sever
ill
time
appropri
antibiot
associ
mortal
identifi
microorgan
sensit
shorter
time
interv
streamlin
antibiot
accord
sensit
result
may
reduc
mortal
evalu
pharmacist
review
patient
clostridium
difficil
infect
background
specialist
pharmacist
second
support
manag
clostridium
difficil
infect
cdi
aim
object
measur
improv
time
resolut
ttr
diarrhoea
day
mortal
length
stay
lo
adher
antimicrobi
protonpump
inhibitor
ppi
guidelin
pharmacist
review
cdi
patient
aim
improv
outcom
outcom
compar
similar
case
previou
year
patient
review
pharmacist
requir
intervent
ttr
diarrhoea
day
shorter
intervent
group
vs
day
lo
day
preintervent
group
day
intervent
group
note
group
discharg
delay
reason
cdi
patient
recurr
cdi
ttr
diarrhoea
reduc
day
length
stay
decreas
day
day
mortal
reduc
although
signific
unclear
appropri
antimicrobi
therapi
within
hour
increas
ppi
review
document
increas
discuss
andor
conclus
appropri
antibiot
prescrib
ppi
review
demonstr
qualiti
benefit
patient
well
improv
ttr
diarrhoea
also
organis
benefit
durat
isol
precaut
reduc
well
consider
reduct
ttr
symptom
patient
recurr
cdi
earlier
discharg
expedit
save
estim
bed
day
month
overal
evalu
support
valu
pharmacist
manag
cdi
led
perman
recruit
post
board
best
practic
express
diarrhoea
roadshow
manjula
natarajan
sonia
mellor
dawn
westmoreland
jenni
lovel
martha
bird
ketter
gener
hospit
foundat
trust
kgh
ft
background
kgh
trajectori
trustattribut
case
c
difficil
infect
cdi
month
case
root
caus
analysi
rca
ribotyp
isol
uncov
specif
area
weak
trend
noncompli
prevent
method
felt
overarch
theme
aim
object
primari
aim
rais
awar
prevent
intervent
reduc
hcai
infect
prevent
control
team
ipct
develop
new
strategi
promot
staff
engag
ownership
healthi
competit
improv
qualiti
care
patient
method
ipct
light
bulb
moment
diarrhoea
road
show
born
key
element
best
practic
express
train
sight
pneumon
becam
screen
saver
carriag
key
messag
ad
everi
fortnight
focu
chang
cdi
free
day
ward
award
achiev
use
sight
pneumon
engag
refresh
practic
colin
oscopi
born
mascot
captur
everyon
imagin
heart
mind
discuss
ward
board
result
enthusiasm
ownership
around
reward
achiev
trajectori
cdi
free
day
infecti
amongst
staff
member
launch
qualiti
improv
qi
programm
turn
practic
focu
get
board
best
practic
express
achiev
trajectori
cdi
case
origin
thought
imposs
task
discuss
andor
conclus
visibl
clinic
leadership
innov
ipc
team
board
engag
made
sustain
success
qi
project
next
step
continu
creat
innov
sustain
improv
throughout
year
conduct
singlecent
observ
studi
effect
daili
bath
norins
chlorhexidineimpregn
washcloth
intens
care
unit
icu
univers
hospit
incid
rate
acquisit
mdro
rate
clabsi
compar
result
overal
rate
mdro
acquisit
case
per
patientday
chlorhexidin
bath
versu
case
per
patientday
introduct
wash
cloth
reduct
overal
rate
clabsi
per
cathet
day
start
wash
period
versu
per
cathet
day
end
reduct
discuss
andor
conclus
introduct
daili
chlorhexidin
wash
appear
effect
intervent
reduc
rate
mdro
acquisit
decreas
infect
rate
icu
aim
object
perform
detail
evalu
aureu
carriag
critic
care
hcw
method
consent
critic
care
hcw
teach
hospit
southern
england
serial
screen
aureu
carriag
month
data
demograph
comorbid
medic
care
collect
longitudin
nasal
carriag
defin
use
carriag
profil
indic
cpi
total
cultureposit
swab
total
swab
measur
associ
calcul
use
multivari
logist
regress
result
hcw
femal
year
preval
comorbid
low
nasal
carriag
studi
entri
identifi
nurs
doctor
physiotherapist
mrsa
nurs
associ
concurr
nurs
home
employ
ci
p
live
partner
ci
p
serial
screen
reveal
hcw
intermitt
carri
aureu
cpi
alway
cultureposit
cpi
alway
cultureneg
cpi
serial
screen
hcw
nurs
p
receiv
cours
antibiot
studi
hcw
receiv
antibiot
twice
like
carri
aureu
intermitt
ci
p
discuss
andor
conclus
longitudin
nasal
carriag
aureu
critic
care
hcw
reveal
divers
intermitt
carriag
profil
associ
receipt
antibiot
work
requir
determin
implic
carriag
profil
transmiss
nuzhath
khan
srinivasulu
reddi
nash
jame
microbiolog
depart
william
harvey
hospit
east
kent
hospit
microbiolog
background
escherichia
coli
e
coli
bacteraemia
rise
incid
compar
mortal
rate
doubl
bacteraemia
includ
methicillin
resist
aureu
mrsa
aim
object
analys
clinic
factor
associ
ecoli
bacteraemia
identifi
risk
factor
associ
allcaus
mortal
cohort
method
retrospect
analysi
e
coli
bacteraemia
case
east
kent
hospit
three
month
appli
risk
factor
analys
includ
age
gender
antibiot
nonsuscept
extendedspectrum
esbl
product
number
hospitalis
previou
year
comorbid
sourc
bacteraemia
binari
logist
regress
model
appli
identifi
risk
factor
mortal
thirtyday
caus
mortal
rate
higher
mortal
rate
associ
male
gender
p
underli
hepatobiliari
focu
p
resist
amoxicillinclavulan
p
resist
amoxicillinclavulan
ciprofloxacin
case
esbl
e
coli
patient
one
previou
hospit
admiss
previou
year
intervent
previou
year
includ
biliari
intervent
one
comorbid
discuss
andor
conclus
result
suggest
elderli
male
patient
may
higher
risk
mortal
e
coli
bacteraemia
need
investig
possibl
link
higher
mortal
hepatobiliari
sourc
high
rate
resist
commonli
use
antibiot
amoxicillinclavulan
highlight
need
maintain
use
appropri
antibiot
effect
univers
decolonis
reduc
mrsa
bacteraemia
critic
care
unit
background
isol
decolonis
two
main
target
control
measur
reduc
transmiss
mrsa
hospit
univers
mrsa
decolonis
critic
care
unit
thought
reduc
mrsa
incid
costeffect
method
control
mrsa
set
critic
care
patient
uhb
receiv
mrsa
decolonis
therapi
june
uhb
implement
revis
strategi
control
mrsa
discontinu
use
univers
decolonis
critic
care
aim
object
review
effect
univers
decolonis
incid
mrsa
acquisit
mrsa
bacteraemia
clinic
care
unit
result
increas
acquisit
p
increas
bacteraemia
p
period
follow
chang
compar
previou
month
given
signific
increas
incid
mrsa
bacteraemia
univers
decolonis
reintroduc
critic
care
reduct
acquisit
p
decreas
bacteraemia
month
period
follow
reintroduct
routin
decolonis
critic
care
audit
reveal
signific
chang
hand
hygien
complianc
appropri
use
person
protect
equip
environment
cleanli
period
clinic
activ
critic
care
chang
time
discuss
andor
conclus
suggest
routin
decolonis
mrsa
critic
care
effect
strategi
reduc
spread
mrsa
incid
mrsa
bacteraemia
id
intrahospit
variat
blood
cultur
contamin
rate
background
blood
cultur
contamin
reduc
use
blood
cultur
diagnost
test
contribut
use
antibiot
aim
object
examin
rate
blood
cultur
contamin
within
larg
citi
hospit
identifi
area
within
hospit
high
contamin
rate
area
low
contamin
ratesmeasur
recommend
benchmark
identifi
factor
could
account
differ
rate
method
laboratori
data
system
interig
identifi
blood
cultur
result
month
period
rate
posit
contamin
rate
calcul
clinic
area
within
hospit
electron
clinic
note
utilis
ensur
accur
alloc
contamin
statu
area
high
low
rate
visit
questionnair
complet
identifi
variat
practic
could
account
contamin
rate
result
contamin
rate
vari
highest
rate
e
one
acut
admiss
unit
question
clinic
area
highest
lowest
rate
reveal
number
factor
could
account
differ
rate
iclud
eas
access
equip
lack
standardis
method
obtain
blood
cultur
discuss
andor
conclus
key
varianc
practic
clinic
area
high
rate
blood
cultur
contamin
low
rate
includ
standardis
method
collect
eas
access
equip
strategi
reduc
contamin
rate
within
qeuh
focu
produc
readili
avail
standard
method
equip
kit
debra
adam
victoria
hine
helen
bucior
wendi
foster
nyarayi
mukumb
jane
ryan
ryan
sandra
smirthwait
jodi
winfield
nh
improv
univers
hospit
north
midland
nh
trust
northampton
gener
hospit
nh
trust
west
hertfordshir
nh
trust
bedford
nh
trust
unit
lincolnshir
hospit
nh
trust
royal
wolverhampton
nh
trust
background
nh
improv
form
nh
improv
respons
overse
foundat
trust
nh
trust
independ
provid
offer
support
provid
need
enabl
deliv
consist
safe
high
qualiti
compassion
care
patient
infect
prevent
control
ipc
remain
high
patient
safeti
agenda
england
estim
around
twothird
healthcar
improv
go
result
sustain
chang
achiev
plan
object
health
foundat
sustain
chang
like
result
model
involv
patient
staff
develop
design
implement
chang
rather
command
controltop
model
health
foundat
respons
four
head
ipc
nh
improv
qualiti
improv
support
specialist
develop
day
ipc
qualiti
improv
qi
collabor
programm
trust
foundat
trust
england
aim
promot
share
learn
best
practic
innov
colleagu
provid
organis
cultiv
new
approach
develop
sustain
effect
ipc
poster
discuss
collabor
approach
use
experi
six
trust
within
midland
east
particip
bedford
hospit
northampton
gener
hospit
royal
wolverhampton
trust
univers
hospit
north
midland
unit
lincolnshir
hospit
west
hertfordshir
hospit
sarah
macalist
hall
jame
mcdonald
ashutosh
deshpand
background
urinari
tract
infect
pregnanc
associ
increas
risk
pyelonephr
may
caus
signific
matern
foetal
morbid
pregnant
women
asymptomat
bacteruria
also
like
develop
pyelonephr
compar
nonpregn
counterpart
recommend
within
nation
local
guidelin
state
ensur
success
treatment
symptomat
asymptomat
bacteruria
pregnant
women
repeat
urin
cultur
day
complet
antibiot
treatment
aim
object
audit
complianc
within
nh
greater
glasgow
clyde
ggc
recommend
repeat
urin
cultur
pregnant
women
previou
posit
urin
cultur
method
retrospect
review
urin
cultur
pregnant
women
within
ggc
month
period
result
april
octob
ggc
process
posit
urin
cultur
pregnant
women
sampl
came
secondari
care
set
primari
care
set
remain
unknown
locat
sampl
repeat
within
period
respect
time
analysi
sampl
repeat
signific
differ
primari
secondari
care
discuss
andor
conclus
audit
show
posit
urin
cultur
less
half
repeat
within
time
period
signific
number
repeat
demonstr
need
increas
awar
recommend
propos
perform
educ
intervent
target
primari
secondari
care
set
reaudit
assess
efficaci
intervent
bent
bloch
hospit
southern
jutland
background
today
patient
care
hospit
highli
specialis
undertaken
high
speed
mani
patient
receiv
complex
treatment
care
often
continu
primari
sector
patient
discharg
aim
object
aim
studi
investig
analys
intersector
collabor
gain
better
understand
collabor
across
health
sector
relat
patient
need
treatmentcar
infect
control
play
import
role
studi
qualit
multipl
case
studi
semi
structur
interview
form
base
empir
knowledg
use
theori
behind
studi
perspect
intersector
collabor
exampl
model
collabor
strength
weak
collabor
result
studi
show
motiv
factor
intersector
collabor
focu
organis
structur
organis
collabor
network
awar
import
clear
commun
path
focu
profession
compet
relat
infect
hygien
structur
collabor
establish
actual
infect
control
organis
result
access
expert
knowledg
secur
among
personnel
well
motiv
work
infect
control
area
focu
discuss
andor
conclus
nosocomi
infect
patient
transfer
one
health
sector
anoth
like
prevent
introduct
knowledg
infect
control
level
personnel
sector
enter
formalis
collabor
across
health
sector
aim
establish
intersector
infect
control
organ
background
leptospirosi
zoonot
infect
occur
worldwid
endem
tropic
countri
clinic
present
heterogen
rang
undifferenti
febril
ill
weil
diseas
serolog
test
main
diagnost
modal
aim
object
review
serolog
test
leptospirosi
institut
period
describ
clinic
featur
case
method
identifi
patient
two
tertiari
care
hospit
edinburgh
unit
kingdom
sampl
sent
public
health
england
refer
laboratori
leptospirosi
test
clinic
laboratori
microbiolog
inform
case
collect
retrospect
complet
detail
unavail
four
case
result
sampl
sent
leptospirosi
igm
elisa
test
neg
posit
four
equivoc
tempor
trend
test
posit
result
came
patient
median
age
year
nine
case
import
mostli
asia
histori
fresh
water
exposur
patient
present
nonspecif
symptom
fever
myalgia
gastrointestin
symptom
headach
laboratori
evid
hepat
acut
kidney
injuri
lymphopenia
common
one
patient
develop
weil
diseas
multiorgan
failur
antimicrobi
administ
seven
case
usual
doxycyclin
death
discuss
andor
conclus
leptospirosi
uncommon
infect
scotland
case
import
contrast
recent
ukwid
data
may
attribut
scottish
climat
clinic
present
protean
mild
hepatoren
involv
common
even
absenc
organ
failur
safeti
efficaci
outpati
parenter
antimicrobi
therapi
opat
infect
endocard
retrospect
analysi
judith
oguguo
oliv
koch
clair
mackintosh
univers
edinburgh
nh
lothian
univers
edinburgh
background
infect
endocard
ie
known
diagnost
difficulti
continu
associ
high
mortal
sever
complic
despit
improv
manag
ie
treat
antibiot
accord
european
societi
cardiolog
guidelin
case
may
amen
outpati
parenter
antimicrobi
therapi
opat
howev
current
littl
literatur
avail
use
opat
ie
aim
object
studi
aim
determin
safeti
efficaci
opat
treat
ie
method
ie
patient
episod
refer
nh
lothian
opat
clinic
review
gather
data
analys
duke
criteria
fulfil
note
possibl
result
mean
patient
age
year
male
accept
opat
streptococci
spp
infect
organ
episod
staphylococcu
spp
enterococcu
spp
respect
episod
prosthet
valv
ie
patient
relev
comorbid
advers
event
record
episod
drugrel
resolv
treatment
chang
patient
requir
elect
valv
replac
surgeri
follow
opat
discharg
episod
complet
month
ago
death
includ
patient
accept
opat
one
death
due
unrel
caus
discuss
andor
conclus
therefor
select
group
possibl
success
treat
ie
use
opat
thu
reduc
number
inpati
day
associ
condit
could
potenti
allow
costeffect
use
resourc
well
reduc
risk
associ
prolong
hospitalis
background
nontyphoid
salmonella
nt
infect
commonli
caus
gastroenter
ingest
contamin
food
bacteraemia
unusu
associ
immunosuppress
incid
nt
bacteraemia
increas
hiv
epidem
potent
immunosuppress
medic
becom
wide
use
patient
also
risk
aim
object
present
case
recurr
nt
bacteraemia
mycot
aortic
aneurysm
patient
take
methotrex
method
case
report
man
present
fever
right
flank
pain
one
month
start
methotrex
wegen
granulomatosi
co
morbid
includ
angina
atrial
fibril
chronic
kidney
diseas
blood
cultur
grew
salmonella
enteritidi
transpir
treat
month
earlier
bacteraemia
organ
ct
show
dissect
aneurysm
abdomin
aorta
extend
right
common
iliac
arteri
larg
surgic
intervent
plan
made
lifelong
antibiot
suppress
result
treatment
complic
pancytopenia
ceftriaxon
seizur
whilst
ciprofloxacin
chang
trimethoprim
amoxicillin
repeat
ct
scan
week
show
progress
dissect
continu
treatment
die
week
later
discuss
andor
conclus
nt
bacteraemia
prompt
investig
immunosuppress
well
search
underli
sourc
mycot
aneurysm
nt
high
mortal
surgic
repair
extend
cours
appropri
antibiot
recommend
patient
may
need
lifelong
suppress
treatment
may
difficult
toler
even
surgic
resect
infect
materi
antibiot
suppress
may
still
fail
manag
mening
larg
teach
hospit
clinic
audit
india
wheeler
libus
ratcliff
kate
vaudrey
sylvian
defr
royal
liverpool
univers
hospit
background
bacteri
mening
meningococc
sepsi
rare
import
condit
associ
seriou
morbid
mortal
earli
recognit
treatment
essenti
minim
deleteri
effect
manag
reli
appropri
use
neuroimag
lumbar
punctur
lp
prompt
antibiot
therapi
avoid
delay
treatment
exemplifi
recent
guidelin
aim
object
investig
manag
mening
adult
year
sinc
public
updat
uk
joint
specialist
societi
guidelin
method
retrospect
audit
electron
paper
case
note
januari
current
guidelin
result
review
record
patient
enter
e
femal
mean
age
year
sd
review
like
bacteri
mening
pneumococc
hsv
pharyng
migrain
immedi
lp
contraind
case
immedi
lp
carri
contraind
lp
perform
within
hour
antibiot
administ
median
time
minut
arriv
hospit
iqr
minut
patient
lp
antibiot
result
audit
reveal
delay
initi
manag
suspect
mening
could
part
due
rout
admiss
hospit
appear
new
guidelin
impact
may
due
lack
awar
hospit
depart
issu
could
address
nation
wider
awar
campaign
julia
colston
burkhard
ludewig
paul
klenerman
oxford
univers
hospit
nh
foundat
trust
kantonsspit
st
gallen
institut
immunobiolog
background
cell
memori
inflat
strike
immunolog
respons
first
report
murin
cytomegaloviru
mcmv
infect
subsequ
human
cmv
hcmv
describ
certain
epitopespecif
cell
respons
gradual
increas
time
maintain
function
effector
memori
popul
blood
tissu
popul
potenti
relev
vaccin
design
howev
limit
set
epitop
exhibit
respons
thu
direct
remain
issu
aim
object
develop
simpl
tractabl
adenovir
model
defin
critic
rule
govern
epitopespecif
memori
inflat
parallel
inform
us
adenovir
vaccin
cell
respons
test
whether
minim
epitopeinsert
adenovir
vector
call
minigen
vector
provid
effect
target
vaccin
respons
rang
epitop
method
vector
contain
epitop
minigen
full
gp
protein
lymphocyt
choriomening
viru
lcmv
develop
test
vivo
result
use
murin
model
immunis
challeng
lcmv
demonstr
robust
virolog
protect
adenovector
discuss
andor
conclus
data
provid
import
insight
natur
adenovir
vector
vaccin
potenti
minim
epitopeinsert
adenovector
vaccin
particularli
relev
set
current
novel
adenovir
vaccin
pathogen
ebola
malaria
rsv
result
patient
attend
clinic
within
audit
period
patient
screen
within
month
hiv
diagnosi
hbv
infect
immun
screen
within
last
year
major
cohort
hbv
immun
non
immun
vaccin
naiv
vaccin
naiv
patient
offer
primari
vaccin
uptak
howev
vaccin
practic
sever
flaw
common
incorrect
number
dose
per
primari
schedul
discuss
andor
conclus
sever
gap
vaccin
practic
compar
nation
guidelin
although
primari
vaccin
offer
accord
bhiva
guidelin
updat
recommend
dose
vaccin
notabl
number
vaccin
vaccin
schedul
met
addit
nonrespond
primari
vaccin
manag
effect
attitud
healthcar
staff
influenc
uptak
influenza
vaccin
muthu
saba
eleanor
mc
namara
cherri
orchard
hospit
health
servic
execut
hse
consult
microbiologist
cherri
orchard
hospit
health
servic
execut
background
irish
intern
guidelin
recommend
annual
influenza
vaccin
healthcar
worker
hcw
protect
reduc
risk
transmiss
hcw
patient
howev
vaccin
uptak
among
hcw
nation
target
aim
identifi
attitud
belief
hcw
toward
influenza
vaccin
influenc
vaccin
uptak
method
studi
design
qualit
retrospect
systemat
review
electron
data
sourc
review
includ
cinahl
medlin
embas
cochran
librari
psycinfo
pubm
search
perform
use
defin
mesh
term
keyword
studi
relat
influenza
vaccin
patient
exclud
background
immun
diphtheria
poliomyel
pertussi
initi
respect
singapor
aim
object
aim
studi
examin
preval
pertussi
diphtheria
polioviru
antibodi
healthcar
personnel
changi
gener
hospit
method
annual
health
screen
healthcar
personnel
changi
gener
hospit
conduct
septemb
residu
sera
health
care
personnel
collect
human
igg
antibodi
bordetella
pertussi
diphtheria
toxoid
polioviru
serotyp
simultan
measur
use
enzymelink
immunosorb
assay
result
total
healthcar
personnel
recruit
healthcar
personnel
age
group
age
group
personnel
age
group
seropreval
antibodi
serotyp
polioviru
ci
decreas
significantli
age
age
group
age
group
age
group
p
presenc
pertussi
antibodi
demonstr
healthcar
personnel
ci
seropreval
decreas
age
group
age
group
age
group
p
seropreval
diphtheria
found
healthcar
personnel
ci
increas
age
group
discuss
andor
conclus
wane
immun
polioviru
begin
age
demonstr
signific
proport
healthcar
personnel
lack
immun
pertussi
routin
pertussi
polio
booster
given
healthcar
personnel
ensur
sustain
immun
diseas
background
septemb
unit
kingdom
becam
first
countri
integr
bexsero
vaccin
meningococc
group
b
nation
immunis
schedul
vaccin
associ
higher
rate
fever
given
alongsid
routin
immunis
compar
routin
immunis
alon
versu
respect
public
health
england
recommend
administr
prophylact
paracetamol
infant
receiv
vaccin
order
decreas
unnecessari
gener
practic
accid
emerg
attend
allevi
parent
concern
distress
child
data
avail
regard
incid
fever
preterm
neonat
receiv
vaccin
recommend
prophylact
paracetamol
specif
preterm
infant
aim
object
aim
monitor
respons
immunis
vulner
popul
method
prospect
collect
data
preterm
neonat
receiv
bexsero
vaccin
tertiari
neonat
unit
record
incid
fever
advers
event
hour
follow
immunis
result
septemb
juli
infant
immunis
gestat
age
birth
rang
median
age
week
immunis
median
age
week
one
infant
develop
fever
degress
hour
postimmunis
signific
event
occur
post
immunis
repiratori
deterior
infant
suspect
sepsi
infant
discuss
andor
conclus
incid
fever
greater
degre
significantli
lower
cohort
preterm
infant
term
infant
immunis
bexsero
high
educ
qualif
current
employ
field
relat
health
visit
gener
physician
gynecologist
regularli
awar
cervic
cancer
correctli
identifi
hpv
infect
involv
pathogenesi
cervic
cancer
awar
hpv
infect
believ
inform
lack
particip
screen
pap
smear
cervic
cancer
least
live
wherea
know
pap
smear
screen
significantli
associ
cervic
cancer
awar
regular
visit
gener
health
physician
gynecologist
particip
age
vaccin
hpv
vaccin
uptak
significantli
associ
cervic
cancer
awar
religion
field
work
studi
regular
visit
gynecologist
background
sever
impact
ebola
zika
viral
diseas
emerg
epidem
public
health
threat
intern
concern
low
middl
incom
countri
echo
graviti
danger
lack
local
intern
function
emerg
prepared
smart
respons
action
remain
concern
african
citizenri
global
commun
aim
object
paper
examin
research
knowledg
gap
strengthen
earli
warn
surveil
strategi
emerg
threat
epidem
prepared
intellig
respons
subsahara
africa
method
systemat
quasiexplor
method
use
assess
relev
peerreview
literatur
emerg
zika
ebola
threat
epidem
gap
prepared
emerg
respons
africa
contin
result
find
show
unpreced
ebola
zika
epidem
gap
consequ
popul
health
economi
thought
us
valu
establish
sustain
local
nation
robust
reliabl
capac
mechan
deal
evolv
futur
crisi
henc
adequ
partnership
commit
financi
invest
scale
oper
research
r
imper
novel
sensit
rapid
diagnosi
develop
effect
safe
zika
ebola
treatment
vaccin
also
contextu
earli
warn
surveil
strategi
evidencebas
commun
alert
educ
engag
particip
coordin
effici
util
local
intern
assist
smart
respons
paramount
discuss
andor
conclus
paper
provid
practic
programmat
recommend
improv
strateg
earli
warn
surveil
strategi
integr
align
local
nation
one
health
strategi
prioriti
program
subsahara
africa
simpl
bundl
target
hub
approach
manag
increas
incid
glycopeptid
resist
enterococcu
without
activ
surveil
manjula
meda
victoria
gentri
amanda
walker
ian
fri
frimley
health
nh
trust
frimley
health
nh
foundat
trust
background
recent
data
glycopeptid
resist
enterococcu
gre
incid
phe
eurosurveil
indic
increas
rate
gre
healthcar
aim
object
investig
manag
increas
gre
incid
hospit
method
janjun
infect
prevent
control
team
investig
increas
number
gre
report
issu
laboratori
use
passiv
surveil
necessari
data
requir
investig
collect
prospect
isol
month
period
sent
type
result
increas
incid
localis
specif
hub
site
hospit
includ
gener
surgic
ward
critic
care
unit
haematooncolog
ward
gener
medic
ward
patient
medic
ward
carri
gre
predominantli
urin
sampl
patient
surgic
critic
care
ward
often
colonis
wound
devic
isol
type
pfge
report
uniqu
strain
one
contact
healthcar
last
year
three
probabl
cross
transmiss
event
antibiot
use
presenc
indwel
devic
common
risk
factor
infect
control
bundl
institut
juli
follow
signific
reduct
gre
note
discuss
andor
conclus
target
invent
control
bundl
surgic
critic
care
haematoonclog
ward
includ
weekli
antibiot
audit
enhanc
environment
clean
cohortingisol
patient
without
recours
activ
surveil
emphasi
hand
hygien
success
reduc
incid
significantli
trust
discuss
andor
conclus
mutidisciplinari
involv
includ
weekli
measur
cdi
number
inform
improv
real
time
chang
test
treatment
cdi
improv
ensur
effect
decontamin
mattress
commod
bedpan
overal
result
reduct
number
hospit
acquir
cdi
id
region
spread
mrsa
mlva
type
netherland
declin
paul
grutek
thij
bosch
annelot
schoffelen
leo
schoul
olvg
hospit
amsterdam
netherland
nation
institut
public
health
environ
rivm
bilthoven
netherland
background
netherland
known
low
preval
mrsa
also
longterm
care
facil
ltcf
howev
mrsa
also
known
spa
note
upcom
mrsa
variant
health
care
facil
amsterdam
region
strike
similar
epidemiolog
genet
mrsa
spa
hong
kong
describ
aim
object
evalu
cours
emerg
netherland
complex
pvlneg
colon
common
seriou
infect
rare
strain
easili
transmiss
healthcar
set
reconstruct
transmiss
rout
within
ltcf
prove
difficult
littl
genet
variabl
limit
use
current
type
method
elucid
microepidemiolog
ng
might
help
although
suffici
number
strain
epidemiolog
data
need
next
year
learn
whether
disappear
remain
endem
level
outbreak
support
team
belgian
answer
emerg
treat
multidrug
resist
organ
mdro
mdrooutbreak
care
facil
barbara
legiest
anni
uwineza
beatric
jan
boudewijn
catri
background
healthcar
associ
infect
caus
multidrug
resist
organ
mdro
signifi
therapeut
impass
infect
difficult
treat
hospitalis
last
longer
consequ
morbid
mortal
hospit
cost
increas
moreov
mdro
easili
transmit
caus
outbreak
often
difficult
contain
care
facil
aim
object
belgium
outbreak
support
team
ost
creat
give
opportun
care
facil
struggl
outbreak
involv
mdro
call
help
extern
partner
without
blame
stigmat
method
ost
collabor
region
health
author
charg
infecti
diseas
scientif
institut
public
health
nation
refer
laboratori
help
offer
ost
includ
scientif
support
site
visit
advic
priorit
action
rare
enforc
result
contribut
ost
outbreak
manag
describ
sever
tool
develop
checklist
inventori
measur
transferand
transport
document
standard
commun
mdro
contamin
patient
initi
increas
knowledg
mdro
care
sector
like
nurs
home
revalid
center
homecar
base
experi
hand
exampl
recurr
trigger
develop
fitfal
control
outbreak
list
discuss
andor
conclus
despit
expertis
present
measur
taken
hospit
ost
help
control
outbreak
nation
level
ost
contribut
coordin
approach
mdro
battl
background
april
four
infant
special
care
babi
unit
babi
requir
ventil
hour
period
two
infant
develop
sign
respiratori
tract
infect
viral
pathogen
suspect
describ
control
measur
place
confirm
aetiolog
pathogen
parainflunza
viru
aim
object
share
timelin
outbreak
describ
evolv
control
measur
put
place
commun
strategi
method
outbreak
manag
seri
outbreak
control
meet
decis
around
closur
unit
cohort
person
protect
equip
staff
visitor
restrict
visitor
polici
enviornment
clean
commun
parent
staff
agre
reveiw
meet
result
twenti
infant
special
care
babi
unit
time
outbreak
start
four
requir
intub
mechan
ventil
two
infant
confirm
postiv
case
requir
ventilatori
support
unit
close
admiss
period
four
day
visit
restrict
parent
ppe
init
includ
full
use
glove
apron
surgic
mask
cotsid
clean
increas
three
time
per
day
parent
receiv
daili
written
updat
situat
believ
cross
tranmiss
follow
identif
potenti
outbreak
discuss
andor
conclus
rapidli
evolv
outbreak
success
control
control
measur
describ
chang
made
light
experi
hope
prevent
similar
outbreak
futur
sink
potenti
sourc
transmiss
carbapenemaseproduc
enterobacteriacea
intens
care
unit
deborah
de
geyter
liev
blommaert
nicol
verbraeken
deni
ingrid
wybo
univers
hospit
brussel
univers
hospit
brusselsmicrobiolog
infect
prevent
background
carbapenemaseproduc
enterobacteriacea
cpe
emerg
pathogen
repres
major
public
health
threat
univers
hospit
brussel
incid
new
patient
cpe
rose
case
case
januari
august
patient
becam
infectedcolon
cpe
stay
room
intens
care
unit
icu
result
time
period
patient
rel
small
although
strain
belong
differ
speci
differ
antibiogram
mechan
resist
hypothesi
environ
could
possibl
sourc
transmiss
investig
suggest
evil
doer
contamin
sink
besid
strain
c
freundii
type
frequent
isol
patient
sink
investig
phylogenet
relationschip
strain
pgfe
perform
strain
isol
patient
sink
implic
room
highli
relat
point
sink
patient
transmiss
sampl
icu
room
also
taken
reveal
sink
contamin
cpe
control
outbreak
sink
plumb
replac
new
one
anoth
structur
flush
everi
morn
glucoprotamin
solut
routin
regard
sink
practic
improv
eight
month
period
replac
sink
one
new
patient
cpe
detect
icu
discuss
andor
conclus
conclus
outbreak
highlight
sink
drain
accumul
strain
resist
gene
becom
potenti
sourc
cpe
method
decemb
three
patient
ward
test
posit
day
rsv
one
case
discharg
home
one
asymptomat
case
remain
ward
final
case
nurs
infect
control
precaut
place
due
presenc
symptom
outbreak
declar
ward
close
admissionstransf
fourth
patient
case
confirm
infect
control
precaut
includ
patient
staff
screen
isol
cohort
case
exclus
symptomat
staff
person
protect
equip
includ
surgic
face
mask
cours
outbreak
situat
assess
outbreak
control
team
use
hospit
infect
incid
assess
tool
hiiat
result
total
patient
staff
test
posit
outbreak
four
patient
case
requir
treatment
ribavarin
immunoglobulin
ward
remain
close
total
day
reopen
outbreak
declar
asymptomat
patient
carrier
detect
possibl
contribut
ongo
cross
transmiss
discuss
andor
conclus
review
undertaken
provid
recommend
includ
isol
patient
symptom
first
detect
explor
near
patient
test
develop
earli
alert
highlight
increas
incid
commun
set
high
risk
patient
group
asymptomat
carriag
import
consider
background
pneumocysti
jirovecii
seriou
opportunist
fungal
infect
immunosuppress
patient
incid
increas
england
previous
associ
hivaid
increasingli
recognis
patient
immunosuppress
due
cancertranspl
treatment
aim
object
describ
learn
investig
outbreak
one
region
includ
diagnost
approach
avail
util
interpret
genotyp
role
environment
sampl
control
measur
also
describ
current
nation
surveil
fungal
infect
includ
pneumocysti
jirovecii
method
incid
identifi
clinic
recognit
hospit
base
surveil
outbreak
declar
control
team
form
descript
epidemiolog
analyt
casecontrol
studi
undertaken
genotyp
undertaken
incid
limit
environment
investig
undertaken
one
detail
repeat
environment
sampl
undertaken
anoth
pcr
combin
clinic
radiolog
find
use
diagnosi
result
three
outbreak
identifi
across
three
differ
teach
hospit
one
region
renal
unit
across
multipl
special
patient
identifi
respect
outbreak
genotyp
avail
show
clonal
isol
obtain
environment
deposit
identifi
one
incid
surfac
air
handl
system
discuss
andor
conclus
pneumocysti
jirovecii
outbreak
difficult
investig
least
lack
systemat
nation
surveil
cultur
current
possibl
divers
genotyp
local
nation
underdevelop
ecolog
epidemiolog
incomplet
understood
investig
advanc
understand
complex
incid
carri
substanti
morbid
mortal
affect
patient
current
studi
evalu
genet
variat
subset
outbreak
clinic
sampl
hypothesi
isol
uniqu
biolog
characterist
serv
prolong
outbreak
method
fit
assay
mutat
rate
whole
genom
sequenc
perform
test
select
advantag
compensatori
mutat
result
fit
mutat
rate
resist
isol
differ
either
refer
strain
suscept
isol
lineag
unrel
isoniazid
suscept
resist
sampl
delet
compar
analysi
detect
delet
demonstr
extens
delet
gene
compar
control
strain
use
snp
total
snp
identifi
virul
gene
affect
least
one
snp
insert
compar
analysi
reveal
presenc
insert
discuss
andor
conclus
detail
analysi
genet
variat
inhr
sampl
suggest
outbreak
consist
success
closelyrel
circul
strain
heterogen
resist
profil
littl
associ
fit
cost
impact
mutat
rate
specif
delet
snp
may
peculiar
featur
isol
potenti
explain
persist
year
method
sampl
patient
pneumocysti
jiroveci
pneumonia
pjp
suspect
analys
pjpcr
singl
public
health
england
phe
laboratori
cycl
time
provid
genotyp
wherev
possibl
case
stratifi
accord
clinicalmicrobiolog
imag
data
environment
sampl
undertaken
within
hospit
ventil
air
handl
unit
intak
extract
filter
surfac
room
air
imping
within
hospit
repeat
specimen
collect
follow
enhanc
deep
clean
use
acticlor
hydrogen
peroxid
vapour
result
genotyp
found
patient
healthcar
environ
stack
air
handl
unit
pjpcr
posit
strain
present
intak
filter
serv
renal
ward
anoth
extract
filter
ward
previous
patient
pjp
surfac
sampl
air
vent
patholog
chute
light
fit
suppli
airvent
pjpcr
posit
genotyp
possibl
air
sampl
neg
pjpcr
follow
deep
clean
sampl
neg
discuss
andor
conclus
work
requir
understand
signific
environment
pj
role
transmiss
pathogenesi
pjp
result
avail
monday
june
three
patient
develop
laboratoryconfirm
rotaviru
infect
june
five
case
three
diarrhoea
vomit
one
diarrhoea
one
vomit
type
result
avail
four
patient
nonvaccin
strain
infect
hospit
acquir
possibl
establish
sourc
result
patient
assess
gastrointestin
symptom
thirteen
stool
sampl
test
five
test
posit
bay
contain
symptomat
patient
close
confirm
case
transfer
side
room
remain
least
day
onset
symptom
asymptomat
hour
whichev
later
enhanc
infect
control
eic
measur
implement
patient
recov
bay
deepclean
reopen
eic
measur
stood
june
discuss
andor
conclus
literatur
rotaviru
rare
describ
caus
diarrhoea
andor
vomit
adult
outbreak
highlight
need
test
pathogen
specif
treatment
identif
rotaviru
enabl
advic
given
durat
isol
import
clinic
set
length
stay
often
exce
infect
period
christina
petrid
fiona
thorburn
barri
atkinson
emma
aaron
rare
import
pathogen
laboratori
public
health
england
rare
import
pathogen
laboratori
phe
background
current
explos
outbreak
zika
viru
zikv
potenti
sexual
transmiss
due
presenc
zikv
semen
signific
consequ
pregnant
women
coupl
plan
pregnanc
due
risk
advers
fetal
outcom
women
becom
infect
pregnanc
zikv
rna
report
semen
day
post
onset
symptom
howev
durat
viral
persist
semen
unknown
transmiss
report
asymptomat
coupl
detect
zikv
rna
uk
perform
public
health
england
porton
rrtpcr
aim
object
determin
durat
detect
zikv
rna
post
onset
symptom
semen
sampl
receiv
phe
method
rrtpcr
perform
semen
sampl
ct
valu
determin
offer
servic
test
patient
detect
rna
determin
whether
clearanc
occur
look
whether
patient
detect
rna
urin
blood
result
longest
durat
viru
semen
day
much
longer
previous
report
day
discuss
andor
conclus
result
suggest
durat
persist
zikv
semen
variabl
may
protract
individu
indic
potenti
prolong
sexual
transmiss
find
use
establish
likelihood
sexual
transmiss
inform
famili
plan
nation
guidelin
current
recommend
asymptomat
male
return
countri
ongo
zikv
transmiss
use
barrier
protect
week
reduc
risk
sexual
transmiss
failur
routin
practic
detect
commun
mrsa
cluster
descript
public
health
investig
background
report
public
health
investig
cluster
genom
relat
isol
epidem
methicllin
resist
staphylococcu
domin
lineag
uk
hospit
longterm
care
facil
isol
identifi
wholegenom
sequenc
wg
patient
resid
geograph
area
regist
gener
practic
cluster
detect
routin
practic
includ
post
infect
review
pir
aim
object
aim
identifi
relat
case
epidemiolog
link
patient
potenti
ongo
transmiss
method
close
relat
mrsa
isol
identifi
use
wg
prospect
observ
studi
conduct
region
microbiolog
laboratori
addit
casefind
public
health
investig
consist
retrospect
analysi
healthcar
data
identifi
potenti
epidemiolog
link
prospect
onsit
observ
sampl
determin
potenti
ongo
transmiss
result
cluster
compris
isol
case
includ
two
bacteraemia
cluster
lack
clear
epidemiolog
link
singl
hospit
suggest
commun
transmiss
onsit
observ
identifi
sever
area
practic
could
improv
sampl
staff
environment
site
neg
mrsa
discuss
andor
conclus
depend
wg
identif
commun
cluster
despit
presenc
two
fatal
bacteraemia
suggest
potenti
benefici
role
target
wg
routin
practic
highlight
studi
commun
spread
mrsa
increasingli
recognis
transmiss
pathway
hospitalcentr
infect
control
procedur
reflect
aim
object
better
characteris
outbreak
retrospect
analysi
measl
case
perform
larg
central
london
teach
hospit
measl
case
london
method
electron
patient
note
laboratori
report
system
use
retrospect
analys
clinic
cours
demograph
inform
patient
laboratoryconfirm
measl
diagnos
rtpcr
posit
andor
igm
positiveequivoc
igg
either
positiveneg
result
patient
confirm
measl
age
older
delay
diagnosi
due
misattribut
measl
rash
drug
reaction
seen
patient
patient
full
clinic
inform
avail
place
respiratori
isol
within
minut
arriv
e
therebi
requir
contact
trace
larg
number
expos
patient
present
hospit
time
first
visit
median
number
hospit
doctor
review
patient
prediagnosi
iqr
rang
discuss
andor
conclus
reason
delay
diagnosi
includ
lack
recognit
measl
clinician
despit
seemingli
classic
present
highlight
clear
need
improv
awar
educ
measl
control
strategi
therefor
focu
clinician
educ
well
awar
regard
infect
control
measur
high
mortal
infect
caus
hyper
toxin
produc
clostridium
difficil
milind
khare
deborah
gnanarajah
helen
forrest
royal
derbi
hospit
background
phe
report
nation
rise
infect
caus
hyper
toxin
produc
clostridium
difficil
origin
thought
pig
calv
increas
incid
report
european
countri
well
aim
object
evalu
clostridium
difficil
infect
method
teach
hospit
patient
c
diff
ribotyp
evalu
result
patient
identifi
c
diff
ribotyp
sinc
januari
femal
male
mean
age
yr
rang
except
one
year
avail
data
resolv
within
day
patient
die
follow
infect
six
die
within
day
whilst
die
day
case
link
cluster
use
vntr
profiledna
finger
print
discuss
andor
conclus
extens
map
done
see
movement
patient
hospit
singl
ward
identifi
patient
care
differ
ward
major
patient
admit
mau
public
health
england
also
undertook
patient
map
link
trust
commun
identifi
believ
equip
environ
key
caus
link
therefor
cleanli
focu
manag
outbreak
hydrogen
peroxid
decontamin
enter
isol
room
done
routin
standard
hyper
toxin
produc
clostridium
difficil
associ
high
mortal
rate
background
malassezia
basidiomycet
fungu
commens
human
anim
skin
although
rare
malassezia
speci
import
caus
nosocomi
infect
fungemia
preterm
neonat
immunocompromis
patient
mpachydermati
colon
stratum
corneum
dog
report
zoonot
transmiss
healthcar
worker
well
document
risk
factor
colonis
neonat
includ
degre
prematur
correspond
skin
condit
endotrach
intub
indwel
vascular
cathet
aim
object
januari
babi
neonat
unit
isol
mpachydermati
ear
swab
taken
part
routin
microbiolog
screen
follow
identif
outbreak
investig
initi
mpachydermati
never
isol
unit
furthermor
chang
made
laboratori
procedur
process
neonat
screen
method
part
outbreak
investig
babi
unit
screen
weekli
infect
control
measur
includ
educ
standard
infect
control
precaut
hand
hygien
complianc
uniform
polici
equip
disinfect
also
review
background
influenza
caus
signific
morbid
mortal
elderli
influenza
vaccin
recommend
highrisk
group
elderli
signific
comorbid
prevent
infect
aim
object
describ
influenza
outbreak
elderli
rehabilit
ward
audit
diagnosi
manag
infect
control
prevent
trust
guidelin
method
follow
identif
influenza
viru
patient
risk
assess
treat
per
trust
protocol
symptomat
patient
oropharyng
swab
taken
confirm
diagnosi
treat
oseltamivir
influenza
vaccin
statu
check
patient
confirm
patient
gp
anonymis
data
collect
staff
member
risk
assess
vaccin
statu
check
staff
consent
use
anonymis
data
research
data
record
staff
type
result
patient
present
ward
patient
vaccin
statu
unknown
patient
vaccin
vaccin
vaccin
patient
patient
symptomat
influenza
posit
nonvaccin
symptomat
found
influenza
posit
zero
patient
influenza
die
requir
higher
care
staff
member
vaccin
outbreak
staff
member
found
high
risk
vaccin
discuss
andor
conclus
anticip
vaccin
patient
lower
rate
influenza
infect
low
rate
vaccin
staff
member
suggest
staff
work
elderli
encourag
undergo
vaccin
reduc
risk
outbreak
transmiss
norway
lose
antimicrobi
innoc
asymptomat
carrier
identifi
screen
contact
trace
blood
cultur
isol
identifi
differ
ward
least
one
patient
vre
pulsedfield
gel
electrophoresi
pfge
multilocu
sequenc
type
mlst
indic
singlestrain
outbreak
discuss
contain
outbreak
costli
tediou
believ
mainli
due
lack
guidelin
standard
laboratori
methodolog
organiz
cultur
despit
increas
rate
colon
hospit
advers
outcom
relat
vre
actual
defin
costeffect
infect
control
intervent
antibiot
resist
know
geograph
border
vre
said
canari
mine
vre
actual
one
main
concern
futur
conclus
vre
erad
form
hospit
must
remain
vigil
prevent
anoth
larg
outbreak
get
back
baselin
may
illus
method
healthcar
facil
outbreak
involv
multidrug
resist
organ
mdro
ask
support
nation
outbreak
support
team
ost
result
septemb
strain
infect
colon
person
among
famili
sever
relaps
observ
index
case
histori
noninvestig
relaps
skin
infect
outbreak
report
month
onset
septemberdecemb
strain
famili
involv
infect
colon
case
hcw
known
camrsa
histori
start
work
ward
day
index
case
identifi
januaryapril
strain
famili
involv
infect
mostli
breast
abscess
colon
patient
hcw
index
case
patient
non
investig
relaps
skin
infect
probabl
contamin
contamin
outbreak
spread
among
mother
babi
outbreak
success
manag
close
collabor
ost
medic
direct
infect
control
team
matern
hcw
laboratori
discuss
andor
conclus
control
spread
camrsa
requir
care
elabor
strategi
although
mother
mostli
good
health
complianc
hand
hygien
recommend
remain
essenti
matern
ward
earli
declar
outbreak
import
screen
mother
skin
diseas
histori
deliveri
could
protect
measur
result
well
describ
organ
infect
categori
care
set
involv
infect
incid
time
period
report
also
highlight
potenti
report
bias
report
found
lower
level
report
cdi
staphylococcu
aureu
expect
given
signific
chang
infect
incid
pathogen
accord
nation
surveil
also
consider
variat
report
report
board
previous
nh
board
requir
report
incid
assess
amber
red
hp
report
hiiat
green
incid
hp
voluntari
bia
exist
possibl
due
variat
applic
hiiat
result
report
discuss
andor
conclus
april
report
nonnoroviru
hiiat
green
incid
made
mandatori
nhsscotland
anticip
mandatori
report
reduc
potenti
report
bias
enabl
hp
provid
accur
pictur
infect
incid
epidemiolog
nhsscotland
studi
provid
baselin
measur
impact
nonnoroviru
hiiat
green
report
may
also
provid
opportun
improv
consist
healthcar
associ
infect
incid
assess
nhsscotland
outbreak
staphylococcu
capiti
bacteraemia
scottish
neonat
unit
teresa
inkster
huma
changez
kate
hamilton
elizabeth
dickson
gillian
bowskil
gillian
mill
jennif
slorach
queen
elizabeth
univers
hospit
glasgow
nhsggc
background
staphylococcu
capiti
emerg
pathogen
nicu
set
recent
outbreak
report
literatur
includ
capiti
clone
nrcsa
characteris
vancomycin
resist
heteroresist
recent
french
studi
scapiti
late
onset
sepsi
found
risk
factor
sever
morbid
advanc
laboratori
method
use
malditof
identif
coagulas
neg
staphylococci
cn
speci
level
perform
frequent
aim
object
describ
outbreak
capiti
scottish
neonat
intens
care
unit
method
patient
capiti
bacteraemia
identifi
day
period
blood
cultur
isol
identifi
use
malditof
subsequ
investig
case
detect
take
total
number
case
month
two
patient
treat
infect
two
consid
contamin
result
puls
field
gel
electrophoresi
pfge
blood
cultur
isol
reveal
pulsotyp
infect
control
measur
implement
includ
increas
environment
clean
educ
review
staff
skin
health
unit
environment
screen
undertaken
neg
sourc
identifi
discuss
andor
conclus
capiti
emerg
pathogen
neonat
sourc
found
outbreak
brought
control
implement
infect
control
measur
use
malditof
pivot
identifi
outbreak
laboratori
give
consider
identifi
cn
neonat
unit
speci
level
enabl
earli
outbreak
detect
catherin
houlihan
catherin
mcgowan
steve
dick
david
mabey
richard
tedder
judith
glynn
ucl
london
school
hygien
tropic
medicin
background
ebola
evd
epidem
west
africa
wa
result
larg
intern
humanitarian
respons
health
care
worker
hcw
wa
disproportion
affect
intern
hcw
infect
aim
object
sinc
asymptomat
evd
describ
test
intern
returne
evd
antibodi
method
onlin
consent
survey
link
distribut
use
snowbal
techniqu
elig
criteria
includ
travel
wa
epidem
never
test
posit
ebola
viru
receiv
filoviru
vaccin
oral
fluid
collect
devic
post
return
use
standard
mail
sampl
test
use
igg
captur
elisa
nonexpos
uk
control
test
result
individu
respond
submit
sampl
women
major
travel
sierra
leon
role
includ
limit
laboratori
clinic
epidemiologistresearch
commun
engagementburi
watersanitationengin
total
returne
spent
time
person
protect
equip
ppe
concern
exposur
remov
describ
possibl
signific
evd
exposur
describ
febrilediarrho
ill
wa
within
month
return
returne
two
reactiv
result
igg
captur
assay
neither
reactiv
competit
elisa
use
plasma
discuss
andor
conclus
high
proport
intern
respond
report
potenti
exposur
evd
report
febril
ill
incub
period
ebola
improv
train
procedur
consist
ppe
equip
remov
may
mitig
background
earli
septemb
three
case
invas
group
streptococc
iga
infect
identifi
share
rare
emm
type
emm
case
investig
east
england
health
protect
team
hpt
identifi
common
link
overse
implement
control
measur
aim
object
identifi
elimin
potenti
sourc
exposur
identifi
link
case
prevent
ongo
transmiss
method
incid
manag
team
imt
conven
discuss
case
epidemiolog
possibl
mechan
transmiss
investig
hpt
agre
action
commun
health
healthcar
trust
infect
control
team
ict
prevent
transmiss
result
initi
investig
identifi
case
resid
geograph
close
mile
receiv
wound
care
bilater
leg
ulcer
commun
nurs
team
commun
healthcar
servic
provid
infect
control
team
ict
assess
nurs
team
preliminari
find
identifi
two
nurs
visit
three
case
incub
period
one
symptomat
tonsillopharyng
staff
screen
antibiot
chemoprophylaxi
arrang
piec
equip
bandag
scissor
also
use
patient
subsequ
taken
use
discuss
andor
conclus
outbreak
highlight
suscept
patient
receiv
wound
care
whilst
prevent
transmiss
asymptomat
carriag
alway
possibl
import
exclus
temporari
redeploy
healthcar
staff
symptomat
infect
highlight
method
retrospect
analysi
case
carri
match
case
two
case
link
control
result
nine
patient
affect
median
age
present
year
rang
year
median
time
diseas
onset
year
posttranspl
rang
year
diagnosi
patient
function
graft
mean
egfr
mlmin
rang
mlmin
significantli
lower
control
mlmin
p
signific
differ
immunosuppress
regimen
patient
lymphopen
diagnosi
mean
l
significantli
lower
control
popul
correspond
time
diagnosi
mean
l
p
four
patient
requir
mechan
ventil
two
requir
dialysi
four
patient
die
within
three
month
present
background
interferongamma
key
cytokin
immun
toward
tuberculosi
receptor
knockout
mice
rapidli
succumb
tuberculosi
pathogen
evolv
mani
way
mitig
effect
regul
surfac
macrophag
one
strategi
aim
object
object
studi
character
mediat
macrophag
respons
mycobacteri
infect
key
host
factor
regul
express
macrophag
respons
tb
infect
explor
dichotomi
profil
suscept
pattern
immunolog
relev
cytokin
method
human
cell
line
murin
bone
marrow
deriv
macrophag
bmdm
human
peripher
blood
mononuclear
cell
pbmc
use
studi
flow
cytometri
confoc
imag
western
blot
employ
investig
result
data
show
tb
bovi
bcg
potent
regul
macrophag
mani
host
factor
signal
pathway
employ
tb
exhibit
phenomenon
tlr
pathway
specif
adaptor
molecul
calcium
homeostasi
pkc
mapk
erk
involv
aid
tb
mediat
receptor
modul
also
gene
calcium
cystein
proteas
pathway
previous
identifi
lab
link
mediat
neg
immun
tb
also
regul
macrophag
respons
tb
infect
discuss
andor
conclus
thu
tb
employ
variou
host
factor
elicit
immun
suppress
effect
downregul
surfac
receptor
express
regul
receptor
level
pathogen
success
abl
avert
protect
effect
emma
boldock
daria
shamarina
tomasz
prajsnar
ba
surewaard
stephen
renshaw
simon
foster
sheffield
teach
hospit
nh
trust
univers
sheffield
background
staphylococcu
aureu
invas
human
pathogen
associ
signific
mortal
hostpathogen
dynam
infect
poorli
understood
recent
work
demonstr
high
dose
inocula
immunolog
bottleneck
allow
clonal
expans
bacteria
go
caus
abscess
model
aureu
infect
character
requir
larg
bacteri
inoculum
impact
surround
microflora
aureu
pathogen
underexplor
aim
object
interrog
clonal
expans
phenomenon
investig
need
larg
bacteri
inoculum
establish
aureu
infect
mix
strain
inocula
test
zebrafish
embryo
murin
model
system
infect
result
infect
model
purifi
particul
bacteri
cell
wall
peptidoglycan
abl
augment
infect
low
dose
aureu
inert
particul
bead
solubilis
peptidoglycan
commens
bacteria
eg
micrococcu
luteu
also
abl
augment
pathogenesi
low
dose
aureu
murin
model
infect
dose
could
lower
cfu
presenc
potenti
liver
appear
focal
point
loss
immun
control
innat
immun
dysfunct
chemokin
dysregul
shown
underpin
augment
phenomenon
discuss
andor
conclus
result
import
ramif
regard
human
aureu
diseas
may
begin
explain
initi
infect
occur
aureu
primarili
enter
via
wound
invas
procedur
data
demonstr
bacteria
even
compon
enabl
aureu
initi
infect
trust
commenc
patient
safeti
initi
amid
report
increas
incid
surgic
site
infect
ssi
time
infect
incid
unclear
data
collect
standardis
aim
object
aim
establish
baselin
ssi
rate
adult
cardiac
surgeri
employ
target
intervent
per
depart
health
nation
institut
health
care
excel
nice
best
evid
guidelin
gave
us
opportun
standardis
practic
improv
patient
outcom
qualiti
safeti
effici
line
organis
target
also
aim
emb
ssi
detail
investig
protocol
mirror
nice
ssi
qualiti
standard
method
develop
establish
use
local
data
collect
protocol
line
public
health
england
recommend
identifi
local
champion
strong
ssi
leadership
help
us
develop
multidisciplinari
collabor
approach
eas
burden
data
collect
optimis
open
commun
enabl
us
address
potenti
practic
concern
effect
seri
initi
result
ssi
rate
fell
cabg
rate
consider
nation
averag
save
estim
year
period
discuss
andor
conclus
use
local
champion
multidisciplinari
collabor
approach
enabl
us
success
implement
evid
base
practic
demonstr
signific
reduct
ssi
incid
background
common
method
caesarean
section
skin
closur
metal
stapl
absorb
sutur
oppos
skin
edg
facilit
wound
heal
stapl
regard
quicker
easier
sutur
use
date
larg
studi
conclus
demonstr
stapl
associ
increas
risk
ssi
morbid
associ
ssi
may
increas
use
stapl
would
outweigh
increas
time
requir
closur
sutur
aim
object
evalu
risk
surgic
site
infect
ssi
caesareansect
wound
closur
surgic
stapl
versu
absorb
subcuticular
sutur
method
nh
hospit
northern
ireland
perform
csection
mandat
perform
prospect
ssi
surveil
inpati
stay
commun
set
cdcnhsn
definit
ssi
use
inform
collect
includ
age
bmi
previou
csection
asascor
urgenc
oper
closur
use
procedur
durat
antibiot
prophylaxi
compar
ssi
rate
stapl
sutur
closur
low
transvers
csection
result
csection
includ
receiv
sutur
stapl
close
stapl
develop
ssi
hospit
compar
sutur
group
p
end
commun
followup
incid
stapl
group
sutur
group
p
median
oper
time
longer
sutur
group
compar
stapl
vs
minut
discuss
andor
conclus
one
largest
studi
demonstr
stapl
closur
associ
significantli
higher
ssi
rate
compar
sutur
closur
surgic
site
infect
ssi
spinal
surgeri
universityassoci
pediatr
hospit
impact
nutrit
insuffici
marielaur
valdeyron
vincent
cunin
christin
bruchon
selilah
amour
ann
tristan
isabel
poirot
jacquelin
grando
noel
peretti
philipp
vanhem
background
onetogeth
collabor
profession
organis
focus
prevent
surgic
site
infect
lack
knowledg
variat
applic
guidanc
identifi
barrier
implement
infect
prevent
practic
ipp
theatr
address
develop
assess
toolkit
systemat
evalu
adher
ipp
across
surgic
pathway
aim
object
undertak
pilot
studi
assess
toolkit
assur
practic
ssi
prevent
method
assess
framework
seven
ipp
standard
develop
base
evidencebas
guidanc
divid
discret
element
element
measur
standard
present
appli
score
compliant
partial
compliant
noncompli
perform
measur
percentag
complianc
standard
pilot
studi
particip
recruit
partnership
chose
theatr
specialti
assess
data
captur
practic
problem
encount
eas
applic
interpret
omiss
result
toolkit
use
seven
hospit
theatr
overal
complianc
rang
score
higher
standard
appli
defin
complianc
score
highest
instrument
asepsi
lowest
preop
warm
skin
disinfect
surgic
environ
toolkit
report
easi
use
valuabl
identifi
gap
ipp
discuss
andor
conclus
pilot
studi
demonstr
noncompli
recommend
ipp
surgic
patient
found
assess
tool
valuabl
identifi
address
defici
toolkit
revis
incorpor
feedback
pilot
studi
final
version
made
avail
organ
space
colon
surgeri
male
sex
stoma
independ
risk
factor
oe
infect
laparoscop
surgeri
oral
prophylaxi
protect
rectal
surgeri
male
sex
surgeri
durat
independ
risk
factor
oe
infect
oral
prophylaxi
protect
readmiss
vs
p
length
stay
vs
p
significantli
higher
rectal
compar
colon
surgeri
differ
clinic
cure
mortal
rate
group
discuss
andor
conclus
colon
rectal
surgeri
differ
incid
risk
factor
organ
space
ssi
although
clinic
cure
mortal
rate
significantli
differ
background
surgic
site
infect
ssi
account
hcai
cost
averag
per
case
report
increas
mortal
morbid
dedic
siss
team
introduc
septemb
knifetoskin
procedur
inpati
survey
post
discharg
surveil
day
aim
object
present
one
trust
first
year
result
follow
introduct
whole
system
approach
surgic
site
infect
surveil
ssi
exceed
nation
uk
expect
method
data
collect
use
combin
electron
manual
method
elect
emerg
patient
exclud
day
case
monthli
feedback
given
surgeon
individu
ssi
rate
procedur
comparison
specialti
perform
result
septemb
septemb
averag
patient
per
month
survey
total
period
ssi
rate
confirm
infect
fell
period
vari
result
special
posit
impact
length
stay
number
readmiss
also
identifi
expand
result
present
poster
discuss
andor
conclus
invest
ssi
team
procur
surveil
system
subsequ
feedback
result
result
reduct
ssi
impact
posit
trust
resourc
patient
safeti
audit
antimicrobi
prophylaxi
spinal
surgeri
part
ssi
surveil
improv
activ
manjusha
narayanan
royal
victoria
infirmari
newcastl
upon
tyne
nh
ft
background
data
collect
part
ssi
surveil
spinal
infect
view
improv
practic
front
reduc
ssi
rate
new
protocol
antibiot
prophylaxi
spinal
surgeri
introduc
last
year
agre
ssi
meet
audit
aim
object
aim
audit
use
antibiot
prophylaxi
spinal
surgeryto
look
time
time
differ
kt
extend
dose
antibiot
oper
last
hour
choic
antibiot
agent
use
data
collect
part
ssi
surveil
spinal
infect
view
improv
practic
method
retrospect
data
collect
variou
element
antibiot
prescrib
relat
antibiot
protocol
carri
period
week
result
data
time
antibiot
administr
relat
kt
knife
skin
choic
antibiot
repeat
dose
cephalosprin
prolong
oper
post
op
antibiot
cover
analys
discuss
andor
conclus
time
antibiot
administr
poor
overal
within
min
kt
unnecessari
administr
antibiot
post
op
choic
antibiot
use
per
protocol
satisfactori
detail
analysi
data
fed
back
relev
anaesthet
surgic
team
help
address
chang
practic
data
collect
difficult
document
mani
differ
placessurginet
checklist
checklist
e
record
often
intra
op
anaesthet
paper
chart
share
audit
surgic
team
id
map
current
futur
prioriti
area
surgic
site
infect
ssi
prevent
surveil
local
nation
rachael
troughton
susan
hopkin
alison
holm
gabriel
birgand
studi
aim
map
surgic
procedur
highest
associ
ssi
burden
term
volum
risk
cost
current
surveil
activ
shape
current
futur
surveil
prioriti
nation
local
level
method
map
studi
compar
multipl
surgeri
type
patient
volum
infect
rate
excess
length
stay
excess
cost
attribut
ssi
proport
hospit
current
undertak
surveil
mean
prioriti
rank
report
phe
survey
trust
nation
map
studi
use
data
hospit
episod
statist
ssiss
literatur
local
level
patient
volum
risk
cost
calcul
laboratori
data
patient
administr
data
financi
data
figur
compar
local
surveil
arrang
result
result
display
matrix
use
heat
map
colour
match
along
row
indic
high
degre
agreement
risk
burden
cost
current
futur
prioriti
caesarean
section
cs
low
agreement
discuss
andor
conclus
signific
mismatch
ssi
burden
current
surveil
particularli
caesarean
section
high
ssi
risk
patient
volum
nation
surveil
mani
trust
indic
cs
prioriti
area
develop
patient
inform
leaflet
take
care
vascular
graft
short
guid
care
graft
surgeri
stephani
thoma
abdul
shaffi
jay
turnergardn
univers
hospit
south
manchest
manchest
univers
background
prosthet
vascular
graft
infect
pvgi
signific
complic
arteri
reconstructivesurgeri
incid
depend
surgic
locat
treatment
extrem
challeng
involv
graft
remov
revascular
debrid
often
empir
broad
spectrum
antibiot
prolong
cours
earli
postop
graft
especi
risk
transient
bacteraemia
secondari
poor
dental
hygien
skin
breakdowndiabet
complic
recurr
urinarytract
infect
constip
poor
gener
hygien
pose
signific
risk
insitu
graft
prevent
better
cure
aim
object
develop
patient
inform
leaflet
given
patient
preop
clinic
inform
educ
limit
risk
pvgi
result
patient
inform
leaflet
construct
clearli
state
risk
transient
bacteraemia
specif
encourag
good
gener
hygien
good
hand
hygien
genitourinari
cleanli
especi
surgeri
scar
locat
groin
keep
dress
clean
check
sign
infect
contact
gp
concern
share
person
item
like
razor
toothbrush
mainten
good
skin
care
keep
skin
moisturis
prevent
crack
regular
diabet
checkup
good
glucos
control
maintain
good
dental
hygien
prevent
plaqu
buildup
regular
dental
checkup
avoid
rins
brush
treatment
genitourinari
infect
good
toilet
habit
avoid
constip
keep
hydrat
male
year
old
report
problem
mani
prostat
relat
discuss
andor
conclus
simpl
effect
leaflet
address
previous
neglect
area
give
basic
inform
maintain
good
health
surgeri
may
help
prevent
catastroph
complic
graft
surgeri
form
pvgi
background
advanc
made
infect
control
practic
ssi
remain
substanti
caus
morbid
prolong
hospit
death
surveil
ssi
feedback
appropri
data
surgeon
shown
import
compon
strategi
reduc
ssi
risk
success
surveil
program
includ
use
epidemiologicallysound
infect
definit
effect
surveil
method
stratif
ssi
rate
accord
risk
factor
associ
ssi
develop
data
feedback
aim
object
report
ssi
pvbi
surgeri
stratifi
risk
index
method
prospect
studi
case
pvbi
surgeri
report
special
denomin
sheet
infect
procedur
report
numer
sheet
case
definit
health
care
associ
ssi
adopt
nation
health
safeti
network
nhsn
studi
start
januari
decemb
case
stratifi
risk
index
assign
surgic
patient
categori
base
presenc
three
major
risk
factor
oper
last
durat
cut
point
wound
class
asa
score
result
total
number
pvbi
risk
index
remain
risk
index
two
procedur
risk
index
infect
cumul
incid
five
procedur
risk
index
infect
cumul
incid
discuss
andor
conclus
immigr
north
subsaharan
africa
resid
african
immigr
campu
tripolilibya
particip
interview
relev
inform
collect
includ
sociodemograph
ethnic
geograph
variabl
sampl
test
hcv
hiv
use
elisa
genotyp
assign
use
specif
genotyp
assay
correl
demograph
factor
result
immigr
studi
posit
hcv
hiv
hcv
hiv
preval
hcv
higher
among
individu
nile
river
north
africa
na
follow
west
africa
wa
horn
africa
hoa
less
among
maghreb
countri
hiv
hcvhiv
coinfect
higher
among
hoa
wa
five
genotyp
detect
includ
genotyp
account
follow
genotyp
strain
genotyp
isol
hoa
wa
individu
preval
hcv
hiv
hcvhiv
coinfect
consid
high
uniqu
dispar
distribut
among
african
immigr
cross
toward
europ
reflect
prevent
effort
europ
north
subsaharan
africa
n
nurs
nurs
assist
overal
coverag
steadi
hcf
hcf
organ
inform
campaign
main
topic
influenza
vaccin
strategi
protect
measur
hcf
carri
vaccin
campaign
organ
share
occup
health
team
oht
ict
hospit
pharmaci
hcw
vaccin
colleagu
oht
ict
poster
remind
wear
mask
present
hcf
mainli
hospit
entranc
mask
avail
emerg
matern
pediatr
depart
discuss
andor
conclus
despit
broad
welldocu
vaccin
campaign
coverag
remain
low
hcw
categori
implement
behavior
chang
hcw
warrant
well
provid
mask
guidanc
appropri
use
besid
vaccin
antimicrobi
suscept
genet
analysi
isol
determin
use
differ
antibiot
pulsedfield
gel
electrophoresi
pfge
character
isol
spatialepidemiolog
analysi
conduct
reflect
chang
pattern
baumannii
within
countri
result
genet
analysi
show
eight
distinct
pfge
pattern
vari
one
region
anoth
signific
increas
clone
west
east
region
strain
show
high
resist
antibiot
test
strain
sensit
gentamicin
carapenem
discuss
andor
conclus
emerg
spread
multidrugresist
baumannii
among
libyan
hospit
care
set
suggest
urgent
intervent
program
prevent
colon
infect
resist
pathogen
aim
object
show
burden
hai
introduc
surveil
method
data
patient
characterist
preval
cathet
antimicrobi
also
collect
method
municip
invit
voluntari
point
preval
survey
pp
septemb
infect
control
nurs
hospit
instruct
collect
data
form
patient
chart
questionnair
modif
protocol
ecdc
data
analysi
feedback
provid
studi
team
result
twentytwo
hospit
municip
particip
collect
data
inpati
receiv
acut
care
rehabilit
longterm
termin
care
studi
day
rang
hospit
patient
least
one
hai
onethird
origin
hospit
common
hai
includ
lower
respiratori
tract
infect
urinari
tract
infect
skin
infect
fourteen
percent
urin
cathet
vascular
cathet
twentynin
percent
receiv
least
one
antimicrobi
commonli
use
antimicrobi
cefuroxim
cefalexin
fluoroquinolon
antimicrobi
use
hai
mrsa
infect
detect
discuss
andor
conclus
hai
surveil
prevent
primari
care
hospit
requir
improv
primari
care
pp
appropri
tool
preval
antimicrobi
use
high
especi
fluoroquinolon
resist
microb
rare
far
compar
analysi
adolescentadult
pertussi
outbreak
school
use
mathemat
model
hiroshi
kamano
sachi
nagao
kagawa
univers
health
center
background
outbreak
adolescentadult
pertussi
becam
public
health
problem
variou
part
world
pertussi
outbreak
matter
public
concern
japan
also
aim
object
studi
epidemiolog
pertussi
outbreak
school
sever
countri
compar
analysi
investig
epidem
curv
pertussi
outbreak
use
regress
analysi
equat
relat
basic
reproduct
number
develop
pertussi
simul
model
method
outbreak
outbreak
case
europ
japan
analyz
regress
analysi
analyz
pertussi
outbreak
use
gompertz
function
simul
model
use
sir
model
result
regress
analysi
studi
adolescentadult
pertussi
outbreak
use
follow
equat
r
exp
exp
simul
model
investig
outbreak
use
sir
model
follow
ds
di
dt
dr
n
r
definit
follow
n
total
popul
suscept
popul
infecti
popul
r
recov
popul
rate
infect
rate
attack
rate
recoveri
drew
simul
curv
use
differenti
equat
discuss
andor
conclus
analyz
sever
case
adolescentadult
pertussi
outbreak
mathemat
estim
basic
reproduct
number
adolescentadult
pertussi
school
statewid
antimicrobi
use
surveil
differ
outcom
differ
health
administr
system
filip
piastrelli
boszczowski
denis
maristela
freir
geraldin
madalosso
hospit
sapopemba
method
antimicrobi
use
incid
mdro
bloodstream
infect
mandatorili
report
intens
care
unit
sao
paulo
state
health
depart
antibiot
group
class
express
defin
daili
dose
ddd
per
patientday
pd
mdro
group
resist
gener
cephalosporin
carbapenem
oxacillin
compar
carbapenem
polymyxin
glycopeptid
use
hospit
group
privat
philanthrop
public
public
hospit
divid
social
organ
former
privat
manag
public
fund
correl
mdro
incid
antibiot
use
investig
result
mean
number
report
hospit
report
hospit
public
cephalosporin
prescrib
drug
although
decreas
trend
period
polymyxin
greatest
increas
use
mostli
public
hospit
among
public
hospit
compar
public
administr
differ
antimicrobi
use
glycopeptid
carbapenem
polymyxin
p
differ
mdro
incid
discuss
andor
conclus
conclus
observ
signific
increas
polymyxin
use
public
level
observ
discrep
incid
mdro
broadspectrum
antibiot
use
differ
administr
regimen
data
guid
public
health
polici
result
total
report
made
includ
report
oper
theatr
report
rate
fell
significantli
period
p
period
ii
analys
content
rate
intraop
manag
deliveri
instrument
significantli
reduc
p
p
respect
convers
rate
equip
dispos
show
chang
rate
hepat
c
virusposit
injuri
show
signific
chang
period
period
ii
suggest
submiss
rate
report
larg
static
result
implement
also
similar
compar
first
year
subsequ
year
background
observ
hand
hygien
audit
ohha
involv
train
observ
monitor
healthcar
worker
complianc
five
identifi
moment
hand
hygien
effect
ohha
uncertain
despit
widespread
adopt
aim
object
examin
effect
ohha
incid
methicillin
resist
staphylococcu
aureu
mrsa
vancomycin
resist
enterococci
vre
bacteraemia
method
conduct
retrospect
time
seri
four
acut
hospit
republ
ireland
period
ohha
intervent
introduc
three
site
fourth
site
act
control
introduc
ohha
compar
chang
incid
methicillin
resist
staphylococcu
aureu
mrsa
bacteraemia
vancomycin
resist
enterococci
vre
bacteraemia
alcohol
base
hand
gel
abhr
consumpt
intervent
versu
control
site
result
signific
reduct
mrsa
bacteraemia
control
p
intervent
p
site
studi
period
differ
differ
compar
statist
signific
differ
p
intervent
control
site
signific
reduct
vre
bacteraemia
control
p
intervent
p
site
signific
increas
abhr
consumpt
intervent
p
site
decreas
abhr
consumpt
control
p
site
differ
differ
compar
statist
signific
p
either
intervent
control
site
discuss
andor
conclus
implement
ohha
appear
associ
reduct
bacteraemia
increas
abhr
consumpt
alan
miln
carolyn
sinclair
fiona
smith
benjamin
parcel
karen
ware
nh
grampian
nhg
grampian
background
enhanc
staphylococcu
aureu
bacteraemia
surveil
esab
standardis
report
sab
infect
introduc
nation
infect
prevent
control
team
ipct
form
group
facilit
appropri
data
collect
focus
risk
contributori
factor
group
aim
determin
sab
avoid
case
review
ensur
manag
line
guidanc
manag
proven
suspect
sab
adult
aim
object
initi
aim
better
understand
caus
sab
determin
potenti
avoid
interven
minim
risk
sab
occur
due
caus
method
use
plan
studi
act
cycl
nation
esab
tool
surveil
form
creat
ipct
investig
sab
identifi
entri
point
sourc
record
procedur
intervent
last
day
assess
made
regard
medic
histori
devic
placement
whether
patient
prosthet
qualiti
improv
group
review
implement
complet
bundl
peripher
central
vascular
urinari
cathet
discuss
andor
conclus
ipct
along
multidisciplinari
team
discuss
result
surveil
identifi
qualiti
improv
audit
ar
carri
sab
found
relat
devic
ipct
engag
clinic
team
assist
implement
bundl
support
audit
clinician
charg
receiv
letter
detail
outcom
sab
surveil
offer
chanc
respond
inform
microbiologist
offer
attend
educ
meet
discuss
cox
model
mortal
risk
multist
model
extra
length
stay
result
among
inpati
stay
present
least
one
ni
proport
inhospit
death
time
higher
among
patient
ni
howev
adjust
hazard
ratio
signific
hr
crude
excess
length
stay
day
albeit
lower
remain
signific
multist
analysi
day
analys
perform
kind
ni
discuss
andor
conclus
result
favour
signific
effect
icuacquir
ni
length
stay
without
signific
effect
mortal
id
epidemiolog
healthcar
associ
infect
hai
neonat
intens
care
unit
nicu
background
newborn
preterm
highest
infect
rate
pediatr
patient
found
introduct
monitor
system
lead
hai
decreas
rate
aim
object
know
incid
hai
appear
unit
method
perform
prospect
observ
epidemiolog
studi
patient
remain
nicu
hour
includ
classif
criteria
hai
neokiss
incid
rate
cumul
incid
variou
infect
well
confid
interv
calcul
result
patient
men
women
studi
patient
weight
less
gram
incid
densiti
overal
per
thousand
stay
accumul
incid
patient
bacteremia
associ
central
venou
cathet
per
thousand
cathet
day
go
pneumonia
associ
mechan
ventil
preterm
infant
less
gram
highest
infect
rate
frequent
germ
escherichia
coli
discuss
andor
conclus
frequent
bacteremia
infect
associ
central
venou
cathet
per
thousand
cathet
day
hai
accord
weight
birth
gram
compar
children
gram
relat
infect
sex
found
men
slightli
higher
risk
infect
women
versu
background
irish
public
hospit
receiv
annual
block
fund
base
histor
spend
activ
pattern
without
explicit
adjust
rate
hospit
acquir
infect
aim
object
aim
ascertain
addit
financi
cost
per
routin
case
clostridium
difficil
infect
cdi
cost
cdi
outbreak
hospit
method
microcost
approach
use
estim
addit
cost
cdi
per
patient
identifi
august
cdi
outbreak
manag
month
resourc
use
quantifi
base
review
patient
chart
pharmaci
prescrib
data
prospect
collect
administr
resourc
input
record
clean
expenditur
result
addit
cost
routin
nonoutbreak
cdi
inpati
august
mean
clean
pharmaceut
addit
length
stay
lo
key
cost
driver
addit
lo
rang
day
day
seven
patient
involv
cdi
outbreak
bed
closur
lost
bed
day
estim
valu
five
outbreak
control
meet
mean
staff
costmeet
aggreg
cost
addit
outbreakrel
clean
cost
repres
addit
cdi
outbreakassoci
cost
exclud
valu
lost
bed
day
outbreak
cost
therefor
total
spend
cdi
august
mean
across
patient
discuss
andor
conclus
invest
diseas
prevent
may
offset
cost
save
analysi
suggest
invest
c
difficil
prevent
could
offer
net
financi
benefit
circumst
well
improv
valu
money
clinic
outcom
method
isol
sampl
across
birmingham
whole
genom
sequenc
vntr
type
wg
data
map
refer
strain
singl
nucleotid
polymorph
snp
core
genom
use
gener
phylogenet
tree
use
bayesian
phylogenet
vntr
data
gener
pcr
amplif
tandem
repeat
loci
result
snpsite
use
construct
phylogenet
tree
reveal
distinct
clade
isol
bhm
clade
diverg
rest
birmingham
popul
remain
isol
divers
wider
rang
diverg
date
variat
repeat
number
observ
loci
show
highest
variabl
map
vntr
data
onto
tip
tree
reveal
isol
two
tandem
repeat
n
map
bhm
clade
isol
tandem
repeat
dispers
throughout
rest
tree
discuss
andor
conclus
wg
provid
high
degre
discrimin
amongst
birmingham
isol
highlight
presenc
highli
relat
clade
identify
specif
repeat
number
one
loci
vntr
result
case
review
femal
averag
age
rang
mode
year
old
care
home
resid
commonest
sourc
bacteraemia
urinari
dehydr
statu
record
admiss
patient
admit
home
record
dehydr
compar
patient
admit
care
home
patient
urosepsi
seen
gp
five
patient
receiv
antibiot
isol
sensit
receiv
antibiot
isol
resist
two
admiss
follow
urinari
cathet
chang
altern
diagnosi
made
urosepsi
consid
remaind
inform
avail
discuss
andor
conclus
prevent
admiss
due
e
coli
bacteraemia
focu
elderli
measur
prevent
urosepsi
howev
patient
urosepsi
seen
gp
admiss
might
opportun
prevent
admiss
correct
antibiot
use
studi
reinforc
import
match
antibiot
formulari
local
sensit
femal
risk
factor
complic
receiv
season
flu
vaccin
influenza
nottyp
influenza
b
one
patient
influenza
nottyp
influenza
b
median
time
sampl
admiss
day
length
inpati
stay
day
length
itu
admiss
day
repeat
respiratori
sampl
perform
day
remain
posit
day
remain
posit
patient
receiv
oseltamivir
median
durat
day
receiv
prolong
cours
escal
zanamivir
nebulisedintraven
due
ongo
symptom
oseltamivir
resist
mutat
detect
patient
test
patient
die
ill
discuss
andor
conclus
result
suggest
urgent
need
improv
vaccin
uptak
equal
highlight
import
increas
clinic
suspicion
speed
diagnost
sampl
well
repeat
sampl
demonstr
respons
antivir
time
instig
resist
test
background
sampl
posit
influenza
matrix
result
present
without
subtyp
routin
one
tube
multiplex
none
associ
travel
especi
sever
diseas
virul
subtyp
suspect
aim
object
investig
determin
unknown
subtyp
part
pandem
plan
method
sampl
report
influenza
without
subtyp
clinic
laboratori
may
st
august
interrog
singleplex
assay
haemagglutinin
sequenc
compar
onlin
sequenc
collect
gisaid
result
influenza
report
report
influenza
subtyp
undetermin
case
first
appear
may
th
reach
peak
case
per
run
mid
june
fade
away
last
one
august
th
ct
consid
weak
mismatch
matrix
subtyp
could
expect
remain
one
identifi
mutat
affect
primer
probe
still
within
cluster
discuss
andor
conclus
investig
unbalanc
result
enabl
us
wit
wave
import
influenza
may
connect
numer
immigr
bangladeshi
worker
singapor
remind
normal
movement
influenza
potenti
unseen
global
travel
mutat
expect
interfer
recommend
primersprob
one
mutat
probe
two
revers
primer
region
background
accord
offici
data
infect
deliveri
poland
rare
aim
object
object
studi
assess
perinat
antibiot
consumpt
method
verifi
offici
data
infect
obstetr
patient
popul
method
evalu
perinat
antibiot
consumpt
data
antibiot
purchas
outpati
care
use
year
analysi
took
consider
antibiot
prescript
within
day
date
deliveri
order
evalu
consumpt
antibiot
daili
defin
dose
ddd
per
deliveri
use
result
analyz
period
deliveri
record
provinc
vagin
cesarean
section
averag
length
hospit
stay
day
group
women
purchas
antibiot
part
outpati
obstetr
care
averag
consumpt
antibiot
studi
popul
ddd
increas
consumpt
antibiot
observ
case
csection
among
youngest
patien
patient
countrysid
discuss
andor
conclus
accord
offici
data
year
fewer
one
patient
per
birth
csection
develop
surgic
site
infect
accord
polish
pp
data
rate
form
infect
among
obstetr
patient
ratio
much
lower
literatur
data
patient
popul
present
result
antibiot
consumpt
show
surveil
infect
popul
pose
challeng
infect
control
team
staff
look
patient
poland
retrospect
analysi
contact
screen
pulmonari
nonpulmonari
tuberculosi
case
lothian
scotland
millic
goodwin
eleanor
strong
ceri
mcsparron
susan
vaughan
janet
stevenson
adam
hill
ian
f
laurenson
univers
edinburgh
lothian
tb
servic
royal
infirmari
edinburgh
background
nice
tuberculosi
clinic
guidelin
updat
januari
amend
guidanc
offer
screen
contact
patient
pulmonari
laryng
tb
revis
limit
test
contact
peopl
potenti
infecti
tb
suggest
nonpulmonari
tb
nptb
infect
pose
risk
aim
object
assess
possibl
impact
chang
guidanc
method
outcom
contact
screen
pulmonari
ptb
nptb
case
within
lothian
prior
guidelin
amend
assess
review
record
patient
ptb
nptb
contact
year
period
inclus
within
lothian
scotland
contact
screen
latent
activ
infect
use
combin
igra
test
chest
xray
tuberculin
skin
test
result
contact
ptb
case
contact
nptb
case
success
screen
contact
ptb
case
latent
tb
infect
whilst
activ
tb
infect
contrast
nptb
contact
latent
tb
infect
consid
activ
tb
latent
tb
identifi
frequent
nptb
contact
p
differ
activ
tb
case
p
discuss
andor
conclus
result
demonstr
nptb
addit
ptb
excel
target
screen
signific
case
find
latent
activ
tb
case
identifi
studi
provid
clear
evid
screen
contact
nptb
case
hinder
scotland
achiev
target
elimin
tb
background
surgic
patient
one
common
patient
group
acquir
nosocomi
bloodstream
infect
bsi
sinc
risk
bsi
relat
length
hospit
stay
bsi
rate
usual
report
patientday
howev
risk
like
vari
patient
characterist
oper
type
aim
object
evalu
risk
outcom
bsi
follow
surgeri
differ
oper
type
method
data
bsi
case
collect
helsinki
univers
hospit
bed
part
nation
hospitalwid
surveil
nosocomi
bsi
number
oper
obtain
hospit
databas
unit
pediatr
surgeri
exclud
result
total
bsi
nosocomi
bsi
follow
oper
identifi
relat
intens
care
rate
highest
cardiovascular
oper
urogenit
surgeri
lowest
gynecolog
orthoped
bsi
primari
secondari
surgic
site
infect
common
sourc
secondari
bsi
common
pathogen
primari
bsi
coagulas
neg
staphylococci
staphylococcu
aureu
secondari
bsi
aureu
escherichia
coli
case
fatal
rang
gynecolog
obstetr
cardiovascular
surgeri
discuss
andor
conclus
risk
outcom
bsi
vari
consider
oper
type
like
partli
relat
patient
underli
ill
besid
surgic
site
infect
remark
proport
bsi
associ
central
line
provid
addit
focu
prevent
effort
background
recent
year
carbapenemresist
klebsiella
pneumonia
crkp
becom
endem
itali
effect
strategi
need
reduc
burden
hospit
set
particularli
high
risk
ward
aim
object
assess
effect
intensifi
infect
control
measur
includ
activ
surveil
gastrointestin
colon
patient
reduc
circul
crkp
incid
crkp
bloodstream
infect
intens
care
unit
icu
equip
nearli
bed
tertiari
acutecar
bed
region
referr
center
univers
hospit
ircc
aou
san
martinoist
genoa
liguria
region
northwest
itali
method
intervent
effect
analyz
interrupt
time
seri
regress
analysi
studi
includ
preintervent
period
januari
decemb
intervent
period
januari
decemb
intensifi
control
measur
particularli
routin
rectal
screen
implement
reach
high
level
adher
monthli
incid
first
posit
cultur
result
crkp
either
includ
exclud
rectal
swab
crkp
bsi
compar
result
preliminari
result
demonstr
incid
first
posit
cultur
result
crkp
includ
rectal
swab
significantli
decreas
intervent
period
compar
preintervent
period
slope
pvalu
similar
result
obtain
also
exclud
rectal
swab
slope
pvalu
decreas
trend
even
though
statist
signific
observ
incid
crkp
bsi
slope
pvalu
result
appli
cdc
definit
case
defin
nontrustapport
use
phe
definit
increas
report
case
case
addit
trustapport
case
accord
cdc
surveil
definit
due
previou
hospitalis
week
prior
posit
specimen
case
defin
nontrustapport
previou
overnight
hospit
stay
week
prior
posit
specimen
within
week
prior
posit
specimen
discuss
andor
conclus
high
proport
c
difficil
case
defin
nontrust
recent
overnight
hospit
hospit
suggest
case
may
attribut
previou
episod
care
phe
consid
includ
previou
hospitalis
epidemiolog
definit
health
careassoci
infect
neurolog
depart
epidemiolog
antibiot
resist
risk
factor
two
year
studi
mansoura
univers
egypt
rawia
badr
rasha
hassan
ena
hammad
hassan
salama
faculti
medicin
mansoura
univers
faculti
medicin
background
health
careassoci
infect
hai
repres
major
problem
neurolog
depart
consider
impact
mortal
morbid
rate
aim
object
prospect
studi
conduct
detect
hai
accord
cdc
definit
main
infect
site
common
microorgan
mortal
rate
risk
factor
age
length
stay
method
studi
carri
neurolog
depart
faculti
medicin
mansoura
univers
egypt
januari
decemb
isol
identif
antimicrobi
suscept
carri
outbreak
uti
due
candida
speci
detect
rflp
done
type
trace
sourc
infect
result
elderli
patient
prolong
length
hospit
stay
higher
risk
acquir
hai
higher
mortal
rate
associ
patient
hai
blood
stream
infect
mechan
ventil
low
glasgow
coma
scale
hai
detect
sampl
three
commonli
report
organ
klebsiella
pneumonia
follow
candida
spp
mrsa
regard
site
infect
urinari
tract
infect
commonest
site
follow
respiratori
tract
infect
blood
stream
infect
wound
infect
imipenem
effect
antibiot
gram
neg
bacteria
vancomycin
imipenem
found
effect
gram
posit
bacteria
discuss
andor
conclus
hai
prevent
repres
real
challeng
minim
hai
limit
mortal
antibiot
resist
outbreak
emerg
epidemiolog
glycopeptid
resist
coagulas
neg
staphylococci
east
midland
sharon
koo
nelun
perera
univers
hospit
leicest
nh
trust
background
coagulas
neg
staphylococcu
con
one
frequent
isol
nosocomi
pathogen
clinic
microbiolog
laboratori
increas
evid
glycopeptid
resist
particularli
teicoplanin
increas
con
aim
object
retrospect
analysi
evalu
teicoplanin
vancomycin
suscept
con
isol
steril
site
sampl
method
con
isol
steril
site
sampl
submit
laboratori
januari
april
evalu
total
con
isol
period
major
isol
blood
cultur
orthopaed
bone
joint
wound
sampl
periton
dialysi
fluid
sternum
etest
strip
use
determin
teicoplanin
mic
vancomycin
suscept
initi
perform
use
etest
strip
chang
commerci
mic
test
system
vitek
octob
mic
valu
interpret
accord
recommend
british
societi
antimicrobi
chemotherapi
isol
mic
mgl
consid
resist
result
sampl
test
vancomycin
suscept
sampl
resist
mic
isol
blood
cultur
one
sampl
test
teicoplanin
deem
suscept
mic
sampl
test
teicoplanin
suscept
con
isol
resist
mic
sampl
mic
sampl
vancomycin
suscept
discuss
andor
conclus
glycopeptid
resist
con
isol
popul
reflect
pattern
seen
investig
countri
carbapenemas
screen
programm
london
teach
hospit
low
rate
detect
kerri
roulston
yvonn
carter
vicki
pang
gemma
vanston
indran
balakrishnan
robin
smith
damien
mack
royal
free
london
nh
foundat
trust
hsl
analyt
background
public
health
england
advis
carbapenemas
screen
cs
highrisk
patient
royal
free
hospit
univers
cs
perform
intens
care
unit
icu
patient
riskbas
cs
perform
privat
renal
liver
haematolog
infecti
diseas
id
stroke
oncolog
patient
aim
object
review
number
patient
screen
carbapenemaseproduc
organ
cpo
case
detect
method
laboratori
inform
system
search
cs
sampl
juli
decemb
cs
perform
use
broth
enrich
cultur
contain
imipenem
disc
decemb
chromid
carba
biomerieux
januari
onward
suspect
cpo
confirm
refer
laboratori
result
cs
perform
sampl
patient
averag
three
sampl
per
patient
median
iqr
major
sampl
icu
privat
renal
patient
patient
screen
new
case
cpo
identifi
detect
rate
per
patient
screen
icu
privat
renal
haematolog
liver
stroke
oncolog
id
specialti
detect
rate
per
patient
screen
increas
significantli
ci
p
discuss
andor
conclus
costeffect
implement
cs
unknown
yield
cs
highrisk
patient
hospit
current
low
howev
detect
rate
increas
significantli
last
two
year
cs
highrisk
patient
import
due
increas
risk
infect
associ
high
mortal
light
surveil
cranial
surgeri
procedur
tertiari
referr
hospit
use
integr
electron
approach
teresa
inkster
ann
kerr
iren
aitken
susan
littl
helen
queen
elizabeth
univers
hospit
glasgow
nhsggc
infect
control
team
background
nh
ggc
ipct
revisit
ssi
surveil
within
cranial
surgeri
procedur
use
realtim
web
applic
design
assist
infect
surveil
neurosurg
ssi
surveil
mandatori
compon
hp
ssi
surveil
programm
ssi
surveil
previous
undertaken
neurosurg
procedur
hospit
involv
manual
paper
base
system
data
collect
aim
object
discuss
use
integr
electron
approach
initi
data
captur
post
surgeri
patient
surveil
readmiss
microbiolog
alert
method
ipc
team
use
icnet
addit
ssi
surveil
packag
enabl
robust
light
surveil
system
provid
real
time
data
import
alert
customis
report
via
intranet
pc
tablet
allow
increas
access
throughout
multipl
hospit
site
also
reduc
burden
requir
staff
complet
paper
form
patient
surgeri
case
identifi
surveil
inclus
automat
display
surveil
nurs
icnet
dashboard
allow
monitor
case
day
post
surgeri
result
method
reli
accur
surgic
procedur
code
data
uniqu
identifi
surveil
inclus
note
procedur
captur
due
code
anomali
howev
identifi
remedi
local
discuss
andor
conclus
use
realtim
web
applic
undertak
ssi
surveil
within
cranial
surgeri
reduc
burden
paper
base
process
ssi
monitor
provid
singl
data
repositori
surveil
data
provid
straightforward
approach
monitor
ssi
outcom
follow
surgeri
review
analyt
methodolog
use
estim
excess
length
stay
due
health
care
associ
infect
sarki
manoukian
salli
stewart
agi
mcfarland
jacqui
reilli
nick
grave
glasgow
caledonian
univers
gcunh
queensland
univers
technolog
background
accur
quantifi
addit
cost
healthcar
associ
infect
hai
essenti
develop
costeffect
infect
prevent
control
measur
major
compon
econom
cost
due
health
care
associ
infect
captur
measur
addit
length
stay
lo
due
infect
aim
object
prefer
model
lo
instead
monetari
valuat
hospit
cost
stem
belief
mani
decis
healthcar
invest
made
short
term
financi
expenditur
made
cost
fix
howev
estim
excess
lo
due
hai
complic
due
fact
infect
increas
durat
hospit
stay
time
risk
infect
increas
durat
stay
problem
endogen
variabl
potenti
address
use
appropri
statist
method
method
systemat
review
examin
paper
pubm
publish
identifi
english
languag
studi
estim
increas
lo
due
hai
result
methodolog
approach
use
literatur
estim
excess
lo
due
hai
includ
case
review
match
comparison
regress
analys
choic
estim
methodolog
affect
accuraci
result
estim
due
estim
lo
vari
wide
studi
review
studi
examin
lo
attribut
hai
vari
consider
design
data
collect
discuss
andor
conclus
review
summaris
recent
statist
methodolog
messag
robust
applic
address
key
gap
understand
hai
effect
healthcar
background
antimicrobi
resist
amr
infecti
complic
follow
transrect
ultrasound
tru
guid
prostat
biopsi
increas
includ
urinari
tract
infect
uti
bloodstream
infect
bsi
aim
object
prospect
multidisciplinari
local
infect
surveil
programm
establish
men
undergo
prostat
biopsi
result
first
two
year
describ
method
ciprofloxacin
standard
prophylaxi
intraven
gentamicin
ad
risk
factor
identifi
preprocedur
amr
assess
man
repres
suspect
infect
investig
manag
accord
local
guidelin
uti
bsi
surveil
within
day
biopsi
use
european
ecdc
definit
perform
rate
express
per
biopsi
root
caus
analysi
rca
complet
confirm
uti
bsi
result
intervent
discuss
biannual
team
meet
result
rate
microbiologicallyconfirm
infect
per
biopsi
decreas
e
coli
caus
pathogen
nonsuscept
ciprofloxacin
contemporan
increas
rate
microbiologicallyunconfirm
infect
despit
complianc
send
blood
cultur
urin
man
repres
suspect
infect
gentamicin
ad
ciprofloxacin
prophylaxi
amr
risk
evid
preprocedur
discuss
andor
conclus
implement
amr
risk
assess
robust
infect
surveil
manag
process
rca
led
reduct
infect
contemporan
increas
nonmicrobiolog
confirm
infect
despit
full
complianc
test
warrant
investig
background
invas
candida
infect
associ
increas
morbid
mortal
standardis
surveil
programm
infect
limit
aim
object
investig
incid
candida
speci
isol
blood
cerebr
spinal
fluid
csf
five
year
period
method
retrospect
review
conduct
januari
decemb
blood
csf
resullt
candida
speci
isol
antifung
suscept
patient
outcom
result
candida
cultur
blood
n
csf
n
patient
nine
patient
document
recurr
infect
averag
time
posit
cultur
day
admiss
male
femal
equal
affect
averag
age
year
rang
year
ten
patient
critic
care
time
cultur
annual
number
case
vari
nine
c
albican
predomin
speci
follow
c
glabrata
c
parapsilosi
proport
nonalbican
speci
vari
time
caspofungin
resist
detect
fluconazol
nonsuscept
uncommon
among
nonglabrata
speci
n
associ
length
stay
azol
consumpt
antifung
increas
period
crude
mortal
rate
discuss
andor
conclus
local
surveil
invas
candidiasi
crucial
monitor
chang
trend
antifung
resist
fluconazol
resist
remain
low
level
howev
signific
proport
isol
c
glabrata
empir
echinocandin
therapi
consid
particularli
critic
unwel
patient
pend
suscept
data
chang
epidemiolog
methicillinresist
staphyloccocu
aureu
sarm
year
period
ana
hornero
sara
grillo
juan
manuel
verg
marto
jordi
camara
angel
dominguez
jordi
carratala
miquel
pujol
background
first
case
mrsa
bellvitg
univers
hospit
detect
earli
nineti
case
nosocomi
origin
caus
domin
clone
iberian
clone
produc
outbreak
especi
intens
care
unit
seriou
infect
associ
invas
devic
implement
intens
control
program
result
initi
signific
decreas
new
mrsa
case
upward
trend
observ
last
year
explain
partial
clone
replac
chang
clinic
epidemiolog
mrsa
aim
object
determin
current
clinic
epidemiolog
mrsa
case
period
year
tertiari
care
hospit
method
prospect
surveil
mrsa
case
report
daili
microbiolog
servic
collect
systemat
inform
regard
acquisit
sampl
sourc
implement
control
program
base
activ
surveil
contact
precaut
decolonis
result
mrsa
case
identifi
signific
chang
regard
clinic
epidemiolog
period
follow
rate
case
detect
activ
surveil
cultur
vs
nosocomi
acquisit
vs
case
incid
rate
nosocomi
mrsa
clinic
sampl
vs
patientsday
incid
rate
nosocomi
bacteraemia
vs
patientsday
discuss
andor
conclus
signific
reduct
nosocomi
mrsa
transmiss
nosocomi
mrsa
bacteraemia
case
observ
throughout
studi
period
surveil
program
mrsa
includ
implement
multifacet
infect
control
program
essenti
reduc
nosocomi
rate
center
result
found
case
e
coli
bsi
fell
per
year
howev
case
rate
rose
per
occupi
bed
day
averag
age
case
lower
rfh
bcf
versu
year
hour
case
versu
year
hour
case
p
decreas
trend
proport
hour
case
bcf
p
nonsignific
increas
trend
rfh
p
multivari
analysi
compar
bcf
case
rfh
often
associ
augment
care
p
nona
e
medicalgeriatr
specialti
p
nonemerg
admiss
p
hour
onset
p
discuss
andor
conclus
analysi
e
coli
bsi
trust
site
reveal
differ
epidemiolog
import
consider
plan
measur
reduc
case
result
e
coli
bsi
case
vari
per
year
howev
proport
like
possibl
healthcar
associ
infect
hcai
fell
chisquar
test
trend
p
multivari
analysi
compar
commun
case
contact
hospit
previou
three
month
proport
hcai
case
significantli
higher
case
diagnos
day
admiss
previou
contact
hospit
within
three
month
case
diagnos
day
admiss
onward
hcai
case
follow
yearonyear
trend
seen
decreas
associ
vascular
access
devic
use
p
increas
associ
invas
devic
use
p
cathet
use
p
surgeri
invas
procedur
p
discuss
andor
conclus
factor
associ
e
coli
bsi
hcai
chang
investig
root
caus
analysi
requir
determin
proport
e
coli
bsi
hcai
may
prevent
background
shift
genet
background
methicillin
resist
staphylococcu
aureu
mrsa
requir
regular
updat
pcr
base
rapid
detect
assay
researchuseonli
xpert
mrsa
nxg
new
cepheid
assay
design
highli
effect
detect
current
mrsa
isol
nasal
swab
without
requir
cold
room
storag
long
shelf
life
detect
media
total
cpe
detect
maci
macd
macc
esbl
tsb
broth
respect
sensit
highest
macd
specif
maximum
maci
perform
media
vari
carbapenem
mic
carbapenemas
gene
associ
cpe
isol
discuss
andor
conclus
singl
method
sensit
specif
cpe
detect
choic
depend
type
carbapenemas
gene
preval
local
combin
media
increas
sensit
specif
id
spread
hospitalacquir
infect
comparison
patient
transfer
network
nariman
nekkab
pascal
astagneau
pascal
conservatoir
nation
de
art
et
metier
ecol
de
haut
etud
en
sant
publiqu
centr
de
coordin
pour
la
lutt
contr
le
infect
aux
soin
background
hospitalacquir
infect
hai
includ
emerg
multidrug
resist
organ
continu
threaten
healthcar
system
aim
object
better
understand
reduc
scale
hai
epidem
spread
compar
explor
characterist
patient
transfer
pattern
french
healthcar
network
identifi
potenti
role
epidem
spread
hai
within
network
method
three
patient
transfer
network
compar
two
hai
relat
patient
specif
sensit
definit
transfer
patient
assess
network
characterist
comput
central
commun
measur
compar
network
erdosrenyi
random
model
network
randomli
select
patient
result
million
patient
transfer
record
franc
million
patient
build
network
hospit
connect
network
specifichai
patient
compos
hospit
connect
patient
transfer
suspectedhai
network
compos
hospit
connect
patient
transfer
network
display
scalefre
structur
hospit
number
connect
transfer
also
featur
smallworld
characterist
commun
within
network
small
averag
inner
distanc
depend
modular
commun
detect
algorithm
discuss
andor
conclus
characterist
may
tremend
effect
diffus
nosocomi
pathogen
addit
differ
patient
inclus
criteria
could
impact
network
characterist
identif
key
hospit
centr
patient
flow
trajectori
region
cluster
may
serv
basi
novel
widescal
hai
control
strategi
use
code
hospit
set
infecti
diseas
antimicrobi
resist
surveil
meghan
perri
catriona
parker
oliv
koch
mark
woolhous
nh
lothian
univers
edinburgh
nh
lothian
background
databas
hospit
admiss
use
intern
classif
diseas
code
could
valuabl
sourc
infecti
diseas
surveil
aim
object
studi
aim
assess
accuraci
code
infecti
diseas
diagnos
record
antimicrobi
resist
method
code
discharg
region
infecti
diseas
unit
western
gener
hospit
edinburgh
start
june
st
record
correspond
discharg
letter
review
verifi
accuraci
code
microbiolog
record
admiss
check
confirm
relev
inform
record
discharg
letter
result
sixtyeight
discharg
appropri
code
relat
discharg
letter
inappropri
code
incomplet
inaccur
unconfirm
diagnosi
one
diagnosi
code
review
microbiolog
result
unrecord
discharg
letter
would
impact
code
sixteen
pathogen
identifi
resist
one
antibiot
howev
discharg
diagnos
mention
antimicrobi
resist
resist
code
use
discuss
andor
conclus
although
small
sampl
size
audit
highlight
use
hospit
databas
epidemiolog
surveil
infecti
diseas
diagnos
antimicrobi
resist
would
current
give
accur
pictur
area
icd
code
format
could
improv
allow
adequ
represent
infecti
diseas
diagnos
includ
record
clinic
impact
antimicrobi
resist
increas
awar
doctor
code
process
educ
coder
recommend
computerassist
risk
assess
hospit
infect
preliminari
implement
polish
hospit
andrzej
jarynowski
damian
marchewka
andrzej
grabowski
jagiellonian
univers
interdisciplinari
research
institut
wroclaw
background
creat
intuit
function
desktop
applic
free
charg
open
licens
support
work
hospit
epidemiologist
prevent
contain
hospit
infect
aim
object
goal
applic
reconstruct
like
path
infect
classifi
place
individu
differ
risk
group
studi
timevari
structur
contact
reconstruct
data
set
collect
polish
swedish
hospit
appli
theori
tempor
network
improv
computerassist
hospit
infect
analys
method
algorithm
process
data
regist
patient
admiss
discharg
hospit
unit
ward
clinic
etc
microbiolog
laboratori
test
result
medic
staff
regist
patient
structur
contact
person
visit
care
facil
function
path
reconstruct
epidemiolog
model
implement
temporari
network
contact
link
provid
path
pathogen
transmiss
result
preliminari
setup
analys
one
alarm
pathogen
mrsa
simul
infect
path
abl
comput
network
measur
patient
obtain
risk
get
infect
base
patient
incom
connect
risk
spread
infect
result
outgo
connect
analog
googl
algorithm
discuss
andor
conclus
provid
costless
prevent
computerassist
tool
hai
biggest
effort
hospit
administr
map
hospit
topolog
enter
manual
hospit
employe
later
data
import
hospit
inform
system
result
algorithm
present
realtim
hospit
epidemiologist
interpret
appli
prevent
control
background
substanti
sustain
increas
incid
invas
pneumococc
diseas
ipd
observ
across
north
east
england
nee
april
revers
declin
background
invas
meningococc
diseas
imd
uk
predominantli
due
serogroup
b
burden
diseas
among
children
year
septemb
uk
implement
target
serogroup
b
vaccin
bexsero
nation
childhood
immunis
schedul
month
aim
object
design
implement
genom
scheme
rapid
scalabl
surveil
vaccin
antigen
respons
select
pressur
method
cultureconfirm
imd
isol
n
uk
mening
research
foundat
meningococcu
genom
librari
republ
ireland
includ
whole
genom
sequenc
host
pubmlst
neisseria
public
databas
http
pubmlstorgneisseria
novel
bexsero
antigen
sequenc
type
bast
scheme
implement
use
analys
presenc
vaccin
antigen
fhbp
nada
nhba
pora
result
isol
bast
determin
uniqu
bast
nine
frequent
occur
bast
account
isol
n
bast
strongli
associ
clonal
complex
cramer
v
bast
larg
stabl
time
except
increas
clonal
complex
associ
frequent
bast
present
area
variat
preval
bast
four
geograph
region
discuss
andor
conclus
mening
research
foundat
meningococcu
genom
librari
publicli
avail
onlin
repositori
imd
isol
facilit
high
resolut
analysi
bacteri
genom
presenc
predomin
bast
tempor
geograph
stabil
suggest
use
associ
vaccin
antigen
could
provid
high
vaccin
coverag
bexsero
vaccin
coverag
estim
great
britain
ireland
use
genom
surveil
use
bexsero
antigen
sequenc
type
bast
discuss
andor
conclus
though
key
factor
success
includ
among
other
multimod
natur
campaign
polit
financi
support
govern
highest
number
observ
opportun
complianc
rate
record
also
attribut
new
onlin
tool
conor
bowman
damien
mack
robin
smith
susan
hopkin
royal
free
london
nh
foundat
trust
background
england
klebsiella
e
coli
bloodstream
infect
bsi
rose
across
england
uk
govern
ambit
half
prevent
gramneg
bsi
aim
object
identifi
differ
two
pathogen
bsi
allow
focus
intervent
develop
method
klebsiella
e
coli
bsi
univers
teach
hospit
extract
laboratori
inform
manag
system
clinic
data
extract
patient
clinic
record
hospit
administr
system
hospitalacquir
bsi
habsi
defin
onset
day
hospit
admiss
result
e
coli
klebsiella
bsi
detect
patient
e
coli
less
like
male
v
older
median
age
v
klebsiella
bsi
greatest
burden
hai
occur
e
coli
compar
klebsiella
v
patient
though
klebsiella
habsi
compar
e
coli
top
two
commonest
sourc
bsi
urinari
tract
e
coli
v
klebsiella
hepatobiliari
bacteria
infect
prevent
infect
assess
like
possibl
e
coli
klebsiella
bsi
predominantli
relat
devic
procedur
inappropri
initi
antibiot
therapi
discuss
andor
conclus
signific
demograph
clinic
differ
e
coli
klebsiella
bsi
howev
target
devic
insert
care
surgic
prophylaxi
empir
treatment
guidelin
could
reduc
habsi
background
new
case
number
papua
easternmost
part
indonesia
archipelago
remain
stabl
although
mani
effort
leprosi
elimin
program
carri
show
transmiss
mycobacterium
lepra
activ
happen
aim
object
aim
studi
detect
mycobacterium
lepra
use
polymeras
chain
reaction
pcr
asymptomat
household
contact
order
observ
transmiss
mycobacterium
lepra
earli
stage
clinic
manifest
observ
risk
factor
transmiss
method
cross
section
descript
design
studi
sampl
popul
symtomat
leprosi
patient
asymptomat
household
contact
patient
environ
factor
observ
period
live
patient
intenc
number
person
hous
nasal
swab
skin
silt
blood
sampl
collect
subject
dna
extract
nasal
skin
silt
result
thirti
five
leprosi
patient
asymptomat
household
contact
recruit
subject
studi
result
show
mycobacterium
lepra
detect
leprosi
patient
household
contact
use
pcr
risk
factor
statist
signific
associ
transmiss
mycobacterium
lepra
period
live
togeth
leprosi
patient
p
discuss
andor
conclus
conclus
studi
pcr
use
detect
mycobacterium
lepra
household
contact
without
clinic
cardin
sign
well
leprosi
patient
cardin
sign
risk
factor
influenc
transmiss
mycobacterium
lepra
period
live
togeth
background
admiss
recommend
import
plasmodium
falciparum
infect
despit
studi
uk
specialist
district
set
claim
safe
selectiveoutpati
manag
establish
admiss
criteria
queen
elizabeth
hospit
woolwich
p
falciparum
present
potenti
benefit
outpati
manag
uk
district
gener
hospit
barrier
implement
aim
object
aim
determin
whether
possibl
implement
ed
riskassess
protocol
outpati
manag
adult
uncompl
p
falciparum
infect
safe
object
determin
appropri
referr
audit
document
outpatientadmiss
criteria
ascertain
whether
outpati
p
falciparum
manag
ration
pursuit
method
patient
note
gather
adult
p
falciparumposit
blood
film
protocol
implement
search
retrospect
document
criteria
use
determin
uncompl
infect
suitabl
outpati
manag
result
studi
period
adult
diagnos
p
falciparum
elig
outpati
manag
heart
rate
admiss
parasitaemia
associ
aki
patient
suitabl
outpati
manag
pathway
implement
refer
outpati
servic
unev
admiss
averag
admiss
day
hospitalbedday
could
save
appropri
outpati
referralpathway
use
discuss
andor
conclus
improv
staff
educ
referralpathway
awar
requir
assess
true
feasibl
outpati
p
falciparum
manag
theori
could
save
qeh
hospitalbeddaysyear
approxim
elig
criteria
welldocu
suitabl
patient
made
quick
recoveri
highpow
multicentr
studi
necessari
establish
statist
safeti
marco
lee
fauzia
rizwanle
teach
hospit
nh
trust
year
old
femal
normal
fit
well
return
one
month
visit
mexico
citi
ate
local
restaur
mani
occas
develop
acut
onset
diarrhoea
attend
privat
clinic
twice
given
cours
ciprofloxacin
cephalexin
symptom
improv
arriv
uk
symptom
abdomin
bloat
vomit
type
stool
result
bloodborn
viru
screen
hiv
hbv
hcv
neg
stool
neg
campylobact
salmonella
shigella
e
coli
rotaviru
adenoviru
c
difficil
toxin
stool
ocp
reveal
cyclospora
cayetanensi
oocyst
diarrhoea
improv
within
day
start
oral
cotrimoxazol
discharg
complet
day
cours
routin
followup
infecti
diseas
outpati
clinic
discuss
andor
conclus
c
cayetanensi
coccidian
protozoan
parasit
diarrhoea
usual
selflimit
prolong
last
week
month
untreat
copiou
explos
transmiss
occur
ingest
contamin
food
water
endem
mani
countri
includ
mexico
outbreak
occur
oocyst
resist
standard
water
chlorin
treatment
standard
laboratori
procedur
ocp
detect
cyclospora
laboratori
notifi
cyclospora
consid
special
techniqu
identifi
cyclospora
includ
acidfast
stain
safranin
stain
lactophenol
cotton
blue
stain
public
health
england
recommend
return
travel
mexico
diarrhoea
test
cyclospora
posit
case
report
phe
sampl
refer
cryptosporidium
refer
unit
swansea
confirm
type
background
cutan
myiasi
caus
tumbu
fli
cordylobia
anthropophagia
african
tropic
bot
fli
dermatobia
homini
latin
america
common
well
report
skin
complaint
travel
resid
endem
area
british
armi
frequent
exercis
oversea
particular
soldier
exercis
beliz
jungl
risk
develop
bot
fli
infest
larva
easi
remov
earli
stage
late
instar
particularli
dermatobia
homini
often
requir
surgic
remov
develop
novel
porcin
model
botfli
remov
aid
train
medic
staff
deploy
exercis
area
endem
cutan
myiasi
commerci
obtain
maggot
insert
skin
pig
trotter
prepar
replic
typic
lesion
student
receiv
lectur
cutan
myiasi
includ
video
photo
remov
multipl
attempt
practic
safe
remov
larva
botfli
model
use
cruciform
incis
simpl
surgic
tool
supervis
receiv
feedback
perform
student
report
increas
confid
abil
safe
remov
larva
train
use
train
materi
easili
obtain
butcher
tackl
shop
make
model
cheap
easi
replic
beyond
pail
two
case
brucellosi
travel
return
india
background
woman
mr
x
present
fever
loin
pain
imag
reveal
psoa
abscess
level
meantim
patient
husband
mr
x
admit
hospit
fever
loss
appetit
review
clinic
histori
reveal
patient
recent
travel
punjab
area
india
spain
four
day
incub
organ
isol
mr
x
blood
cultur
although
identifi
routin
malditof
mass
spectrometri
organ
confirm
brucella
melitensi
day
later
organ
isol
husband
blood
cultur
discuss
mr
mr
x
nonfoc
focal
brucellosi
respect
coupl
mostli
like
acquir
diseas
recent
trip
punjab
report
drink
unpasteuris
milk
suppli
local
farmer
incid
brucellosi
mani
part
world
particularli
asia
remain
larg
unknown
recognis
diseas
may
endem
india
like
diagnos
report
learn
point
brucella
melitensi
reliabl
identifi
malditof
mass
spectrometri
clinic
laboratori
potenti
complic
diagnost
process
delay
appropri
patient
manag
despit
understand
need
boil
milk
prior
consumpt
mr
mr
x
alway
adher
advic
highlight
signific
role
human
behaviour
acquisit
transmiss
infecti
diseas
topic
viral
infect
id
hear
hoov
think
zebra
hors
case
seri
atyp
present
hepat
e
charlott
brookfield
dimitrio
mermer
joel
paul
pennin
acut
hospit
trust
background
hepat
e
hev
gener
mild
infect
associ
sever
diseas
atyp
manifest
commonest
genotyp
seen
indigen
uk
spread
mainli
consumpt
pork
product
increas
incid
hev
commonli
consid
initi
differenti
diagnosi
investig
patient
abnorm
liver
function
test
aim
object
present
four
recent
case
confirm
hev
infect
consid
like
initi
clinic
present
method
patient
case
record
review
result
case
one
twentythre
year
old
man
background
diabet
substanc
abus
initi
manag
base
presum
paracetamol
overdos
case
two
middl
age
woman
present
weak
dri
cough
back
pain
patient
requir
intens
care
support
syndrom
third
case
seventyseven
year
old
gentleman
present
bronchopneumonia
requir
itu
support
note
jaundic
fourth
case
eighti
year
old
man
enjoy
good
health
present
weight
loss
jaundic
investig
pancreat
malign
gall
bladder
patholog
discuss
andor
conclus
common
patient
derang
alt
bilirubin
normal
inr
none
patient
hev
consid
earli
present
although
screen
hepat
virus
present
case
remind
peopl
consid
hev
increas
caus
typic
atyp
present
hepat
preval
human
central
nervou
system
infect
paediatr
popul
lothian
fiona
hamilton
fraser
barbour
kate
templeton
specialist
virolog
centr
univers
edinburgh
background
enceph
sever
neurolog
diseas
associ
multipl
sequela
high
healthcar
cost
mortal
caus
enceph
includ
rang
infecti
noninfecti
diseas
process
major
case
result
viral
infect
aetiolog
enceph
remain
unknown
case
uk
granerod
et
al
aim
object
realtim
polymeras
chain
reaction
pcr
central
diagnosi
viral
enceph
identif
caus
pathogen
howev
human
known
caus
enceph
routin
screen
uk
studi
aim
determin
preval
neurolog
infect
paediatr
popul
lothian
throughout
result
use
realtim
pcr
cerebrospin
fluid
csf
sampl
test
identifi
sampl
dna
congenit
integr
host
genom
correspond
blood
sampl
also
test
patient
correspond
blood
sampl
test
sampl
neg
blood
posit
csf
indic
likelihood
activ
infect
discuss
andor
conclus
identif
aetiolog
enceph
crucial
manag
condit
studi
provid
evid
suggest
inclus
routin
diagnost
screen
csf
may
benefici
manag
result
base
infect
control
inspect
identifi
multipl
rout
potenti
transmiss
poor
hand
hygien
inappropri
ppe
usag
environment
cleanli
issu
issu
around
phlebotomi
practic
use
reusabl
ascept
non
touch
techniqu
antt
tray
found
multipli
phlebotomi
procedur
reus
antt
tray
often
inadequ
clean
instanc
soil
blood
dispos
antt
tray
use
separ
phlebotomi
procedur
despit
fact
exact
rout
rout
infect
identifi
inappropri
hygien
standard
parenter
treatment
lead
viral
hepat
transmiss
like
sourc
transmiss
discuss
andor
conclus
report
highlight
transmiss
healthcareassoci
hcv
infect
continu
occur
result
suggest
use
sequenc
reduc
ambigu
potenti
transmiss
event
healthcar
inform
infect
prevent
control
rout
transmiss
result
patient
confirm
exposur
influenza
infect
year
pregnant
children
six
month
age
diabet
one
chronic
condit
cardiovascularliv
neurologicalrenalrespiratori
sever
immunosuppress
obes
risk
factor
influenza
vaccin
statu
record
patient
median
length
stay
day
rang
day
patient
receiv
oseltamivir
prophylaxi
one
patient
receiv
zanamivir
prophylaxi
patient
develop
influenza
hospit
prophylaxi
one
stroke
patient
inhal
zanamivir
day
oseltamivir
prophylaxi
discuss
andor
conclus
antivir
drug
use
substitut
influenza
vaccin
costeffect
vaccin
individu
oppos
offer
chemoprophylaxi
opportun
vaccin
long
stay
patient
hospit
explor
method
cepheid
analys
place
design
test
area
junior
medic
staff
unit
train
perform
test
standard
oper
procedur
collect
analysi
sampl
written
guidanc
manag
patient
contact
provid
electron
record
interrog
obtain
data
time
admiss
result
avail
isol
antivir
prescript
result
interim
data
analysi
show
signific
reduct
median
time
admiss
result
avail
hour
hour
median
time
isolationdischarg
hour
hour
median
time
initi
antivir
treatment
hour
hour
discuss
andor
conclus
interim
data
indic
poct
influenza
assess
suit
aid
manag
patient
influenza
reduc
exposur
suscept
contact
noroviru
diseas
lead
higher
hospit
rate
older
adult
chronic
medic
condit
thoma
verstraeten
baoguo
jiang
john
weil
pharmacovigil
epidemiolog
servic
takeda
develop
center
america
background
noroviru
main
caus
acut
gastroenter
across
age
group
older
adult
particularli
risk
sever
diseas
potenti
lead
hospit
estim
us
adult
least
one
one
chronic
medic
condit
aim
object
assess
impact
noroviru
acut
gastroenter
nge
hospit
among
older
us
adult
variou
chronic
underli
condit
method
retrospect
cohort
studi
use
marketscan
data
compar
rate
hospit
nge
patient
one
chronic
condit
renal
cardiovascular
respiratori
